Viral vectors encoding antigen-displaying protein nanoparticles

By fusing vaccine antigens into self-assembled protein nanoparticles within a viral vector, the problem of insufficient antibody response in existing viral vector vaccines is solved, resulting in a more robust immune response and a durable protective antibody response.

CN123124990APending Publication Date: 2026-11-17BAVARIAN NORDIC AS
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202580029485.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-05-17
Filing Date
2025-05-16
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing viral vector vaccines have shortcomings in inducing antibody responses, especially in achieving robust and durable immune responses against infectious diseases, and T-cell responses are often weak and biased towards Th2 type.

Method used

By expressing foreign vaccine antigens in a viral vector and fusing them to subunits of self-assembled protein nanoparticles, and displaying them on the surface of the protein nanoparticles, an immune response can be enhanced.

Benefits of technology

It enhances the immune response to vaccine antigens, particularly the strength and persistence of antibody responses, while maintaining the effectiveness of T-cell responses, thus improving the immune protection against infectious diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure FT_1
    Figure FT_1
  • Figure FT_2
    Figure FT_2
  • Figure FT_3
    Figure FT_3
Patent Text Reader

Abstract

This invention relates to recombinant virus-based vectors, such as recombinant modified Ankara vaccinia virus (MVA) and viral replicon particles (VRP), said recombinant virus-based vectors encoding fusion proteins containing disease-associated antigens that bind to subunits of self-assembled protein nanoparticles; and the medical use of said recombinant virus-based vectors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of vaccines. More specifically, it relates to viral vectors, such as modified Ankara vaccinia virus (MVA) and viral replicon particles (VRP), said viral vectors encoding fusion proteins, wherein vaccine antigens are fused to subunits of self-assembled protein nanoparticles. The invention also relates to pharmaceutical compositions comprising such vectors and their medical use in disease prevention. Background Technology

[0002] Recombinant viral vectors encoding foreign disease-associated antigens have long been described as highly efficient inducers of potent and specific immune responses, and they have been successfully used as vaccines against infectious diseases such as Ebola virus disease (e.g., Mvabea). ® ) and 2019 coronavirus disease (COVID-19; for example, Vaxzevria ® These viral vectors deliver genetic material of exogenous antigens that are not inherent to the vector backbone (i.e., transgenes), which is transcribed and translated into corresponding antigen proteins by the host cells of the vaccine recipient.

[0003] The fully characterized viral vector is MVA-BN ® It was developed from modified Ankara vaccinia virus (MVA) stock solution. MVA is derived from the prototype species of vaccinia virus (VACV) in the genus Orthopoxaviiridae of the family Poxviridae. The cutaneous VACV Ankara strain (chorioallantoic Ankara vaccinia virus, CVA) is a replicating vaccinia virus [1]. Attenuated CVA-derived virus MVA was obtained by continuously propagating CVA in primary chicken embryo fibroblasts (CEF) for more than 570 generations. This MVA was further passaged by Bavarian Nordic to produce a further attenuated MVA strain, namely MVA-BN. ® [2]. Compared with the ancestral CVA virus, MVA-BN ® Approximately 15% of the genome is missing (a 31 kb loss resulting in six major deletion sites). These deletions affect many virulence and host-range genes, as well as type A inclusion body genes. MVA-BN ® It can attach to and enter human cells, and express the virus-encoded genes very efficiently in infected human cells. However, the assembly and release of progeny viruses do not occur in human cells. Therefore, MVA-BN ® This is a safe and versatile vaccine vector capable of efficiently expressing transgenic antigens for use in vaccination methods targeting diseases for which medical needs have not yet been met (e.g., Mvabea for Ebola virus disease). ® [3]). In clinical studies, MVA-BN ®Formulations of the derivatives have been administered to many types of animals and more than 10,500 human subjects, including immunocompromised individuals, without any serious adverse events.

[0004] Viral replicon particles (VRPs) are viral vectors derived from alphaviruses, containing a self-amplifying, positive-sense single-stranded RNA genome packaged in a shell composed of capsid proteins and a heterodimeric envelope protein embedded in a lipid membrane derived from the production cell. VRPs used for vaccination encode foreign antigens in place of the viral capsid and envelope genes. Because they lack the genes for these structural proteins, VRPs cannot replicate in transduced cells, but they induce high levels of transgenic expression, thereby inducing a robust immune response.

[0005] Upon administration to recipients, viral vector vaccines exhibit multiple characteristics of true viral infection, thereby inducing a strong immune response against both the delivered vaccine antigen and the vector itself, without the need for adjuvant support. Viral vector vaccines are excellent inducers of T helper (Th)1-biased T-cell responses. Conversely, antibody responses induced by viral vector vaccines targeting transgenic antigens tend to be lower than those induced by antigens delivered as proteins in adjuvants or as virus-like particles (VLPs), at least within short-interval vaccination schedules intended for rapid induction of protective antibody levels.

[0006] However, inducing robust and durable antibody responses is generally a highly desirable characteristic of vaccines against infectious diseases. There is a broad scientific consensus that immunization with protein antigens polymerized in a regular array (whether as VLPs or displayed on any other type of nanoparticle) induces the strongest antibody responses [4, 5]. However, the T-cell responses induced by these antigens tend to be weak and Th2-biased, a drawback that can be partially overcome by formulation with suitable and potent adjuvants.

[0007] Therefore, advanced vaccines that induce improved immune responses are needed. Summary of the Invention

[0008] The purpose of this invention is to provide means and methods for improving the immune response of vaccine recipients to vaccine antigens.

[0009] The objective of this invention is to provide a recombinant viral vector expressing at least one foreign vaccine antigen and additionally expressing a subunit of a self-assembled protein nanoparticle, such that the antigen is displayed on the surface of the protein nanoparticle.

[0010] In particular, the present invention is defined by the appended claims and the following aspects and embodiments.

[0011] In a first aspect, the present invention provides a pharmaceutical composition comprising a recombinant virus-based vector comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle.

[0012] In a second aspect, the present invention provides a recombinant viral replicon particle (VRP) comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof being bound to a subunit of a self-assembled protein nanoparticle.

[0013] In another aspect, the present invention provides a pharmaceutical composition comprising a recombinant virus-based vector as described herein, the pharmaceutical composition being used for the prevention or treatment of a disease, preferably for the prevention of infectious diseases or cancer.

[0014] In another aspect, the present invention provides a recombinant VRP as described herein, the recombinant VRP being used for the prevention or treatment of disease, preferably for the prevention or treatment of infectious diseases or cancer.

[0015] In another aspect, the present invention provides a process for preparing recombinant VRP as described herein, the process comprising the following steps: (1) Provide plasmid DNA encoding a self-amplifying replicon RNA, preferably a replicon RNA controlled by a cytomegalovirus (CMV) promoter, the replicon RNA encoding a fusion protein containing a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle; (2) Transfect VRP production cells with the plasmid DNA provided in step (1), and further transfect the VRP production cells with a packaging plasmid driven by a first CMV promoter encoding alphavirus capsid protein and a packaging plasmid driven by a second CMV promoter encoding alphavirus envelope protein; (3) Cultivate the transfected VRP production cells described in step (2); (4) Obtain the recombinant VRP.

[0016] In another aspect, the present invention provides a plasmid DNA encoding a self-amplifying replicon RNA, preferably a replicon RNA controlled by a cytomegalovirus (CMV) promoter, the replicon RNA encoding a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle.

[0017] In another aspect, the present invention provides a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle.

[0018] In another aspect, the present invention provides a nucleic acid that encodes a fusion protein as described herein.

[0019] In another aspect, the present invention provides a self-assembled protein nanoparticle comprising a fusion protein as described herein.

[0020] In another aspect, the present invention provides a method for preventing or treating infectious diseases or cancer, the method comprising the steps of administering to a subject a composition as described herein, such as a composition comprising a vector based on a recombinant virus or recombinant VRP as described herein.

[0021] In another aspect, the present invention provides a method for inducing an immune response against an infectious disease or cancer, the method comprising the steps of administering to a subject a composition as described herein, such as a composition comprising a vector based on a recombinant virus or recombinant VRP as described herein. Attached Figure Description

[0022] Figure 1 This schematically illustrates the SARS-CoV-2 spike RBD antigen construct.

[0023] Component-1: The SARS-CoV-2 spike protein receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein is fused at its N-terminus to the secretory signal peptide of human tissue plasminogen activator (htPA SP).

[0024] Component-2: SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori ( H. pylori The SARS-CoV-2 S protein's RBD is fused to bullfrog / Helicobacter pylori heterozygous ferritin (BFF) via a 9-amino acid linker at its C-terminus, and to htPA SP at its N-terminus.

[0025] Figure 2 Protein expression analysis of the SARS-CoV-2 spike RBD monomer and the SARS-CoV-2 spike RBD-BFF fusion protein encoded by recombinant MVA is shown.

[0026] HeLa cells were infected with recombinant MVA encoding construct-1 or construct-2. Cell lysates and supernatants were analyzed by Western blot using an anti-RBD antibody. Lysates were subjected to polyacrylamide gel electrophoresis (PAGE) under denaturing conditions (A); supernatants were subjected to PAGE under denaturing conditions (B) or non-denaturing (native) conditions (C). Lanes were labeled according to construct number (1: RBD monomer; 2: RBD-BFF).

[0027] Figure 3 Protein expression analysis of the SARS-CoV-2 spike RBD monomer and the SARS-CoV-2 spike RBD-BFF fusion protein encoded by VRP is shown.

[0028] HEK293T cells were transfected with a plasmid encoding a VEEV replicon controlled by a CMV promoter, which in turn encodes the VEEV TrD83 nonstructural protein, and construct-1 or construct-2 controlled by a VEEV subgenomic promoter. Cell lysates and supernatants were analyzed by Western blotting using an anti-RBD antibody. Lysates were subjected to polyacrylamide gel electrophoresis (PAGE) under denaturing conditions (A); supernatants were subjected to PAGE under denaturing conditions (B) or non-denaturing (native) conditions (C). Lanes were labeled according to construct number (1: RBD monomer; 2: RBD-BFF).

[0029] Figure 4 The in vivo immunogenicity of SARS-CoV-2 spike RBD monomers and BFF fusion proteins encoded by recombinant MVA or VRP was demonstrated.

[0030] On day 0 (initial vaccination) and day 21 of AC, use 1×10 8 Balb / c mice were intramuscularly immunized with recombinant MVA encoding the RBD monomer (MVA-RBD monomer) or RBD-BFF (MVA-RBD-BFF), or with buffer (control). On day 0 (primary immunization) and day 21 of DF, 1×10⁻⁶ MVA was administered. 8Balb / c mice were intramuscularly immunized with VRP or buffer (control) encoding the RBD monomer (VRP-RBD monomer) or RBD-BFF (VRP-RBD-BFF). Blood was drawn from AB and DE on day 34 post-primary immunization for serum separation. In A and D, anti-RBD Ig titers in serum were analyzed by ELISA on RBD-coated plates using anti-mouse IgG (H+L) antibodies at an initial dilution of 1:300 to determine total anti-RBD Ig titers. Random titers (AU = arbitrary units) were calculated using a 4PL fitted curve with an intercept of OD = 0.3. In B and E, RBD-binding antibody titers were assessed using the cPass SARS-CoV-2 neutralizing antibody detection kit (Genscript), and titers at 50% inhibition compared to the negative control were plotted. In C and F, mice were sacrificed on day 35 post-primary immunization, and single-cell suspensions of spleen cells were prepared. 0.5 × 10⁶ cells were used to separate the cells. 6 Cells were seeded in coated IFN-γ ELISpot plates and restimulated with spike peptide pool A (containing the RBD region) or control medium. The ELISpot plates were incubated overnight at 37°C, followed by color development. Data are presented as mean ± SEM.

[0031] Figure 5 It demonstrates improved germinal center formation and RBD-specific memory B cell induction by MVA-RBD-BFF.

[0032] Day 0, use 1×10 8 Balb / c mice were intramuscularly immunized with InfU of MVA-RBD monomer or MVA-RBD-BFF, or buffer (control). Inguinal and popliteal lymph nodes were isolated and collected on days 7 and 14 post-immunization. Single cells were stained with fluorescently labeled antibodies and fluorescently labeled RBD proteins and analyzed by flow cytometry to identify (A) germinal center (GC) B cells and (B) memory B cells. Data are presented as mean ± SEM.

[0033] Figure 6 The protein expression analysis of SARS-CoV-2 spike RBD monomers and BFF fusion proteins encoded by mRNA, saRNA, or plasmid DNA is shown.

[0034] HEK293T cells were transfected with mRNA, self-amplified RNA (saRNA), or plasmid DNA encoding construct-1 or construct-2, respectively. Cell lysates and supernatants were analyzed by Western blotting using an anti-RBD antibody. Lysates were subjected to polyacrylamide gel electrophoresis (PAGE) under denaturing conditions (A); supernatants were subjected to PAGE under denaturing conditions (B) or non-denaturing (native) conditions (C). Lanes were labeled according to construct number (1: RBD monomer; 2: RBD-BFF).

[0035] Figure 7 The in vivo immunogenicity of the SARS-CoV-2 spike RBD antigen encoded by saRNA was demonstrated.

[0036] Balb / c mice were intramuscularly immunized on days 0 (primary immunization) and 21 with 2.5 µg of saRNA-RBD monomer or saRNA-RBD-BFF mixed with in vivo-jetPEI®, or buffer (control). Serum was separated on day 41 post-primary immunization. Anti-RBD Ig titers in the serum were analyzed by ELISA. A standard for serum antibody quantification was established using anti-RBD antibodies. Mice were sacrificed on day 42 post-primary immunization, and single-cell suspensions of spleen cells were prepared. 0.5 × 10⁶ cells were then used to prepare the suspensions. 6 Cells were seeded in coated IFN-γ ELISpot plates and restimulated with spike peptide pool A (containing the RBD region) or control medium. IFN-γ-producing cells were visualized using a biotin-conjugated anti-IFNγ antibody in combination with streptavidin-HRP and AEC substrate. Spots were counted using an ELISpot reader. Data are presented as mean ± SEM.

[0037] Figure 8 The EBV gp350 antigen construct is illustrated schematically.

[0038] Construct-3A: The tetrameric EBV gp350-GCN4 (“gp350-GCN4”) in MVA-mBN443. A fragment (aa 1-434) of Epstein-Barr virus (EBV) glycoprotein 350 (gp350) is fused to a tetrameric domain derived from GCN4 via a 13-amino acid linker at the C-terminus.

[0039] Component-3B:Tetrameric EBV gp350-GCN4 (“gp350-GCN4”) in VRP. A fragment (aa 4-434) of Epstein-Barr virus (EBV) glycoprotein 350 (gp350) is fused at its C-terminus to a tetrameric domain derived from GCN4 via a 13-amino acid linker and at its N-terminus to the signal peptide IgK LC.

[0040] Component-4: EBV gp350-Bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“gp350-BFF”). A fragment of EBV gp350 (aa 2-434) is fused to bullfrog / Helicobacter pylori heterozygous ferritin (BFF) via a 10-amino acid linker at its C-terminus and to the signal peptide IgK LC at its N-terminus.

[0041] Figure 9 Protein expression analysis of the tetrameric EBV gp350 and BFF fusion protein encoded by recombinant MVA is shown.

[0042] HeLa cells were infected with recombinant MVA encoding construct-3A or construct-4. Cell lysates and supernatants were analyzed by Western blotting using an anti-gp350 antibody. Lysates were subjected to polyacrylamide gel electrophoresis (PAGE) under denaturing conditions (A); supernatants were subjected to PAGE under denaturing conditions (B) or non-denaturing (native) conditions (C). Lanes were labeled according to construct number (3A: gp350 tetramer; 4: gp350-BFF).

[0043] Figure 10 The in vivo immunogenicity of the EBV gp350-GCN4 and BFF fusion protein encoded by recombinant MVA or VRP was demonstrated.

[0044] On day 0 (initial vaccination) and day 21 of A and B, use 1×10 7 Balb / c mice were intramuscularly immunized with InfU of MVA-gp350-GCN4 (mBN443B) or MVA-gp350-BFF (mBN510), or buffer (control). On days C and D, day 0 (primary immunization) and day 21, 1×10⁻⁶ ions were administered. 8Balb / c mice were intramuscularly immunized with TU VRP-gp350-GCN4 [+gHgL] or VRP-gp350-BFF [+gHgL], or buffer (control). Blood was drawn from mice A and C on day 35 (MVA) or day 42 (VRP) post-primary immunization for serum separation. Serum anti-gp350 IgG titers were analyzed by ELISA on the same day. Standards for serum antibody quantification were established using anti-gp350 antibodies. Spleen cells were isolated from mice B and D on day 35 (MVA) or day 42 (VRP) post-primary immunization and restimulated with a gp350 peptide pool on anti-IFNγ-coated ELISPOT plates. Cells producing IFNγ were visualized using a combination of biotin-conjugated anti-IFNγ antibody, streptavidin-HRP, and AEC substrate. Spots were counted using an ELISPOT plate reader. Data are presented as mean ± SEM.

[0045] Figure 11 The in vivo immunogenicity of the EBV gp350 tetramer and BFF fusion protein encoded by recombinant MVA in outbred mice was demonstrated.

[0046] On day 0 (initial vaccination) and day 21 of A and B, use 1×10 8 Intramuscular immunization was performed on outbred CD1 mice using InfU of MVA-gp350-GCN4, MVA-gp350-BFF (mBN510), or TBS buffer (control). A. Blood was collected on day 40 post-immunization for serum separation to analyze anti-gp350 IgG titers by ELISA. A standard for serum antibody quantification was established using anti-gp350 antibodies. B. Spleen cells were isolated on day 41 post-immunization and restimulated with a gp350 peptide pool on anti-IFNγ-coated ELISpot plates. IFNγ-producing cells were visualized using a biotin-conjugated anti-IFNγ antibody combined with streptavidin-HRP and AEC substrates. Spots were counted using an ELISpot reader. Data are presented as mean ± SEM.

[0047] Figure 12 This illustration illustrates the Lyme disease antigen construct.

[0048] Component-5: A tandem of the C-terminal fragments of serotypes 1, 5, and 6 of OspA (“OspA ST1-5-6”). The signal peptide of human tissue plasminogen activator (htPA SP) is fused to the tandem of the C-terminal fragments (CF) of serotypes 1, 5, and 6 of OspA. The OspA CFs are separated from each other by (GGGGS)4 linkers.

[0049] Component-6:OspA serotypes 1, 5, and 6 C-terminal tandem fragments-Bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“OspA ST1-5-6-BFF”). The OspA C-terminal tandem fragments described above are fused to bullfrog / Helicobacter pylori heterozygous ferritin (BFF) at their C-terminus via a 9-amino acid linker.

[0050] Figure 13 The in vivo immunogenicity of the OspA-ST1-5-6 and BFF fusion protein encoded by recombinant VRP was demonstrated.

[0051] On day 0 (initial vaccination) and day 21, use 1×10 8 Balb / c mice were intramuscularly immunized with VRP encoding VRP-OspA-ST1-5-6 or VRP-OspA-ST1-5-6-BFF, or with buffer (control). Blood was collected on day 35 post-primary immunization for serum separation. Serum anti-OspA-ST1 Ig titers were analyzed by ELISA on OspA-ST1-coated plates using an HRP-conjugated anti-mouse IgG (Fc) antibody at an initial dilution of 1:300 to determine total anti-OspA-ST1 Ig titers. Random titers (AU = arbitrary units) were calculated using a 4PL fitted curve with an intercept of OD = 0.3. Data are presented as mean ± SEM.

[0052] Figure 14 Other nanoparticle candidates for fusion into antigens are described.

[0053] Nanoparticle candidates HisB, PdhC, DPS, SOR, and MrsD were identified using the Protein Database (PDB). Gaussian surface representation plots are shown to scale. White circles indicate N-termini, and black circles indicate C-termini. Tables detail the donor organisms, protein characteristics, and native functions of the particles. Images were generated using PyMol using PDB bioassemblies 5XDS, 1B5S, 1JTS, 2CB2, and 1P3Y.

[0054] Figure 15 This schematically illustrates a SARS-CoV-2 spike RBD antigen construct in which the antigen is fused to the N-terminus of a nanoparticle candidate.

[0055] Component-7: SARS-CoV-2 spike RBD-HisB fusion protein (“RBD-HisB”).

[0056] Component-8: SARS-CoV-2 spike protein RBD-PdhC fusion protein (“RBD-PdhC”).

[0057] Component-9: SARS-CoV-2 spike protein RBD-DPS fusion protein (“RBD-DPS”).

[0058] Component-10: SARS-CoV-2 spike protein RBD-SOR fusion protein (“RBD-SOR”).

[0059] Component-11: SARS-CoV-2 spike protein RBD-MrsD fusion protein (“RBD-MrsD”).

[0060] In constructs-7 to-11, the RBD of the SARS-CoV-2 spike protein is fused to [a specific structure / component] via a 9-amino acid linker. Figure 14 The N-terminus of one of the nanoparticle candidates shown is fused to htPA SP at the N-terminus of RBD.

[0061] Figure 16 Protein expression analysis of the SARS-CoV-2 spike RBD-nanoparticle candidate fusion protein is shown.

[0062] HEK293T cells were transfected with a plasmid encoding a VEEV replicon controlled by a CMV promoter, which encodes the VEEV TrD83 nonstructural protein, and one of constructs-5 through-9 controlled by a VEEV subgenomic promoter. Cell lysates and supernatants were analyzed by Western blotting using an anti-RBD antibody. Lysates were subjected to polyacrylamide gel electrophoresis (PAGE) under denaturing conditions (A); supernatants were subjected to PAGE under either denaturing conditions (B) or non-denaturing (native) conditions (C). Lanes were labeled according to construct number (7: RBD-HisB; 8: RBD-PdhC; 9: RBD-DPS; 10: RBD-SOR; 11: RBD-MrsD).

[0063] Figure 17 This schematically illustrates a SARS-CoV-2 spike RBD antigen construct in which the antigen is fused to the C-terminus of a nanoparticle candidate.

[0064] Construct-12 HisB-SARS-CoV-2 spike RBD fusion protein ("HisB-RBD").

[0065] Construct-13 DPS-SARS-CoV-2 spike RBD fusion protein (“DPS-RBD”).

[0066] Component-14:SOR-SARS-CoV-2 spike RBD fusion protein (“SOR-RBD”).

[0067] Component-15: MrsD-SARS-CoV-2 spike RBD fusion protein (“MrsD-RBD”).

[0068] In constructs-12 to-15, the RBD of the SARS-CoV-2 spike protein is fused to the C-terminus of the nanoparticle candidate via a 9-amino acid linker, and the RBD is then fused to htPA SP at its N-terminus.

[0069] Figure 18 The protein expression analysis of the SARS-CoV-2 spike RBD-nanoparticle candidate fusion protein, in which the antigen is fused to the C-terminus of the nanoparticle candidate, is shown.

[0070] HEK293T cells were transfected with a plasmid encoding a VEEV replicon controlled by a CMV promoter, which encodes the VEEV TrD83 nonstructural protein, and one of constructs-10 to-13 controlled by a VEEV subgenomic promoter. Cell lysates and supernatants were analyzed by Western blotting using an anti-RBD antibody. Lysates were subjected to polyacrylamide gel electrophoresis (PAGE) under denaturing conditions (A); supernatants were subjected to PAGE under either denaturing conditions (B) or non-denaturing (native) conditions (C). Lane 12: HisB-RBD; lanes were labeled according to construct number (13: DPS-RBD; 14: SOR-RBD; 15: MrsD-RBD).

[0071] Figure 19 The in vivo immunogenicity of the SARS-CoV-2 spike RBD antigen encoded by VRP and fused to the nanoparticle candidate was demonstrated.

[0072] On day 0 (initial vaccination) and day 21 of AC, use 1×10 8Balb / c mice were intramuscularly immunized with VRP-RBD monomers of TU, ​​VRPs encoding C-terminal (VRP-RBD-DPS) or N-terminal (VRP-DPS-RBD) fused to DPS, or VRPs encoding N-terminal fused to HisB (VRP-HisB-RBD). Blood was collected from AB on day 35 post-primary immunization for serum separation. A used anti-mouse IgG (H+L) antibody to analyze serum anti-RBD Ig titers on RBD-coated plates by ELISA at an initial dilution of 1:300 to determine total anti-RBD Ig titers. Random titers (AU = arbitrary units) were calculated using a 4PL fitted curve with an intercept of OD = 0.3. B assessed RBD-binding antibody titers using the cPass SARS-CoV-2 neutralizing antibody assay kit (Genscript) and plotted titers at 50% inhibition compared to the negative control. Mice were sacrificed 35 days after the initial immunization, and a single-cell suspension of spleen cells was prepared. 0.5 × 10⁻⁶ cells were then added. 6 Cells were seeded in IFNγ ELISpot plates and restimulated with spike peptide QPYRVVVLSFELLHAPA or control medium. The ELISpot plates were incubated overnight at 37°C before color development. Data are shown as mean ± SEM.

[0073] Figure 20 The in vivo immunogenicity of the SARS-CoV-2 spike RBD antigen encoded by VRP was demonstrated in outbred mice.

[0074] On day 0 (initial vaccination) and day 21 of A and B, use 1×10 8 Intramuscular immunization was performed on outbred CD1 mice using TU's VRP-RBD monomer, VRP-HisB-RBD, VRP-DPS-RBD, and VRP-RBD-BFF, or buffer (control). A. Blood was collected on day 42 post-primary immunization for serum separation to analyze anti-RBD IgG titers by ELISA. Standards for serum antibody quantification were established using anti-RBD antibodies. B. Spleen cells were isolated on day 42 post-primary immunization and restimulated with an RBD peptide pool on anti-IFNγ-coated ELISpot plates. IFNγ-producing cells were visualized using a biotin-conjugated anti-IFNγ antibody combined with streptavidin-HRP and AEC substrates. Spots were counted using an ELISpot reader. Data are presented as mean ± SEM.

[0075] Figure 21 The EBV gp350 antigen construct is illustrated schematically, in which the antigen is fused to the N-terminus of a nanoparticle candidate.

[0076] Component-16:EBV gp350-PdhC fusion protein (“gp350-PdhC”).

[0077] Component-17: EBV gp 350-DPS fusion protein (“gp350-DPS”).

[0078] In constructs-16 and-17, fragments of EBV gp350 (aa 2-434) are fused to PdhC and DPS via a 10-amino acid linker at their C-terminus, respectively, and to the signal peptide IgK LC at their N-terminus.

[0079] Figure 22 The in vivo immunogenicity of the gp350 antigen encoded by VRP and fused to the nanoparticle candidate was demonstrated.

[0080] Use 5 × 10 7 Balb / c mice were immunized intramuscularly with VRP-gp350-GCN4, VRP-gp350-BFF, VRP-DPS-gp350, or VRP-PdhC-gp350 as a primary-boost immunization. Buffer injection served as a control. Three weeks post-boost immunization (day 40), serum anti-gp350 IgG titers were analyzed by ELISA. For this purpose, ELISA plates were coated with gp350 protein and supplemented with serum at different dilutions. A standard for serum antibody quantification was established using an anti-gp350 antibody (clone 2L10; Merck) calculated using a standard curve in GraphPad Prism. Data are presented as mean ± SEM.

[0081] Figure 23 The constructs expressing multi-antigen nanoparticles are illustrated schematically, the multi-antigen nanoparticles containing SARS-CoV-2 spike RBD and EBV gp350 respectively fused to BFF.

[0082] Component-18: The EBV gp350-BFF fusion protein and the SARS-CoV-2 spike protein RBD-BFF fusion protein (“RBD-BFF-gp350-BFF”) are separated by the T2A site. EBV gp350 is fused to BFF and then to IgK LC SP via a 10-amino acid linker. The T2A site follows the sequence of the fusion protein. The RBD of the SARS-CoV-2 spike protein is fused to BFF and then to htPA SP via a 9-amino acid linker.

[0083] Figure 24Protein expression analysis of multiantigen nanoparticles is shown, which contain SARS-CoV-2 spike RBD and EBV gp350 fused to BFF respectively.

[0084] HEK293T cells were transfected with a plasmid encoding a VEEV replicon controlled by the CMV promoter. This VEEV replicon encodes the VEEV TrD83 nonstructural protein, and construct-18, construct-2, or construct-4 controlled by the VEEV subgenomic promoter. The cell supernatant was subjected to polyacrylamide gel electrophoresis (PAGE) under non-denaturing (native) conditions, and analyzed by Western blotting using anti-RBD, anti-gp350, or antiferritin antibodies. Lanes were labeled according to construct number (18: RBD-BFF-gp350-BFF; 2: RBD-BFF; 4: gp350-BFF).

[0085] Figure 25 The in vivo immunogenicity of multi-antigen nanoparticles was demonstrated, which contain SARS-CoV-2 spike RBD and EBV gp350 fused to BFF respectively.

[0086] On day 0 (initial vaccination) and day 21 of AD, use 1×10 8 Balb / c mice were intramuscularly immunized with TU's VRP-RBD-BFF, VRP-gp350-BFF, or VRP-RBD-BFF-gp350-BFF, or buffer (control). Blood was drawn from mice A and B on day 35 post-immunization for serum separation. Serum anti-gp350 and anti-RBD IgG titers were analyzed by ELISA. Standards for serum antibody quantification were established using anti-RBD antibody (A) or anti-gp350 antibody (B). Mice C and D were sacrificed on day 35 post-immunization, and single-cell suspensions of spleen cells were prepared. 0.5 × 10 6 Cells were seeded in coated IFN-γ ELISpot plates and restimulated with either spike peptide pool A (C) or gp350 pool D. The ELISpot plates were incubated overnight at 37°C before color development. Data are presented as mean ± SEM.

[0087] Figure 26 The Lyme disease antigen constructs are illustrated schematically, including constructs for displaying two different Lyme disease antigens on a BFF encoded by recombinant VRP.

[0088] Component-19:OspA serotypes 2, 4, and 3 C-terminal fragment tandem-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“OspA ST2-4-3-BFF”). The signal peptide of human tissue plasminogen activator (htPA SP) is fused to a tandem of the C-terminal fragments (CF) of OspA serotypes 2, 4, and 3. The OspA CFs are separated from each other by (GGGGS)4 linkers, and the tandem fragments are fused to bullfrog / Helicobacter pylori heterozygous ferritin (BFF) at their C-terminus via a 9-amino acid SSGGASVLA linker.

[0089] Component-20: The OspA ST2-4-3-BFF fusion protein and the OspA ST2-4-3-BFF fusion protein separated by the T2A site.

[0090] Figure 27 The in vivo immunogenicity of OspA-ST5-6-1 and OspA-ST5-6-1 encoded by VRP and fused to BFF was shown.

[0091] On day 0 (initial vaccination) and day 21 of AB, use 1×10 8 TU VRP-OspA-ST1-5-6-BFF plus 1×10 8 TUVRP-OspA-ST2-4-3-BFF or 1×10 8 Balb / c mice were intramuscularly immunized with TU VRP-OspA-ST1-5-6-BFF-ST2-4-3-BFF. Blood was collected on day 35 post-primary immunization for serum separation. A) Using an HRP-conjugated anti-mouse IgG (Fc) antibody on an OspA-ST1-coated plate, serum anti-OspA-ST1 Ig titer was determined by ELISA at an initial dilution of 1:300. B) Using an HRP-conjugated anti-mouse IgG (Fc) antibody on an OspA-ST2-coated plate, serum anti-OspA-ST2 Ig titer was determined by ELISA at an initial dilution of 1:300. Random titers (AU = arbitrary units) were calculated using a 4PL-fitted curve with an intercept of OD = 0.3. Data are presented as mean ± SEM.

[0092] Figure 28 The design of the reorganized MVA is explained.

[0093] A schematic representation of the transgenes contained in recombinant MVA-res065 and MVA-res067, respectively encoding the RBD secreted from the SARS-CoV-2 S protein (Wuhan-Hu-1 isolate) and the same RBD fused to the BFF protein that forms nanoparticles. Also shown is recombinant MVA mBN443B containing the designated transgene derived from Epstein-Barr virus (EBV). In mBN443, gp350 is fused to the GCN4 domain, resulting in tetramerization of the expressed gp350 domain. MVA-mBN510 contains the same transgenes as mBN443B, but arranged in a different design. Furthermore, in MVA-mBN510, amino acids 2-434 of the EBV gp350 are fused to the BFF protein that forms nanoparticles, instead of the GCN4 tetramerized domain.

[0094] Brief description of the sequence

[0095] SEQ ID NO: 1 is a nucleic acid sequence encoding the SARS-CoV-2 spike RBD.

[0096] SEQ ID NO: 2 is the amino acid sequence of the SARS-CoV-2 spike RBD.

[0097] SEQ ID NO: 3 is a nucleic acid sequence encoding EBV gp350.

[0098] SEQ ID NO: 4 is the amino acid sequence of EBV gp350.

[0099] SEQ ID NO: 5 is the nucleic acid sequence of bullfrog / Helicobacter pylori heterozygous ferritin.

[0100] SEQ ID NO: 6 is the amino acid sequence of bullfrog / Helicobacter pylori heterozygous ferritin.

[0101] SEQ ID NO: 7 is the nucleic acid sequence encoding HisB.

[0102] SEQ ID NO: 8 is the amino acid sequence of HisB.

[0103] SEQ ID NO: 9 is the nucleic acid sequence encoding PdhC.

[0104] SEQ ID NO: 10 is the amino acid sequence of PdhC.

[0105] SEQ ID NO: 11 is the nucleic acid sequence encoding DPS.

[0106] SEQ ID NO: 12 is the amino acid sequence of DPS.

[0107] SEQ ID NO: 13 is a nucleic acid sequence encoding SOR.

[0108] SEQ ID NO: 14 is the amino acid sequence of SOR.

[0109] SEQ ID NO: 15 is the nucleic acid sequence encoding MrsD.

[0110] SEQ ID NO: 16 is the amino acid sequence of MrsD.

[0111] SEQ ID NO: 17 is the nucleic acid sequence encoding the SARS-CoV-2 spike RBD (“constructor-1”) with the htPA signal peptide in the MVA.

[0112] SEQ ID NO: 18 is the nucleic acid sequence in VRP encoding the SARS-CoV-2 spike RBD (“constructor-1”) with the htPA signal peptide.

[0113] SEQ ID NO: 19 is the nucleic acid sequence encoding the SARS-CoV-2 spike RBD (“constructor-1”) with the htPA signal peptide in mRNA, saRNA and plasmid DNA.

[0114] SEQ ID NO: 20 is the amino acid sequence encoding the SARS-CoV-2 spike RBD (“constructor-1”) with the htPA signal peptide.

[0115] SEQ ID NO: 21 is the nucleic acid sequence in the MVA encoding a SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) with the htPA signal peptide.

[0116] SEQ ID NO: 22 is the nucleic acid sequence of VRP encoding a SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) with htPA signal peptide.

[0117] SEQ ID NO: 23 is the nucleic acid sequence of mRNA, saRNA and plasmid DNA encoding a SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) with htPA signal peptide.

[0118] SEQ ID NO: 24 is the amino acid sequence of a SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) with the htPA signal peptide.

[0119] SEQ ID NO: 25 is the nucleic acid sequence encoding the EBV gp350-GCN4 fusion protein (“constructor-3A”) in the MVA.

[0120] SEQ ID NO: 26 is the nucleic acid sequence of the EBV gp350-GCN4 fusion protein (“constructor-3B”) encoded with an IgK LC signal peptide in VRP.

[0121] SEQ ID NO: 27 is the amino acid sequence of the EBV gp350-GCN4 fusion protein (“constructor-3A, construct-3B”).

[0122] SEQ ID NO: 28 is the nucleic acid sequence of the EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-4”) encoded in the MVA with an IgK LC signal peptide.

[0123] SEQ ID NO: 29 is the nucleic acid sequence of VRP encoding an EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“constructor-4”) with an IgK LC signal peptide.

[0124] SEQ ID NO: 30 is the amino acid sequence of an EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-4”) with an IgK LC signal peptide.

[0125] SEQ ID NO: 31 is the nucleic acid sequence in VRP encoding a tandem fragment of OspA serotype 1, 5 and 6 C-terminal fragments with htPA signal peptide (OspA ST1-5-6) (“construct-5”).

[0126] SEQ ID NO: 32 is the amino acid sequence of the OspA serotype 1, 5 and 6 C-terminal fragment tandem (OspA ST1-5-6) (“construct-5”) containing the htPA signal peptide in VRP.

[0127] SEQ ID NO: 33 is the nucleic acid sequence in VRP encoding a tandem fragment of OspA serotype 1, 5 and 6 C-terminal fragments (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-6”).

[0128] SEQ ID NO: 34 is the amino acid sequence of the OspA serotype 1, 5 and 6 C-terminal fragment tandem (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-6”) with htPA signal peptide in VRP.

[0129] SEQ ID NO: 35 is the nucleic acid sequence of the SARS-CoV-2 spike RBD-HisB fusion protein (“constructor-7”) encoded with the htPA signal peptide in VRP.

[0130] SEQ ID NO: 36 is the amino acid sequence of the SARS-CoV-2 spike RBD-HisB fusion protein (“constructor-7”) with the htPA signal peptide.

[0131] SEQ ID NO: 37 is the nucleic acid sequence of VRP encoding the SARS-CoV-2 spike RBD-PdhC fusion protein (“constructor-8”) with the htPA signal peptide.

[0132] SEQ ID NO: 38 is the amino acid sequence of the SARS-CoV-2 spike RBD-PdhC fusion protein (“construct-8”) with the htPA signal peptide.

[0133] SEQ ID NO: 39 is the nucleic acid sequence of the SARS-CoV-2 spike RBD-DPS fusion protein (“construct-9”) encoded with the htPA signal peptide in VRP.

[0134] SEQ ID NO: 40 is the amino acid sequence of the SARS-CoV-2 spike RBD-DPS fusion protein (“constructor-9”) with the htPA signal peptide.

[0135] SEQ ID NO: 41 is the nucleic acid sequence of the SARS-CoV-2 spike RBD-SOR fusion protein (“constructor-10”) encoded with the htPA signal peptide in VRP.

[0136] SEQ ID NO: 42 is the amino acid sequence of the SARS-CoV-2 spike RBD-SOR fusion protein (“constructor-10”) with the htPA signal peptide.

[0137] SEQ ID NO: 43 is the nucleic acid sequence of VRP encoding the SARS-CoV-2 spike RBD-MrsD fusion protein (“constructor-11”) with the htPA signal peptide.

[0138] SEQ ID NO: 44 is the amino acid sequence of the SARS-CoV-2 spike RBD-MrsD fusion protein (“construct-11”) with the htPA signal peptide.

[0139] SEQ ID NO: 45 is the nucleic acid sequence of the HisB-SARS-CoV-2 spike RBD fusion protein (“constructor-12”) encoded with the htPA signal peptide in VRP.

[0140] SEQ ID NO: 46 is the amino acid sequence of the HisB-SARS-CoV-2 spike RBD fusion protein (“constructor-12”) with the htPA signal peptide.

[0141] SEQ ID NO: 47 is the nucleic acid sequence of the DPS-SARS-CoV-2 spike RBD fusion protein (“constructor-13”) encoded with the htPA signal peptide in VRP.

[0142] SEQ ID NO: 48 is the amino acid sequence of the DPS-SARS-CoV-2 spike RBD fusion protein (“constructor-13”) with the htPA signal peptide.

[0143] SEQ ID NO: 49 is the nucleic acid sequence of the SOR-SARS-CoV-2 spike RBD fusion protein (“constructor-14”) encoded with the htPA signal peptide in VRP.

[0144] SEQ ID NO: 50 is the amino acid sequence of the SOR-SARS-CoV-2 spike RBD fusion protein (“constructor-14”) with the htPA signal peptide.

[0145] SEQ ID NO: 51 is the nucleic acid sequence of the MrsD-SARS-CoV-2 spike RBD fusion protein (“constructor-15”) encoded with the htPA signal peptide in VRP.

[0146] SEQ ID NO: 52 is the amino acid sequence of the MrsD-SARS-CoV-2 spike RBD fusion protein (“construct-15”) with the htPA signal peptide.

[0147] SEQ ID NO: 53 is the nucleic acid sequence of the EBVgp350-PdhC fusion protein (“constructor-16”) encoded with an IgK LC signal peptide in VRP.

[0148] SEQ ID NO: 54 is the amino acid sequence of the EBVgp350-PdhC fusion protein (“constructor-16”) containing the IgK LC signal peptide in VRP.

[0149] SEQ ID NO: 55 is the nucleic acid sequence of VRP encoding the EBVgp350-DPS fusion protein (“Constructor-17”) with an IgK LC signal peptide.

[0150] SEQ ID NO: 56 is the amino acid sequence of the EBVgp350-DPS fusion protein (“constructor-17”) containing the IgK LC signal peptide in VRP.

[0151] SEQ ID NO: 57 is the nucleic acid sequence of VRP encoding EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with IgK LC signal peptide and SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with htPA signal peptide (“Constructor-18”).

[0152] SEQ ID NO: 58 is the amino acid sequence of an EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with an IgK LC signal peptide and a SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with an htPA signal peptide (“constructor-18”).

[0153] SEQ ID NO: 59 is the nucleic acid sequence in VRP encoding a tandem fragment of OspA serotype 2, 4 and 3 C-terminal fragments (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-19”).

[0154] SEQ ID NO: 60 is the amino acid sequence of the OspA serotype 2, 4 and 3 C-terminal fragment tandem (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-19”) with htPA signal peptide in VRP.

[0155] SEQ ID NO: 61 is the nucleic acid sequence in VRP encoding the OspA serotype 1, 5 and 6 C-terminal fragment tandem with htPA signal peptide separated by T2A sites (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein and the OspA serotype 2, 4 and 3 C-terminal fragment tandem with htPA signal peptide (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“Constructor-20”).

[0156] SEQ ID NO: 62 is the amino acid sequence of the tandem fragments of OspA serotype 1, 5 and 6 C-terminal fragments with htPA signal peptide (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein and the tandem fragments of OspA serotype 2, 4 and 3 C-terminal fragments with htPA signal peptide (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“Constructor-20”) separated by the T2A site (T2A site is indicated in bold).

[0157] SEQ ID NO: 63 is a nucleic acid sequence encoding the SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0158] SEQ ID NO: 64 is the amino acid sequence of the SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0159] SEQ ID NO: 65 is a nucleic acid sequence encoding the EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0160] SEQ ID NO: 66 is the amino acid sequence of the EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0161] SEQ ID NO: 67 is a nucleic acid sequence encoding the OspA serotype 1, 5 and 6 C-terminal tandem fragment (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0162] SEQ ID NO: 68 is the amino acid sequence of the OspA serotype 1, 5 and 6 C-terminal tandem fragment (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0163] SEQ ID NO: 69 is the nucleic acid sequence encoding the SARS-CoV-2 spike RBD-PdhC fusion protein.

[0164] SEQ ID NO: 70 is the amino acid sequence of the SARS-CoV-2 spike RBD-PdhC fusion protein.

[0165] SEQ ID NO: 71 is the nucleic acid sequence encoding the SARS-CoV-2 spike RBD-DPS fusion protein.

[0166] SEQ ID NO: 72 is the amino acid sequence of the SARS-CoV-2 spike RBD-DPS fusion protein.

[0167] SEQ ID NO: 73 is the nucleic acid sequence encoding the HisB-SARS-CoV-2 spike RBD fusion protein.

[0168] SEQ ID NO: 74 is the amino acid sequence of the HisB-SARS-CoV-2 spike RBD fusion protein.

[0169] SEQ ID NO: 75 is a nucleic acid sequence encoding the DPS-SARS-CoV-2 spike RBD fusion protein.

[0170] SEQ ID NO: 76 is the amino acid sequence of the DPS-SARS-CoV-2 spike RBD fusion protein.

[0171] SEQ ID NO: 77 is the nucleic acid sequence encoding the EBVgp350-PdhC fusion protein.

[0172] SEQ ID NO: 78 is the amino acid sequence of the EBVgp350-PdhC fusion protein.

[0173] SEQ ID NO: 79 is the nucleic acid sequence encoding the EBV gp350-DPS fusion protein.

[0174] SEQ ID NO: 80 is the amino acid sequence of the EBVgp350-DPS fusion protein.

[0175] SEQ ID NO: 81 is a nucleic acid encoding the OspA serotype 2, 4 and 3 C-terminal tandem fragment (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0176] SEQ ID NO: 82 is the amino acid sequence of the OspA serotype 2, 4 and 3 C-terminal fragment tandem (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0177] SEQ ID NO: 83 is a nucleic acid sequence encoding the htPA signal peptide.

[0178] SEQ ID NO: 84 is the amino acid sequence of the htPA signal peptide.

[0179] SEQ ID NO: 85 is a nucleic acid sequence encoding the IgK LC signal peptide.

[0180] SEQ ID NO: 86 is the amino acid sequence of the IgK LC signal peptide.

[0181] SEQ ID NO: 87 is a nucleic acid sequence encoding the 9aa linker sequence.

[0182] SEQ ID NO: 88 is the amino acid sequence of the 9aa linker sequence.

[0183] SEQ ID NO: 89 is a nucleic acid sequence encoding the 10aa linker sequence.

[0184] SEQ ID NO: 90 is the amino acid sequence of the 10aa linker sequence.

[0185] SEQ ID NO: 91 is a nucleic acid sequence encoding the 13aa linker sequence.

[0186] SEQ ID NO: 92 is the amino acid sequence of the 13aa linker sequence.

[0187] SEQ ID NO: 93 is a nucleic acid sequence encoding the (GGGGS)4 linker sequence.

[0188] SEQ ID NO: 94 is the amino acid sequence of the 1(GGGGS)4 linker sequence.

[0189] SEQ ID NO: 95 is the nucleic acid sequence encoding the T2A site.

[0190] SEQ ID NO: 96 is the amino acid sequence at the T2A site.

[0191] Nucleic acid sequence of SEQ ID NO: 97 Pr13.5 promoter.

[0192] Nucleic acid sequence of SEQ ID NO: 98 GCN4 polymerized domain.

[0193] The amino acid sequence of the GCN4 polymerized domain of SEQ ID NO: 99.

[0194] SEQ ID NO: 100 is the nucleic acid sequence encoding the fusion protein of the OspA C-terminal fragment ST1-5-6.

[0195] SEQ ID NO: 101 is the amino acid sequence of the fusion protein of the OspA C-terminal fragment ST1-5-6.

[0196] SEQ ID NO: 102 is the nucleic acid sequence encoding the fusion protein of the OspA C-terminal fragment ST2-4-3.

[0197] SEQ ID NO: 103 is the amino acid sequence of the fusion protein of the OspA C-terminal fragment ST2-4-3. Detailed Implementation

[0198] A potential objective of the present invention is to provide improved vaccines, particularly those that induce improved antibody responses. Protein antigens polymerized in regular arrays, such as protein antigens displayed on protein nanoparticles, are known to elicit strong antibody responses [4, 5]. An example of self-assembled nanoparticles used for antigen polymerization is bullfrog / Helicobacter pylori hybrid ferritin (BFF), a hybrid protein containing a portion of bullfrog ferritin and a portion of Helicobacter pylori ferritin, as described in Kanekiyo et al. 2015 [6]; WO 2015 / 054639.

[0199] Three different model antigens were used, namely, those from three different borborygmus ( Borrelia This paper reports a fusion protein consisting of the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein, the N-terminal domain fragment of Epstein-Barr virus (EBV) surface glycoprotein 350 (gp350), and the outer surface protein A (OspA) fragment. Enhanced antibody responses were observed in mice when antigens expressed by viral vectors, such as viral replicon particles (VRPs) derived from modified Ankara vaccinia virus (MVA) or Venezuelan equine encephalitis virus (VEEV), were conjugated to the BFF and delivered as an antigen-nanoparticle fusion protein. Similarly, the robust T-cell responses inherent in these viral vector vaccines were maintained. Importantly, the increased antibody and T-cell responses induced by MVA or VRP were obtained without adjuvant.

[0200] Therefore, viral vectors that deliver genes containing nanoparticle-conjugated antigens combine two highly desirable properties of vaccines: potent induction of humoral and cellular immunity.

[0201] In addition, it was shown that a similar immune response was achieved when the SARS-CoV-2 spike RBD presenting the BFF was encoded by RNA or DNA in the absence of a viral vector.

[0202] Furthermore, displaying antigens on the same BFF nanoparticles elicited antibody responses against SARS-CoV-2 RBD and EBVgp350. Similarly, antibody responses were observed against two different OspA antigens displayed on the same BFF nanoparticles.

[0203] However, antigen-nanoparticle conjugation methods are not applicable to all protein nanoparticles. This paper shows that nanoparticles formed from imidazole glycerol phosphate dehydratase (HisB), acetyltransferase complex (PdhC), or DNA-binding protein (DPS) from starved cells have proven to be useful alternatives to BFF. Enhanced antibody responses and maintained T-cell responses were observed in mice when the SARS-CoV-2 spike RBD antigen was displayed on HisB or DPS nanoparticles, and enhanced antibody responses were also observed when the EBV gp350 antigen was displayed on PdhC or DPS nanoparticles. In contrast, antigen-nanoparticle fusion proteins that form self-assembled nanoparticles with thiol oxidase / reductase (SOR) or mercasacin decarboxylase (MrsD) have also failed to be successfully secreted in cell culture.

[0204] BFF and PdhC can fuse to the antigen only via its C-terminus. However, HisB and DPS have exposed N-termini and C-termini, and the antigen can therefore fuse to the nanoparticle core protein via either its C-terminus or N-terminus. This study shows that conjugation of DPS to the SARS-CoV-2 spike RBD enhances antibody responses in mice while maintaining T-cell responses, regardless of the orientation of the nanoparticle and antigen fusion. In contrast, in cell culture, HisB fused to the SARS-CoV-2 spike RBD was successfully secreted and assembled only when the N-terminus of the antigen conjugated to the C-terminus of the nanoparticle. Since some antigens are naturally anchored at their N-terminus, the advantage of nanoparticles such as HisB and DPS is that nanoparticle antigen presentation can also be achieved with such antigens that maintain the orientation of the protein on the surface of bacteria or eukaryotic cells, viruses, or nanoparticles.

[0205] definition

[0206] It is important to note that, unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “described” as used herein include plural indicators. Therefore, for example, referring to “a nucleic acid sequence” includes one or more nucleic acid sequences.

[0207] As used herein, the connecting term "and / or" between multiple listed elements is understood to encompass both individual and combined options. For example, when two elements are connected by "and / or," the first option refers to the applicability of the first element in the absence of the second element. The second option refers to the applicability of the second element in the absence of the first element. The third option refers to the applicability of the first and second elements together. Any of these options is understood to fall within the aforementioned meaning and therefore satisfies the requirement of the term "and / or" as used herein. Simultaneous applicability of more than one option is also understood to fall within the aforementioned meaning and therefore satisfies the requirement of the term "and / or."

[0208] Throughout the specification and appended claims, unless the context otherwise requires, the word “comprise” and variations such as “comprises” and “comprising” should be understood to imply inclusion of the specified features but not exclusion of any other features. When used in the context of one aspect or embodiment of the invention, the term “comprise” may be modified and thus replaced by the terms “containing” or “including,” or, as used herein, by the term “having.” Similarly, any of the foregoing terms (comprise, containing, including, having), whenever used in the context of one aspect or embodiment of the invention, includes the terms “consisting of” or “substantially consisting of,” each carrying a specific legal meaning depending on the jurisdiction.

[0209] When used herein, "consisting of" excludes any feature, element, step, or ingredient not specified in the claims. When used herein, "consisting substantially of" does not exclude features, materials, or steps that do not materially affect the essential and novel features of the claims.

[0210] "Aspect" refers to the concept of the invention in its broadest sense; it may correspond to an independent claim. "Scheme" is a particular form or implementation or specific instance of the invention; it may correspond to a dependent claim.

[0211] As used herein, the term "recombinant" refers to a nucleic acid that is not naturally occurring but is produced through genetic engineering. For example, a "recombinant MVA" is an MVA containing a nucleic acid sequence inserted into its genome that is not naturally present in wild-type viruses (i.e., is foreign or heterologous for the MVA). Therefore, a recombinant MVA is an MVA artificially composed of two or more segments of a nucleic acid sequence of synthetic or semi-synthetic origin, said nucleic acid sequence not found in nature or linked to another nucleic acid in an arrangement not found in nature. A recombinant MVA is a genetically engineered or genetically modified MVA. As used herein, the term "recombinant MVA" includes an MVA in which at least one recombinant nucleic acid (preferably in the form of a transcription unit) has been integrated into its genome. Recombinant MVAs can express heterologous peptides, polypeptides, or proteins (antigens) under the induction of regulatory elements (e.g., promoters).

[0212] As used in the context of viral vectors in this article, the term "heterologous nucleic acid" means that the nucleic acid is foreign to the viral vector, that is, it is not naturally present in the viral vector.

[0213] As used herein, the term "construct" refers to an artificial nucleic acid, peptide, or protein produced through genetic engineering. Nucleic acid constructs may contain viral vectors, RNA, or plasmid DNA as described herein.

[0214] The term "viral replicon particle" or "VRP" refers to a genetically engineered infectious viral particle that is unable to produce progeny viruses due to the partial or complete deletion of at least one structural gene. VRPs comply with guidelines for safe vaccines and gene delivery systems.

[0215] As used herein, the term "replicon" refers to a nucleic acid containing the following: the 5' UTR of an alphavirus (such as Venezuelan equine encephalitis virus (VEEV)), the gene encoding non-structural proteins (nsp) 1, 2, 3, and 4 of the alphavirus, the alphavirus subgenome promoter and subgenome 5' UTR, the gene for expressing a heteropeptide, polypeptide, or protein (antigen), the alphavirus 3' UTR, and the poly(A) sequence.

[0216] The term "fusion protein" refers to a recombinant protein comprising at least two independent amino acid segments or proteins (e.g., protein domains) that are artificially conjugated to be transcribed and translated into a single protein. In most cases, the two independent amino acid segments are conjugated using a linker sequence, but they can also conjugate directly with each other. As used herein, the term "fusion protein" generally describes a protein formed by the fusion of an antigen and a protein nanoparticle subunit.

[0217] As used herein, the term "signal peptide" refers to a peptide added to the N-terminus of a newly synthesized protein in a cell, which allows the protein to translocate to the cell membrane and subsequently be secreted.

[0218] As used herein, the term “self-assembling protein nanoparticles,” sometimes simply “self-assembling nanoparticles,” “protein nanoparticles,” or “nanoparticles,” refers to polymer assemblies of monomeric peptides (called “subunits”) that can guide their self-assembly into nanoparticles.

[0219] As used herein, the term "multi-antigen protein nanoparticle" refers to a self-assembled protein nanoparticle assembled from two or more different fusion proteins that display two or more different antigens but share the same nanoparticle forming subunits, thereby enabling the nanoparticle to display multiple antigens on its surface, in contrast to homotype self-assembled protein nanoparticles that display a single type of antigen.

[0220] A “2A site,” “T2A site,” or “P2A site” is a peptide sequence that causes translation to terminate and restart in a co-translational manner, leaving a peptide bond to allow the expression of a separate protein in an open reading frame (ORF).

[0221] As used herein, the term "adjuvant" refers to a compound that enhances the immune response to an antigen. For example, a pharmaceutical composition containing both a vaccine antigen and an adjuvant will elicit an enhanced immune response in a subject compared to a pharmaceutical composition containing a vaccine antigen but no adjuvant.

[0222] abbreviation

[0223] Implementation plan and other aspects

[0224] Aspects and implementation schemes related to recombinant virus-based vectors

[0225] In one aspect, a recombinant virus-based vector is provided, the recombinant virus-based vector comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated protein or a portion thereof, the disease-associated protein or a portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle.

[0226] In one implementation scheme, the vector based on the recombinant virus is derived from a DNA virus or an RNA virus.

[0227] In one implementation, the vector based on the recombinant virus is a recombinant DNA virus, preferably a recombinant poxvirus.

[0228] In one implementation, the vector based on the recombinant virus is a recombinant RNA virus, preferably a recombinant viral replicon particle (VRP).

[0229] In one embodiment, the recombinant virus-based vector further comprises another heterologous nucleic acid operatively linked to a promoter, wherein the other heterologous nucleic acid encodes a fusion protein comprising another disease-associated protein or a portion thereof, the other disease-associated protein or a portion thereof binding to a subunit of a self-assembled protein nanoparticle, preferably wherein the disease-associated protein and the other disease-associated protein are different. More preferably, the subunits of the self-assembled protein nanoparticles binding to the disease-associated protein and the subunits of the self-assembled protein nanoparticles binding to the other disease-associated proteins belong to the same type of self-assembled protein nanoparticle.

[0230] In another aspect, a recombinant virus-based vector is provided, the recombinant virus-based vector comprising: (a) A first heteronucleotide operatively linked to a promoter, wherein the first heteronucleotide encodes a first fusion protein comprising a first disease-associated protein or a portion thereof, the first disease-associated protein or a portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; and (b) A second heteronucleotide operatively linked to a promoter, wherein the second heteronucleotide encodes a second fusion protein comprising a second disease-associated protein or a portion thereof, the second disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle.

[0231] Preferably, the first disease-related protein and the second disease-related protein are different. More preferably, the subunits of the self-assembled protein nanoparticles that bind to the first disease-associated protein and the subunits of the self-assembled protein nanoparticles that bind to the second disease-associated protein belong to the same type of self-assembled protein nanoparticles.

[0232] In one embodiment of the recombinant virus-based vector, the first and second heteronucleotides are conjugated by a heteronucleotide encoding a 2A peptide, preferably the T2A peptide as shown in SEQ ID NO: 96. Alternatively, the first and second heteronucleotides may be conjugated by an internal ribosome entry site (IRES).

[0233] Aspects and implementation plans related to recombinant poxvirus

[0234] In one aspect, a recombinant poxvirus is provided comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated protein or a portion thereof, the disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle.

[0235] In one embodiment, the poxvirus is an orthopoxvirus, preferably a vaccinia virus, more preferably a modified Ankara vaccinia virus (MVA), and most preferably MVA-BN. ® .

[0236] In one implementation, the recombinant poxvirus is derived from a member of the genera *Avianpoxvirus*, *Orthopoxvirus*, or *Paraphoxvirus*.

[0237] In one implementation of the recombinant poxvirus, members of the genus *Avavivirus* are selected from the group consisting of: canarypoxvirus, fowlpoxvirus, mynapoxvirus, pigeonpoxvirus, and quailpoxvirus.

[0238] In one implementation, members of the Parapoxvirus genus are selected from the group consisting of: bovine papuloblastic stomatitis virus, ORF virus, New Zealand red deer parapoxvirus, and pseudovaccinia virus.

[0239] In one implementation, members of the genus Orthopoxvirus are selected from the group consisting of: buffalopoxvirus, camelpoxvirus, cowpoxvirus, mousepoxvirus, monkeypoxvirus, raccoonpoxvirus, smallpox virus / variolavirus, or vaccinia virus (VACV).

[0240] In one implementation, the recombinant poxvirus is a recombinant vaccinia virus.

[0241] In one embodiment, the recombinant vaccinia virus is derived from wild-type vaccinia virus or attenuated vaccinia virus strains, preferably selected from the group consisting of: vaccinia virus-Western Reserve strain, vaccinia virus-Copenhagen strain, Dryvax (vaccinia virus-Wyeth), ACAM2000, chorioallantoic Ankara vaccinia virus (CVA), or modified Ankara vaccinia virus (MVA).

[0242] In one implementation, the recombinant poxvirus is derived from an attenuated poxvirus vector selected from the group consisting of ALVAC (canary poxvirus-based vector), NYVAC (vaccinia virus vector), and MVA.

[0243] In one implementation, the recombinant poxvirus is a recombinant MVA.

[0244] In one embodiment, the recombinant MVA is derived from wild-type MVA or an MVA derivative, which has the ability to reproduce in vitro in chicken embryonic fibroblast (CEF) cells but not in human keratinocyte line HaCaT, human osteosarcoma cell line 143B, human embryonic kidney cell line 293, and human cervical adenocarcinoma cell line HeLa.

[0245] In one implementation, the recombinant MVA is derived from an MVA-BN deposited on August 30, 2000, at the European Collection of Animal Cell Cultures (ECACC) with accession number V00083008. ® .

[0246] In one implementation of recombinant poxvirus, the promoter is a poxvirus promoter.

[0247] In one implementation, the vaccinia virus promoter is selected from the group consisting of: promoters Pr11, Pr7.5, PrSSL, PrATI, and PrS; Pr13.5long / Pr13.5, PrHyb, Pr1328, PrH2R, and PrH5m, preferably Pr13.5long.

[0248] In one implementation, the poxvirus promoter comprises or is composed of a nucleic acid as shown in SEQ ID NO: 97.

[0249] In one embodiment, the recombinant vaccinia virus is a recombinant MVA, and the heterologous nucleic acid is inserted into an intergenic region (IGR) in the MVA genome, wherein the IGR is selected from the group consisting of: IGR 44 / 45, 51 / 52, 64 / 65, 88 / 89 and 148 / 149, preferably IGR 64 / 65.

[0250] In one embodiment, the recombinant vaccinia virus is a recombinant MVA comprising a heterologous nucleic acid operatively linked to a vaccinia virus promoter, wherein the heterologous nucleic acid encodes a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle, wherein the vaccinia virus promoter is Pr13.5long and the heterologous nucleic acid is inserted at IGR 64 / 65 in the MVA genome. Preferably, the disease-associated antigen is derived from SARS-CoV-2, preferably SARS-CoV-2 S RBD, or from EBV, preferably EBV gp350. Preferably, the self-assembled protein nanoparticle is BFF.

[0251] In one embodiment, the recombinant vaccinia virus is a recombinant MVA comprising a heterologous nucleic acid operatively linked to a vaccinia virus promoter, wherein the heterologous nucleic acid encodes an EBV gp350 antigen or an antigenic moiety thereof, the antigen or antigenic moiety thereof binding to a subunit of a self-assembled protein nanoparticle. Preferably, the vaccinia virus promoter is Pr13.5long. Preferably, the heterologous nucleic acid is inserted at IGR 64 / 65 in the MVA genome. Preferably, the self-assembled protein nanoparticle is BFF.

[0252] In one implementation, the recombinant vaccinia virus is a recombinant MVA, the recombinant MVA comprising: (i) a first heterologous nucleic acid operatively linked to a vaccinia virus promoter, wherein the heterologous nucleic acid encodes an EBVgp350 antigen or an antigenic moiety thereof, the antigen or antigenic moiety thereof binding to a subunit of a self-assembled protein nanoparticle; preferably, wherein the vaccinia virus promoter is Pr13.5long; preferably, wherein the self-assembled protein nanoparticle is BFF; and (ii) A second heterologous nucleic acid operatively linked to a vaccinia virus promoter, wherein the heterologous nucleic acid encodes EBV gH and / or EBV gL, preferably gH and gL separated from each other by a P2A site, or an antigenic portion thereof; preferably, wherein the vaccinia virus promoter is PrS; Preferably, the first heteronucleotide and the second heteronucleotide are inserted at IGR 64 / 65 in the MVA genome.

[0253] In one embodiment, the recombinant vaccinia virus is a recombinant MVA comprising (i) a first heteronucleotide as described above and (ii) a second heteronucleotide as described above, said recombinant MVA further comprising: (iii) A third heteronucleotide operatively linked to a vaccinia virus promoter, wherein the heteronucleotide encodes a BZLF1-BRLF1 fusion protein or an antigenic portion thereof, preferably wherein the vaccinia virus promoter is Pr13.5long; and (iv) A fourth heteronucleotide operatively linked to a vaccinia virus promoter, wherein the heteronucleotide encodes EBNA3A or its antigenic portion, preferably wherein the vaccinia virus promoter is Pr1328; Preferably, the third heteronucleotide and the fourth heteronucleotide are inserted at IGR 88 / 89 in the MVA genome.

[0254] In one embodiment, the recombinant poxvirus further comprises another heterologous nucleic acid operatively linked to a promoter, wherein said other heterologous nucleic acid encodes a fusion protein comprising another disease-associated protein or a portion thereof, said other disease-associated protein or a portion thereof binding to a subunit of a self-assembled protein nanoparticle, preferably wherein said disease-associated protein and said other disease-associated proteins are different. More preferably, the subunits of the self-assembled protein nanoparticles binding to the disease-associated protein and the subunits of the self-assembled protein nanoparticles binding to other disease-associated proteins belong to the same type of self-assembled protein nanoparticle.

[0255] In another aspect, a recombinant poxvirus is provided, the recombinant poxvirus comprising: (a) A first heteronucleotide operatively linked to a promoter, wherein the first heteronucleotide encodes a first fusion protein comprising a first disease-associated protein or a portion thereof, the first disease-associated protein or a portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; and (b) A second heteronucleotide operatively linked to a promoter, wherein the second heteronucleotide encodes a second fusion protein comprising a second disease-associated protein or a portion thereof, the second disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle; Preferably, the first disease-related protein and the second disease-related protein are different; More preferably, the subunits of the self-assembled protein nanoparticles that bind to the first disease-associated protein and the subunits of the self-assembled protein nanoparticles that bind to the second disease-associated protein belong to the same type of self-assembled protein nanoparticles.

[0256] In one embodiment of the recombinant vaccinia virus, the first and second heteronucleotides are conjugated by a heteronucleotide encoding a 2A peptide, preferably the T2A peptide as shown in SEQ ID NO: 96. Alternatively, the first and second heteronucleotides may be conjugated by an internal ribosome entry site (IRES).

[0257] In another aspect, a process for preparing a recombinant poxvirus as described herein is provided, the process comprising the following steps: (1) Provide transcription units as described herein.

[0258] (2) Insert the transcription unit prepared in step (1) into the vaccinia virus genome; (3) Obtain the recombinant poxvirus.

[0259] Aspects and implementation plans related to VRP restructuring

[0260] In one aspect, a recombinant viral replicon particle (VRP) is provided, the recombinant VRP comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated protein or a portion thereof, the disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle.

[0261] In one implementation, recombinant VRP is a recombinant alphavirus replicon particle.

[0262] In one implementation, the recombinant VRP is derived from Venezuelan equine encephalitis virus (VEEV), preferably from VEEV TC83 strain and / or TrD strain.

[0263] In one implementation of recombinant VRP, the promoter is the VEEV TC83 genome promoter.

[0264] In one implementation of recombinant VRP, the promoter is the VEEV TC83 subgenome promoter.

[0265] In one embodiment, the recombinant VRP further comprises another heterologous nucleic acid operatively linked to a promoter, wherein said other heterologous nucleic acid encodes a fusion protein comprising another disease-associated protein or a portion thereof, said other disease-associated protein or a portion thereof binding to a subunit of a self-assembled protein nanoparticle, preferably wherein said disease-associated protein and said other disease-associated proteins are different. More preferably, the subunits of the self-assembled protein nanoparticles binding to the disease-associated protein and the subunits of the self-assembled protein nanoparticles binding to other disease-associated proteins belong to the same type of self-assembled protein nanoparticle.

[0266] In another aspect, a recombined VRP is provided, the recombined VRP comprising: (a) A first heteronucleotide operatively linked to a promoter, wherein the first heteronucleotide encodes a first fusion protein comprising a first disease-associated protein or a portion thereof, the first disease-associated protein or a portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; and (b) A second heteronucleotide operatively linked to a promoter, wherein the second heteronucleotide encodes a second fusion protein comprising a second disease-associated protein or a portion thereof, the second disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle; Preferably, the first disease-related protein and the second disease-related protein are different. More preferably, the subunits of the self-assembled protein nanoparticles that bind to the first disease-associated protein and the subunits of the self-assembled protein nanoparticles that bind to the second disease-associated protein belong to the same type of self-assembled protein nanoparticles.

[0267] In one embodiment of recombinant VRP, the first and second heteronucleotides are conjugated by a heteronucleotide encoding a 2A peptide, preferably the T2A peptide as shown in SEQ ID NO: 96. Alternatively, the first and second heteronucleotides may be conjugated by an internal ribosome entry site (IRES).

[0268] In another aspect, a process for preparing recombinant VRP as described herein is provided, the process comprising the following steps: (1) Provide plasmid DNA encoding a self-amplifying replicon RNA, preferably a replicon RNA controlled by a cytomegalovirus (CMV) promoter, the replicon RNA encoding a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof being linked to a subunit of a self-assembled protein nanoparticle as described herein; (2) Transfect VRP production cells, preferably HEK293T suspension cells, with the recombinant replicon plasmid provided in step (1). Further transfect the VRP production cells with a packaging plasmid driven by a first CMV promoter encoding the alphavirus capsid protein (preferably derived from pcDNA3.1) and a packaging plasmid driven by a second CMV promoter encoding the alphavirus envelope protein (preferably derived from pcDNA3.1). (3) Cultivate the transfected VRP production cells described in step (2); (4) Obtain the recombinant VRP.

[0269] In another aspect, a plasmid DNA is provided that encodes a self-amplifying replicon RNA, preferably a replicon RNA controlled by cytomegalovirus (CMV), the replicon RNA encoding a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle.

[0270] Aspects and implementation schemes related to transcription units

[0271] In one aspect, a transcription unit is provided comprising a nucleic acid operatively linked to a promoter, wherein the nucleic acid encodes a fusion protein comprising a disease-associated protein or a portion thereof, the disease-associated protein or a portion thereof being bound to a subunit of a self-assembling protein nanoparticle.

[0272] In one implementation, the transcription unit is contained within a poxvirus. In this case, the nucleic acid is heterologous relative to the poxvirus.

[0273] In one implementation, the transcription unit is contained within the VRP. In this case, the nucleic acid is heterologous relative to the VRP.

[0274] In one implementation of the transcription unit, the promoter is a poxvirus promoter.

[0275] In one embodiment of the transcription unit, the vaccinia virus promoter is selected from the group consisting of: promoters Pr11, Pr7.5, PrSSL, PrATI, and PrS; Pr13.5long / Pr13.5, PrHyb, Pr1328, PrH2R, and PrH5m, preferably Pr13.5long.

[0276] In one implementation, the poxvirus promoter comprises or is composed of a nucleic acid as shown in SEQ ID NO: 97.

[0277] In one implementation of the transcription unit, the nucleic acid further encodes a signal peptide that binds to the fusion protein.

[0278] In another aspect, there is provided the use of a transcription unit as described herein for the preparation of recombinant vaccinia virus, preferably recombinant vaccinia virus, more preferably recombinant MVA.

[0279] In another aspect, a use of transcription units as described herein for the preparation of VRPs is provided.

[0280] Aspects and implementation methods related to RNA molecules

[0281] In one aspect, an RNA molecule is provided that encodes a fusion protein comprising a disease-associated antigen or a portion thereof, the disease-associated protein or a portion thereof binding to a subunit of a self-assembled protein nanoparticle.

[0282] In one implementation, the RNA molecule is the pharmacologically active agent. For example, nucleic acids can induce the translation of antigen proteins in a subject.

[0283] In one implementation, the RNA molecule is not contained in a virus-based vector.

[0284] In one embodiment, the RNA molecule is messenger RNA (mRNA) or self-amplifying RNA (saRNA). Preferably, the RNA molecule is saRNA.

[0285] In one embodiment, the mRNA or saRNA further comprises a poly(A) tail of multiple adenines, the poly(A) tail being located downstream of the heteronucleotide encoding the fusion protein, preferably more than 100 adenines, and most preferably 120 adenines.

[0286] In one implementation, the mRNA or saRNa may further include a capped structure or a pseudo-capped structure.

[0287] In one implementation, the RNA molecule further encodes a signal peptide that binds to the fusion protein.

[0288] In one embodiment, the RNA molecule further comprises another heterologous nucleic acid, wherein the other nucleic acid encodes a fusion protein comprising another disease-associated protein or a portion thereof, the other disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle, preferably wherein the disease-associated protein and the other disease-associated protein are different, more preferably wherein the nanoparticles are the same.

[0289] In another aspect, an RNA molecule, preferably mRNA or saRNA, is provided, said RNA molecule comprising: (a) A first segment of a heterologous nucleic acid, wherein the first segment encodes a first fusion protein comprising a first disease-associated protein or a portion thereof, the first disease-associated protein or a portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; and (b) A second segment of a heterologous nucleic acid, wherein the second segment encodes a second fusion protein comprising a second disease-associated protein or a portion thereof, the second disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle; The first disease-related protein and the second disease-related protein are different, and more preferably, the self-assembled protein nanoparticles are the same.

[0290] In one embodiment of the recombinant virus-based vector, the first and second heteronucleotides are conjugated by a heteronucleotide encoding a 2A peptide, preferably the T2A peptide as shown in SEQ ID NO: 96. Alternatively, the first and second heteronucleotides may be conjugated by an internal ribosome entry site (IRES).

[0291] In another aspect, a process for preparing RNA molecules as described herein is provided, the process comprising the following steps: (1) Provide a nucleic acid encoding a fusion protein as described herein, the fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle as described herein; (2) Generate an RNA molecule containing the nucleic acid provided in step (1); (3) Obtain the RNA molecule produced in step (2).

[0292] Aspects and implementation methods related to expression plasmids

[0293] In one aspect, a DNA molecule is provided that encodes a fusion protein comprising a disease-associated antigen or a portion thereof, the disease-associated protein or a portion thereof binding to a subunit of a self-assembled protein nanoparticle.

[0294] In one implementation, the DNA molecule is an expression plasmid.

[0295] In another aspect, an expression plasmid is provided comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated protein or a portion thereof, the disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle.

[0296] In one implementation, the expression plasmid is based on pcDNA 3.1.

[0297] In one implementation, the promoter is the cytomegalovirus (CMV) promoter.

[0298] In one embodiment, the expression plasmid further comprises another heterologous nucleic acid, wherein the other nucleic acid encodes a fusion protein comprising another disease-associated protein or a portion thereof, the other disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle, preferably wherein the disease-associated protein and the other disease-associated protein are different, more preferably wherein the nanoparticles are the same.

[0299] In another aspect, an expression plasmid is provided, the expression plasmid comprising: (a) A first segment of a heterologous nucleic acid, wherein the first segment encodes a first fusion protein comprising a first disease-associated protein or a portion thereof, the first disease-associated protein or a portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; and (b) A second segment of a heterologous nucleic acid, wherein the second segment encodes a second fusion protein comprising a second disease-associated protein or a portion thereof, the second disease-associated protein or a portion thereof being bound to a subunit of a self-assembled protein nanoparticle; The first disease-related protein and the second disease-related protein are different, and more preferably, the self-assembled protein nanoparticles are the same.

[0300] In one embodiment of the expression plasmid, the first and second heteronucleotides are conjugated by a heteronucleotide encoding a 2A peptide, preferably the T2A peptide as shown in SEQ ID NO: 96. Alternatively, the first and second heteronucleotides may be conjugated by an internal ribosome entry site (IRES).

[0301] In another aspect, a process for preparing expression plasmids as described herein is provided, the process comprising the following steps: (1) Provide a nucleic acid encoding a fusion protein as described herein, the fusion protein comprising a disease-associated antigen or an antigenic portion thereof as described herein, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle as described herein; (2) Insert the nucleic acid provided in step (1) into the expression plasmid; (3) Obtain the expression plasmid generated in step (2).

[0302] Implementation plans related to heterologous nucleic acids

[0303] The following implementation schemes may relate to any aspect described herein.

[0304] In one implementation of recombinant poxvirus, the heterologous nucleic acid is DNA.

[0305] In one implementation of recombinant VRP, the heterologous nucleic acid is RNA.

[0306] In one implementation, the heterologous nucleic acid further encodes a signal peptide that binds to the fusion protein.

[0307] In one embodiment, the heterologous nucleic acid comprises or is composed of a nucleic acid as shown in or composed of any of the following: SEQ ID NO: 17, 18, 19, SEQ ID NO: 21, 22, 23, SEQ ID NO: 25, 26, SEQ ID NO: 28, 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47 or SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61. In one embodiment, the fusion protein is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with a nucleic acid sequence shown as one of the following: SEQ ID NO: 17, 18, 19, SEQ ID NO: 21, 22, 23, SEQ ID NO: 25, 26, SEQ ID NO: 28, 29, SEQ ID NO: 31, SEQ ID NO: 33, SEQ ID NO: 35, SEQ ID NO: 37, SEQ ID NO: 39, SEQ ID NO: 41, SEQ ID NO: 43, SEQ ID NO: 45, SEQ ID NO: 47, SEQ ID NO: 49, SEQ ID NO: 51, SEQ ID NO: 53, SEQ ID NO: 55, SEQ ID NO: 57, SEQ ID NO: 59, SEQ ID NO: 61.

[0308] In one embodiment, the heterologous nucleic acid comprises or consists of a nucleic acid encoding or having an amino acid sequence as shown in one of the following: SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62. In one embodiment, the fusion protein is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with an amino acid sequence shown in one of the following: SEQ ID NO: 20, SEQ ID NO: 24, SEQ ID NO: 27, SEQ ID NO: 30, SEQ ID NO: 32, SEQ ID NO: 34, SEQ ID NO: 36, SEQ ID NO: 38, SEQ ID NO: 40, SEQ ID NO: 42, SEQ ID NO: 44, SEQ ID NO: 46, SEQ ID NO: 48, SEQ ID NO: 50, SEQ ID NO: 52, SEQ ID NO: 54, SEQ ID NO: 56, SEQ ID NO: 58, SEQ ID NO: 60, SEQ ID NO: 62.

[0309] In one aspect, the use of heterologous nucleic acids for the preparation of virus-based vectors, recombinant poxviruses, or recombinant VRPs is provided.

[0310] Implementation plans related to fusion proteins

[0311] The following embodiments relate to a fusion protein encoded by a virus-based vector, recombinant poxvirus, recombinant VRP, RNA molecule, or expression plasmid, and these may relate to any of the aspects described herein.

[0312] In one embodiment, the fusion protein can participate in the self-assembly of the fusion protein into self-assembled protein nanoparticles, preferably into oligomeric or polymeric proteins composed of monomeric fusion proteins.

[0313] In one embodiment, the fusion protein maintains the ability for subunits of self-assembling protein nanoparticles contained in the fusion protein to participate in the self-assembly of the fusion protein into self-assembling protein nanoparticles.

[0314] In one embodiment, the linker is located between a disease-related protein or a portion thereof and a subunit of the self-assembled nanoparticle.

[0315] In one embodiment, the linker is a nine-amino acid linker, preferably SSGGASVLA, preferably as shown in SEQ ID NO: 88, and / or encoded by a nucleic acid as shown in SEQ ID NO: 87.

[0316] In one embodiment, the linker is a nine-amino acid linker that binds an antigen, preferably SARS-CoV-2 RBD or an antigen derived from Leptospira OspA, to the BFF.

[0317] In one embodiment, the linker is a nine-amino acid linker that binds the antigen, preferably SARS-CoV-2 RBD, to HisB, PdhC, or DPS.

[0318] In one embodiment, the linker is a ten-amino acid linker, preferably PKPSTPPGSS, preferably as shown in SEQ ID NO: 90, and / or encoded by a nucleic acid as shown in SEQ ID NO: 89.

[0319] In one embodiment, the linker is a ten-amino acid linker that binds the antigen, preferably EBV350, to BFF, PdhC, or DPS.

[0320] In one implementation, the fusion protein is encoded by a nucleic acid molecule as described herein, such as a heterologous nucleic acid as described herein.

[0321] In one embodiment, the fusion protein is encoded by a nucleic acid comprising or composed of one of the following: SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81. In another embodiment, the fusion protein is encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with one of the following: SEQ ID NO: 63, SEQ ID NO: 65, SEQ ID NO: 67, SEQ ID NO: 69, SEQ ID NO: 71, SEQ ID NO: 73, SEQ ID NO: 75, SQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81.

[0322] In one embodiment, the heteronucleotide comprises or is composed of a nucleic acid encoding or having an amino acid sequence as shown in one of the following: SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 80, SEQ ID NO: 82. In one embodiment, the fusion protein is encoded by a nucleic acid sequence having an amino acid sequence identity of at least 80%, 85%, 90%, 95%, 97%, or 99% with an amino acid sequence as shown in one of the following: SEQ ID NO: 64, SEQ ID NO: 66, SEQ ID NO: 68, SEQ ID NO: 70, SEQ ID NO: 72, SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 80, SEQ ID NO: 82.

[0323] Implementation plans related to disease-associated proteins

[0324] The following implementation schemes may relate to any aspect described herein.

[0325] In one implementation, the disease-associated protein is selected from the group consisting of: viruses, bacteria, fungi, plants, parasites, non-human animals, and human proteins.

[0326] In one implementation, the disease-related protein is a gene therapy protein.

[0327] In one implementation, the disease-associated protein or a portion thereof contains one or more antigenic determinants (i.e., antigenic portions recognized by the immune system, also known as epitopes).

[0328] In one implementation, the disease-associated protein is a disease-associated antigen.

[0329] In one implementation, a portion of the disease-associated protein is its antigenic portion.

[0330] In one implementation, the disease-associated protein is an infectious disease-associated antigen.

[0331] In one embodiment, the disease-associated antigen is a viral antigen, preferably derived from a virus selected from the group consisting of: alpha virus, adenovirus, Chikungunya virus, Coxsackie virus, Crimean-Congo hemorrhagic fever virus, cytomegalovirus (CMV), dengue virus, Ebola virus, Epstein-Barr virus (EBV), Eastern equine encephalitis virus, Western equine encephalitis virus, or Venezuelan equine encephalitis virus (EEV), Guanarito virus. Herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2), human herpesvirus type 8 (HHV-8), hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), hepatitis D virus (HDV), hepatitis E virus (HEV), human immunodeficiency virus (HIV), influenza virus, Juninvirus, Lassa virus, Machupo virus, Marburg virus, measles virus, human metapneumovirus, mumps virus, Norwalk virus, human papillomavirus (HPV), parainfluenza virus, parvovirus, poliovirus, rabies virus, respiratory syncytial virus (RSV), rhinovirus, rotavirus, rubella virus, Sabia virus, severe acute respiratory syndrome virus 2. (SARS-CoV-2), Middle East Respiratory Syndrome Coronavirus (MERS-CoV), Varicella-zoster virus, Smallpox virus, West Nile virus, Yellow fever virus, and Zika virus.

[0332] In one embodiment, the disease-associated antigen is derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), preferably comprising or consisting of a receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein or an antigenic portion thereof (SARS-CoV-2 S RBD).

[0333] In a preferred embodiment, the disease-associated antigen is encoded by a nucleic acid sequence as shown in SEQ ID NO: 1.

[0334] In a preferred embodiment, the disease-associated antigen comprises or is composed of an amino acid sequence as shown in SEQ ID NO: 2.

[0335] In a preferred embodiment, the disease-associated antigen is encoded by a nucleic acid, which encodes an amino acid sequence as shown in SEQ ID NO: 2.

[0336] In a more preferred embodiment, the disease-associated antigen comprises or consists of amino acids 331-524 of the SARS-CoV-2 S protein. Most preferably, the disease-associated antigen comprises or consists of amino acids 320-537 of the full-length SARS-CoV-2 S1 domain.

[0337] In another embodiment, the disease-associated antigen is derived from Epstein-Barr virus (EBV), preferably selected from the group consisting of: EBV protein BLLF1a / b (gp350 / 220), BALF4 (gB, gp110), BXLF2 (gH, gp85), BKRF2 (gL, gp25), BZLF2 (gp42), BILF2 (gp78), BDLF3 (gp150), BBRF3 (gM), BLRF1 (gN), BMRF2, EBNA1, EBNA2, EBNA3, LMP1, LMP2, BRLF1, or BZLF1 protein, preferably EBV surface glycoprotein 350 (EBV gp350) or an antigenic portion thereof.

[0338] In a preferred embodiment, the disease-associated antigen is encoded by a nucleic acid sequence as shown in SEQ ID NO: 3.

[0339] In a preferred embodiment, the disease-associated antigen comprises or is composed of an amino acid sequence as shown in SEQ ID NO: 4.

[0340] In a preferred embodiment, the disease-associated antigen is encoded by a nucleic acid, which encodes an amino acid sequence as shown in SEQ ID NO: 4.

[0341] In a more preferred embodiment, the disease-associated antigen comprises or consists of amino acids 2-434 of EBV gp350.

[0342] In one embodiment, the disease-associated antigen is a bacterial antigen, preferably derived from bacteria selected from the group consisting of: Bacillus anthracis (…). Bacillus anthracis Bordetella pertussis ( ) Bordetella pertussis ), Borrelia burgdorferi in the narrow sense ( Borrelia burgdorferi sensu stricto ), generalized Borrelia burgdorferi ( Borrelia burgdorferi sensu lato Brucella abortus ( ) Brucella abortus Brucella canis (Brucella canis Brucella medullaris () Brucella melitensis ), swine brucellosis ( Brucella suis Burkholderia mallei, Burkholderia mallei (…), Burkholderia mallei (…) Burkholderia pseudomallei ), Campylobacter jejuni ( Campylobacter jejuni ), Chlamydia pneumoniae ( Chlamydia pneumoniae ), Chlamydia trachomatis ( Chlamydia trachomatis ), Chlamydia psittaci ( Chlamydophila psittaci ), Clostridium botulinum ( Clostridium botulinum Clostridium difficile ( Clostridium difficile Clostridium perfringens ( Clostridium perfringens Clostridium tetani Clostridium tetani Corynebacterium diphtheriae Corynebacterium diptheriae ), Enterococcus faecalis ( Enterococcus faecalis ), Enterococcus faecalis ( Enterococcus faecium ), Escherichia coli ( Escherichia coli ), enterotoxigenic Escherichia coli, enteropathogenic Escherichia coli, Escherichia coli 157:H7, Tula Francisella ( Francisella tularensis Haemophilus influenzae ( ) Haemophilus influenza Helicobacter pylori ( Helicobacter pylori Legionella pneumophila ( Legionella pneumophila ), question mark hook-tip spiral ( Leptospira interrogans Listeria monocytogenes ( Listeria monocytogenes Mycobacterium leprae ( Mycobacterium leprae ), Mycobacterium tuberculosis ( Mycobacterium tuberculosis Mycoplasma pneumoniae () Mycoplasma pneumoniae ), Neisseria gonorrhoeae ( Neisseria gonorrhoeae ), Neisseria meningitidis ( Neisseria meningitidis ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa ), Rickettsia rickettsii ( Rickettsia rickettsia ), Salmonella typhi Salmonella typhi Salmonella typhimurium ( Salmonella typhimurium Shigella sonnei ( Shigella sleepy Staphylococcus aureus Staphylococcus aureus Staphylococcus epidermidis () Staphylococcus epidermis ), saprophytic Staphylococcus ( Staphylococcus saprophyticus ), agalactococcus ( Streptococcus agalactiae Streptococcus pneumoniae () Streptococcus pneumoniae ), Streptococcus pyogenes ( Streptococcus pyogenes ), Treponema pallidum ( Treponema pallidum ), Vibrio cholerae ( Vibrio cholera ) and Yersinia pestis ( Yersinia pestis ).

[0343] In another embodiment, the disease-associated antigen is a Lyme disease antigen. Preferably, the disease-associated antigen is derived from borborygmus, more preferably from borborygmus outer surface protein A (OspA) or its antigenic portion.

[0344] In a preferred embodiment, the disease-associated antigen comprises or consists of one, two, three or more antigen fragments of OspA. Even more preferably, the disease-associated antigen comprises or consists of a tandem of three C-terminal fragments of OspA, preferably separated from each other by (GGGGS)4 linkers.

[0345] In a more preferred embodiment, the disease-associated antigen comprises or is composed of the following fusion proteins: amino acids 126-273 of OspA serotype 1 (ST1) from Borrelia burgdorferi (strain B31), amino acids 126-273 from Borrelia gamaliformis (strain B31), and amino acids 126-273 from Borrelia gamaliformis (strain B31). Borrelia garinii Amino acids 126-273 of OspA ST5 from (PHei strain) and amino acids 126-274 of OspA ST6 from Borrelia galbana (DK29) are separated from each other by (GGGGS)4 linkers.

[0346] In another preferred embodiment, the disease-associated antigen comprises or is composed of the following fusion protein: derived from *Borrelia argentis* (… Borrelia afzelii The amino acid composition of OspA serotype 2 (ST2) from strain K78 was 126-273, derived from *Breospirochetes bavaria*. Borrelia bavariensis Amino acids 126-273 of OspA ST4 from (PBi strain) and amino acids 126-274 of OspA ST3 from Gorgorhizium anisopliae (PBr) are separated from each other by (GGGGS)4 linkers.

[0347] In a particularly preferred embodiment, the disease-associated antigen is encoded by a nucleic acid sequence as shown in SEQ ID NO: 100 or SEQ ID NO: 102.

[0348] In a particularly preferred embodiment, the disease-associated antigen comprises or consists of an amino acid sequence as shown in SEQ ID NO: 101 or SEQ NO: 103.

[0349] In a particularly preferred embodiment, the disease-associated antigen is encoded by a nucleic acid, which encodes an amino acid sequence as shown in SEQ ID NO: 101 or SEQ ID NO: 103.

[0350] In one embodiment, the disease-associated antigen is a fungal antigen, preferably derived from fungi selected from the group consisting of Aspergillus lanceolata. (Aspergillus clavatus) Aspergillus flavus (Yellow Aspergillus) Aspergillus fumigatus (Aspergillus fumigatus) Aspergillus nidus (Aspergillus nidulans) Aspergillus niger (Aspergillus black) Aspergillus terreus (Aspergillus terreus) dermatitis blastomyces (Blastomyces dermatitidis) Candida albicans (Candida albicans) Candida dublin (Candida dubliniensis) Candida glabrata (Candida glabrata) Candida glabrata (Candida parapsilosis) Candida folds (Candida wrinkled) Tropical Candida (Candida tropicalis) Cryptococcus albus (Cryptococcus albidus) Cryptococcus greteensis (Cryptococcus gattii) Cryptococcus laureate (Cryptococcus laurentii) Cryptococcus neoformans (Cryptococcus neoformans) Histoplasma capsulatum (Histoplasma capsulatum) , Microsporum canis (Microsporum canis) Pneumocystis carinii (Pneumocystis carinii) Pneumocystis jirovecii (Pneumocystis jirovecii) Schenck's Sporothrix (Sporothrix schenckii) paper grape spike mold (Stachbotrys paper) Tinea benign prostatic hyperplasia (Beard moth) Tinea capitis (Captive tinea) Tinea corporis (Thrush body) Tinea cruris (Leg ringworm) tinea (Face ringworm) Hidden Tinea (Incognito ringworm) Black Tinea (Black moth) Tinea versicolor (Tinea versicolor) Trichophyton rubrum (Trichophyton rubrum) and Trichophyton truncatum (Trichophyton tonsurans).

[0351] In some embodiments, the disease-associated antigen is a parasitic antigen, preferably from parasites selected from the group consisting of: *Anisakis* genus (… Anisakis spp .), Babesia ( Babesia spp. ), Raccoon Bellis roundworm ( Baylisascaris procyonisCryptosporidium ( ) Cryptosporidium spp. ), Cayetana Cyclospora ( Cyclospora cayetanensis ), genus *Cephalotaxus* ( Diphyllobothrium spp. ), Dracina worm ( Dracunculus medinensis ), Entamoeba histolytica ( Entamoeba histolytica Giardia lamblia ( ) Giardia duodenalis Giardia lamblia ( Giardia intestinalis ), Giardia lamblia ( Giardia lamblia Leishmania ( ) Leishmania sp. ), Plasmodium falciparum ( Plasmodium falciparum ), Plasmodium vivax ( Plasmodium vivax Schistosoma mansoni ( Schistosoma mansoni Schistosoma haematobium ( Schistosoma haematobium ), Schistosoma japonicum ( Schistosoma japonicum ), Taenia genus ( Taenia spp .), Toxoplasma gondii ( Toxoplasma gondii Trichinella ( ) Trichinella spiralis ) and Trypanosoma cruzi ( Trypanosoma cruzi ).

[0352] In one implementation, the disease-related protein is a tumor-specific antigen (TSA) or a tumor-associated antigen (TAA).

[0353] Implementation schemes related to self-assembled protein nanoparticles

[0354] The following implementation schemes may relate to any aspect described herein.

[0355] In one implementation, the subunits of the self-assembled protein nanoparticles are monomeric proteins.

[0356] In one embodiment, the self-assembled protein nanoparticles are oligomeric or polymeric proteins composed of monomeric subunits.

[0357] In one implementation, the subunits of the self-assembling protein nanoparticles are capable of participating in the subunit self-assembly into self-assembling protein nanoparticles.

[0358] In one embodiment, the subunits of the self-assembled protein nanoparticles are full-length subunits of the self-assembled protein nanoparticles.

[0359] In one embodiment, the subunit of the self-assembling protein nanoparticle is a functional fragment of the full-length subunit, that is, a fragment that maintains the ability of the full-length subunit to participate in the subunit self-assembly into the self-assembling protein nanoparticle.

[0360] In one embodiment, the functional fragment comprises at least 50, 75, 100, or 150 consecutive amino acids of the full-length subunit of a self-assembled protein nanoparticle.

[0361] In one embodiment, the functional fragment comprises an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence of the full-length subunit of the self-assembled protein nanoparticle.

[0362] In one embodiment, the self-assembled protein nanoparticles consist of 12, 24, or 60 subunits.

[0363] In one implementation, the subunits constituting the self-assembled protein nanoparticles are arranged in tetrahedral, octahedral, or icosahedral symmetry.

[0364] In one embodiment, the 12, 24, or 60 subunits constituting the self-assembling protein nanoparticles can self-assemble into 12-polymer, 24-polymer, or 60-polymer protein nanoparticles, respectively.

[0365] In one embodiment, the subunits of the self-assembled protein nanoparticles are capable of binding to disease-related proteins via the N-terminus and / or C-terminus of the subunit.

[0366] In one embodiment, the self-assembled protein nanoparticles are selected from the group consisting of: heterozygous bullfrog / Helicobacter pylori heterozygous ferritin (BFF), imidazole glycerol phosphate dehydratase (HisB), acetyltransferase of pyruvate dehydrogenase (PDH) complex (PdhC), and DNA-binding protein (DPS) from starved cells.

[0367] In one embodiment, the self-assembled protein nanoparticles are hybrid proteins BFF. Preferably, the BFF comprises bullfrog (American bullfrog) Rana catesbeiana Ferritin consists of amino acids 2-9 and Helicobacter pylori ferritin consists of amino acids 3-167 or the same.

[0368] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence as shown in SEQ ID NO: 5. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the nucleic acid sequence shown in SEQ ID NO: 5.

[0369] In one embodiment, the self-assembled nanoparticles comprise or consist of an amino acid sequence as shown in SEQ ID NO: 6. In another embodiment, the self-assembled nanoparticles comprise or consist of an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 6.

[0370] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence as shown in SEQ ID NO: 6. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO: 6.

[0371] In one embodiment, the self-assembled protein nanoparticles are HisB, PdhC, or DPS, preferably HisB or DPS.

[0372] In one implementation, HisB is derived from Mycobacterium tuberculosis.

[0373] In one embodiment, the self-assembled protein nanoparticles contain or consist of amino acids 9-210 of HisB.

[0374] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence as shown in SEQ ID NO: 7. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the nucleic acid sequence shown in SEQ ID NO: 7.

[0375] In one embodiment, the self-assembled nanoparticles comprise or consist of an amino acid sequence as shown in SEQ ID NO: 8. In another embodiment, the self-assembled nanoparticles comprise or consist of an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 8.

[0376] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence as shown in SEQ ID NO: 8. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO: 8.

[0377] In one implementation, PdhC is derived from *Bacillus stearothermophilus*. Geo- ) Bacillus stearothermophilus (PdhC).

[0378] In one embodiment, the self-assembled protein nanoparticles comprise or consist of amino acids 185-428 of PdhC.

[0379] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence as shown in SEQ ID NO: 9. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the nucleic acid sequence shown in SEQ ID NO: 9.

[0380] In one embodiment, the self-assembled nanoparticles comprise or consist of an amino acid sequence as shown in SEQ ID NO: 10. In another embodiment, the self-assembled nanoparticles comprise or consist of an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 10.

[0381] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence as shown in SEQ ID NO: 10. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 10.

[0382] In one implementation, DPS are derived from Escherichia coli.

[0383] In one embodiment, the self-assembled protein nanoparticles comprise or consist of amino acids 11-167 of DPS.

[0384] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence as shown in SEQ ID NO: 11. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the nucleic acid sequence shown in SEQ ID NO: 11.

[0385] In one embodiment, the self-assembled nanoparticles comprise or consist of an amino acid sequence as shown in SEQ ID NO: 12. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence shown in SEQ ID NO: 12.

[0386] In one embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence as shown in SEQ ID NO: 12. In another embodiment, the self-assembled nanoparticles are encoded by a nucleic acid sequence that encodes an amino acid sequence having at least 80%, 85%, 90%, 95%, 97%, or 99% sequence identity with the amino acid sequence as shown in SEQ ID NO: 12.

[0387] In one embodiment, the self-assembled protein nanoparticle is BFF, and the disease-associated antigen is SARS-CoV-2S RBD, EBV gp350, or derived from OspA.

[0388] In one implementation, the self-assembled protein nanoparticles are HisB, PdhC, or DPS, and the disease-associated antigen is SARS-CoV-2 S RBD.

[0389] In one embodiment, the self-assembled protein nanoparticle is a BFF, wherein the N-terminus of the BFF is bound to the C-terminus of a disease-associated antigen.

[0390] In one embodiment, the self-assembled protein nanoparticle is PdhC, wherein the N-terminus of PdhC is bound to the C-terminus of a disease-associated antigen.

[0391] In one embodiment, the self-assembled protein nanoparticle is a DPS, wherein the N-terminus of the DPS is attached to the C-terminus of a disease-associated antigen, or wherein the C-terminus of the DPS is attached to the N-terminus of a disease-associated antigen.

[0392] In one embodiment, the self-assembled protein nanoparticle is HisB, wherein the C-terminus of HisB is bound to the N-terminus of a disease-associated antigen.

[0393] In one implementation, the N-terminus of BFF is conjugated to the C-terminus of SARS-CoV-2 S RBD, EBV gp350, or an antigen derived from OspA.

[0394] In one implementation, the N-terminus of PdhC is conjugated to the C-terminus of SARS-CoV-2 S RBD or EBV gp350.

[0395] In one implementation, the N-terminus of DPS is conjugated to the C-terminus of SARS-CoV-2 S RBD or EBV gp350.

[0396] In one implementation, the C-terminus of the DPS binds to the N-terminus of the SARS-CoV-2 S RBD.

[0397] In one implementation, the C-terminus of HisB binds to the N-terminus of the SARS-CoV-2 S RBD.

[0398] Implementation schemes related to signal peptides

[0399] The following implementation schemes may involve any aspect as described herein.

[0400] In one embodiment, the signal peptide that binds to the fusion protein can allow or promote the cellular secretion of the fusion protein.

[0401] In one embodiment, the signal peptide is the human tissue plasminogen activator (htPA) signal peptide or the mouse immunoglobulin κ light chain (IgK LC) signal peptide.

[0402] In one embodiment, the signal peptide is encoded by a nucleic acid sequence as shown in SEQ ID NO: 83 or SEQ ID NO: 85.

[0403] In one embodiment, the signal peptide comprises or consists of an amino acid sequence as shown in SEQ ID NO: 84 or SEQ ID NO: 86.

[0404] In one implementation, the disease-associated antigen is SARS-CoV-2 S RBD, and the signal peptide is the htPA signal peptide.

[0405] In one implementation, the disease-associated antigen is EBV gp350, and the signal peptide is an IgK LC signal peptide.

[0406] In one implementation, the disease-associated antigen is SARS-CoV-2 S RBD, the self-assembled protein nanoparticles are selected from the group consisting of BFF, HisB, PdhC and DPS, and the signal peptide is the htPA signal peptide.

[0407] In one embodiment, the disease-associated antigen is EBV gp350, the self-assembled protein nanoparticle is BFF, and the signal peptide is IgK LC signal peptide.

[0408] In one embodiment, the signal peptide binds to the N-terminus of the fusion protein.

[0409] In one embodiment, the N-terminus of a subunit of a self-assembled protein nanoparticle is attached to the C-terminus of a disease-associated antigen, and a signal peptide is attached to the N-terminus of the disease-associated antigen.

[0410] In one embodiment, the C-terminus of a subunit of a self-assembled protein nanoparticle is attached to the N-terminus of a disease-associated antigen, and a signal peptide is attached to the N-terminus of a subunit of the self-assembled protein nanoparticle.

[0411] Aspects and implementation methods related to the pharmaceutical composition

[0412] In one aspect, a pharmaceutical composition is provided comprising a recombinant virus-based vector, recombinant poxvirus, recombinant VRP, RNA molecule, or expression plasmid as described herein.

[0413] In one embodiment, the pharmaceutical composition is a vaccine.

[0414] In one embodiment, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier or excipient.

[0415] In one embodiment, the pharmaceutical composition comprising a recombinant virus-based vector, recombinant poxvirus, or recombinant VRP does not contain an adjuvant.

[0416] In one embodiment, the pharmaceutical composition comprising an RNA molecule or an expression plasmid includes an adjuvant.

[0417] In one embodiment, the pharmaceutical composition comprises an RNA molecule or expression plasmid and also comprises a pharmaceutically acceptable nucleic acid transfection reagent, i.e., a component that allows or supports the uptake of nucleic acids into cells.

[0418] In one embodiment, the pharmaceutical composition comprises an mRNA molecule and also comprises a lipid-based carrier, i.e., a component having the ability to encapsulate and deliver nucleic acids to a target tissue, such as lipid nanoparticles (LNPs).

[0419] In another aspect, a process for preparing a pharmaceutical composition as described herein is provided, the process comprising the following steps: (1) Provide a nucleic acid encoding a fusion protein as described herein, the fusion protein comprising a disease-related protein or a portion thereof, the disease-related protein or a portion thereof binding to a subunit of a self-assembled protein nanoparticle; (2) Generate a vector, recombinant vaccinia virus, recombinant VRP, RNA molecule or expression plasmid as described herein that contains the nucleic acid provided in step (1); (3) Obtain the recombinant virus-based vector, the recombinant poxvirus, the recombinant VRP, the RNA molecule or the expression plasmid generated in step (2); (4) Combine the recombinant virus-based vector, the recombinant poxvirus, the recombinant VRP, the RNA molecule or the expression plasmid obtained in step (3) with a pharmaceutically acceptable vector or excipient.

[0420] Aspects and implementation plans related to the reagent kit

[0421] In one aspect, a kit or kit is provided comprising a first container and a second container, optionally including at least one other container, each container containing a pharmaceutical composition as described herein.

[0422] In one implementation, the kit or kit is designed for a primary-boost regimen.

[0423] Aspects and implementation plans related to medical use

[0424] In one aspect, a vector, recombinant poxvirus, recombinant VRP, RNA molecule, or expression plasmid based on recombinant viruses as described herein is provided for the prevention or treatment of disease, preferably for the prevention of disease.

[0425] In another aspect, a pharmaceutical composition as described herein is provided for the prevention or treatment of a disease, preferably for the prevention of a disease.

[0426] In another aspect, there is provided the use of a recombinant virus-based vector, recombinant poxvirus, recombinant VRP, RNA molecule, expression plasmid or pharmaceutical composition as described herein for the manufacture of an agent for the prevention or treatment of disease, preferably for the prevention of disease.

[0427] In one implementation, the disease is an infectious disease or cancer.

[0428] In one implementation, the disease is cancer associated with an infectious disease.

[0429] In one implementation, the disease is a viral or bacterial infectious disease.

[0430] In one implementation, the disease is a malignant tumor associated with or caused by a viral or bacterial infection.

[0431] In one implementation, the disease is COVID-19 or long COVID.

[0432] In one implementation, the disease is EBV infection, such as infectious mononucleosis.

[0433] In one implementation, the disease is an EBV-related cancer, such as Hodgkin lymphoma, Burkitt lymphoma, or nasopharyngeal carcinoma.

[0434] In one implementation, the disease is Lyme disease or spirochetal infection.

[0435] In one embodiment, the pharmaceutical composition is administered to the subject intramuscularly, subcutaneously, or intranasally, preferably intramuscularly.

[0436] In one implementation, the drug composition is administered to the subject once, twice, three times, or more.

[0437] In one implementation, the drug composition is administered to the subject as part of a primary-boost regimen.

[0438] In one implementation, the subject is a mammal, such as a farm animal, pet, or human, preferably a human.

[0439] Aspects and implementation plans related to medical treatment

[0440] In one aspect, a medical treatment for a disease, or a disease prevention measure, or a vaccination or vaccination regimen is provided, including administering a pharmaceutical composition or vaccine as described herein to a subject.

[0441] In one aspect, the present invention provides a method for preventing or treating an infectious disease or cancer, the method comprising the step of administering to a subject a composition as described herein, such as a composition comprising a recombinant virus-based vector, recombinant poxvirus, recombinant VRP, RNA molecule, or expression plasmid as described herein. The present invention provides a method for preventing or treating an infectious disease or cancer, the method comprising the step of administering to a subject a pharmaceutical composition or vaccine as described herein. In some embodiments, the step of administering the composition includes intramuscular injection of the composition.

[0442] In one aspect, the present invention provides a method for inducing an immune response to an infectious disease or cancer, the method comprising the step of administering to a subject a composition as described herein, such as a composition comprising a recombinant virus-based vector, recombinant poxvirus, recombinant VRP, RNA molecule, or expression plasmid as described herein. The present invention also provides a method for inducing an immune response to an infectious disease or cancer, the method comprising the step of administering to a subject a pharmaceutical composition or vaccine as described herein. In some embodiments, the step of administering the composition includes intramuscular injection of the composition.

[0443] In some embodiments, the step of administering a composition as described herein to a subject induces an immune response in the subject, such as the production of antibodies (e.g., neutralizing antibodies). In this manner, the present invention provides a method for stimulating an immune response in a subject, the method comprising the step of administering a pharmaceutical composition or vaccine to the subject thereby inducing an immune response. For example, an immune response is allegedly induced in the subject if antibodies specific to a disease-related protein are present in the subject after administration of the composition. For example, an immune response is allegedly induced in the subject if antibodies recognizing a full-length disease-related protein or a portion thereof or an antigenic determinant are generated in the subject after administration of a recombinant virus-based vector, recombinant VRP, fusion protein, and / or self-assembled protein nanoparticles. The measurement of antibodies in the subject can be any of a variety of methods well known in the art.

[0444] In some embodiments, the administration of the recombinant MVA and / or pharmaceutical composition induces the production of antigen-binding antibodies, the induction of antigen-specific T-cell responses (preferably CD8 T-cell responses), and / or the induction of antigen-specific B-cell responses. Preferably, the antigen-binding antibodies, T-cell responses, and / or B-cell responses are against the full-length disease-associated protein or a portion thereof or an antigenic determinant. In one embodiment, the composition as described herein is administered to a subject more than once, for example, as an initial dose and one or more subsequent "boost" doses.

[0445] Aspects and implementation schemes related to recombinant virus-based vectors encoding multi-antigen protein nanoparticles

[0446] In one aspect, a recombinant virus-based vector is provided, the recombinant virus-based vector comprising: (a) A first heteronucleotide operatively linked to a promoter, wherein the first heteronucleotide encodes a first fusion protein comprising a first disease-associated antigen or an antigenic portion thereof, the first disease-associated antigen or an antigenic portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; and (b) A second heteronucleotide operatively linked to a promoter, wherein the second heteronucleotide encodes a second fusion protein comprising a second disease-associated antigen or an antigenic portion thereof, the second disease-associated antigen or an antigenic portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; The first disease-associated antigen and the second disease-associated antigen are different, and the self-assembled protein nanoparticles are the same in each case.

[0447] In one embodiment, the recombinant virus-based vector encoding multi-antigen protein nanoparticles is a recombinant vaccinia virus, preferably a recombinant vaccinia virus, and more preferably a recombinant modified Ankara vaccinia virus (MVA).

[0448] In one embodiment, the recombinant virus-based vector encoding the multi-antigen protein nanoparticles is a recombinant viral replicon particle (VRP), preferably derived from Venezuelan equine encephalitis virus (VEEV), more preferably from VEEV TC83 strain and / or TrD strain.

[0449] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the self-assembled protein nanoparticles are selected from the group consisting of: heterozygous bullfrog / Helicobacter pylori heterozygous ferritin (BFF); imidazole glycerol phosphate dehydratase (HisB), preferably derived from Mycobacterium tuberculosis; acetyltransferase of pyruvate dehydrogenase (PDH) complex (PdhC), preferably derived from Bacillus stearothermophilus; and DNA-binding protein (DPS) from starved cells, preferably derived from Escherichia coli.

[0450] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the self-assembled protein nanoparticles are HisB, PdhC, or DPS.

[0451] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the self-assembled protein nanoparticles are selected from the group consisting of BFF, PdhC, and DPS, and wherein in each case the N-terminus of a subunit of the self-assembled nanoparticle is attached to the C-terminus of a disease-associated antigen.

[0452] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the self-assembled protein nanoparticles are HisB or DPS, and in each case the C-terminus of a subunit of the self-assembled nanoparticle is attached to the N-terminus of a disease-associated antigen.

[0453] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the first disease-associated antigen and / or the second disease-associated antigen are infectious disease-associated antigens, preferably viral or bacterial antigens.

[0454] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the first infectious disease-associated antigen or the second infectious disease-associated antigen is derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), preferably comprising or composed of the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein (SARS-CoV-2 SRBD).

[0455] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the first infectious disease-associated antigen or the second infectious disease-associated antigen is derived from Epstein-Barr virus (EBV), preferably comprising or composed of EBV surface glycoprotein 350 (EBV gp350).

[0456] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the first disease-associated antigen or the second disease-associated antigen is derived from *Treponema pallidum*, preferably from the outer surface protein A (OspA) of *Treponema pallidum*. In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the first disease-associated antigen or the second disease-associated antigen comprises or is composed of one, two, three or more antigen fragments of OspA, preferably as described in more detail above in the "Embodiments Related to Disease-Associated Proteins" section.

[0457] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the first infectious disease-associated antigen is derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), preferably comprising or composed of the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein (SARS-CoV-2 S RBD), and the second infectious disease-associated antigen is derived from Epstein-Barr virus (EBV), preferably comprising or composed of EBV surface glycoprotein 350 (EBVgp350), or vice versa.

[0458] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, a first infectious disease-associated antigen is derived from *Treponema pallidum*, preferably from *Treponema pallidum* extracorporeal surface protein A (OspA), and a second infectious disease-associated antigen is derived from *Treponema pallidum*, preferably from *Treponema pallidum* extracorporeal surface protein A (OspA), wherein the first infectious disease-associated antigen and the second infectious disease-associated antigen are different.

[0459] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, a first disease-associated antigen is encoded by a nucleic acid encoding an amino acid sequence as shown in SEQ ID NO: 101, and a second disease-associated antigen is encoded by a nucleic acid encoding an amino acid sequence as shown in SEQ ID NO: 103, and vice versa.

[0460] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, the first heteronucleotide and the second heteronucleotide are separated by a nucleic acid encoding a 2A site (preferably the T2A site).

[0461] In one embodiment of the recombinant virus-based vector encoding multi-antigen protein nanoparticles, each of the first and second heteronucleotides further encodes a signal peptide that binds to the fusion protein, preferably, the signal peptide is a human tissue plasminogen activator (htPA) signal peptide or a mouse immunoglobulin κ light chain (IgK LC) signal peptide.

[0462] In one aspect, a process is provided for preparing a recombinant virus-based vector encoding multi-antigen protein nanoparticles, the process comprising the following steps: (1) A first heteronucleic acid operatively linked to a promoter is provided, wherein the first heteronucleic acid encodes a first fusion protein comprising a first disease-associated antigen or an antigenic portion thereof, the first disease-associated antigen or an antigenic portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; (2) Provides a second heteronucleic acid operatively linked to a promoter, wherein the second heteronucleic acid encodes a second fusion protein comprising a second disease-associated antigen or an antigenic portion thereof, the second disease-associated antigen or an antigenic portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle; The first disease-associated antigen and the second disease-associated antigen are different, and the self-assembled protein nanoparticles are the same in each case; (3) Prepare a virus-based vector from the recombinant virus-based vector containing the first heterologous nucleic acid provided in step (1) and the second heterologous nucleic acid provided in step (2); (4) Obtain the vector based on the recombinant virus.

[0463] In one aspect, a pharmaceutical composition is provided comprising a recombinant virus-based vector encoding multiantigen protein nanoparticles, optionally further comprising a pharmaceutically acceptable carrier or excipient.

[0464] In one aspect, a recombinant virus-based vector encoding multi-antigen protein nanoparticles is provided, the recombinant virus-based vector being used for the prevention or treatment of diseases, preferably infectious diseases or cancer.

[0465] Recombinant virus-based vectors encoding multi-antigen protein nanoparticles are used to prevent or treat two different diseases.

[0466] In one embodiment of a recombinant virus-based vector encoding multi-antigen protein nanoparticles for the prevention or treatment of two different diseases, the first infectious disease-associated antigen is derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the second infectious disease-associated antigen is derived from Epstein-Barr virus (EBV), or vice versa, and the two different infectious diseases are COVID-19 or long-term COVID and EBV infection or EBV-associated cancer.

[0467] In one embodiment of a recombinant virus-based vector encoding multiantigen protein nanoparticles for the prevention or treatment of disease, a first disease-associated antigen is derived from *Treponema pallidum*, preferably from *Treponema pallidum* extracorporeal surface protein A (OspA), and a second disease-associated antigen is derived from *Treponema pallidum*, preferably from *Treponema pallidum* extracorporeal surface protein A (OspA), wherein the first and second disease-associated antigens are different, and the infectious disease is Lyme disease or *Treponema pallidum* infection.

[0468] Other aspects and implementation plans

[0469] In one aspect, a fusion protein is provided, the fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle.

[0470] In one embodiment of the fusion protein, the self-assembled protein nanoparticles are imidazole glycerol phosphate dehydratase (HisB), preferably derived from Mycobacterium tuberculosis; an acetyltransferase of pyruvate dehydrogenase (PDH) complex (PdhC), preferably derived from Bacillus stearothermophilus; and a DNA-binding protein (DPS) from starved cells, preferably derived from Escherichia coli, preferably HisB or DPS.

[0471] In one respect, a nucleic acid encoding a fusion protein is provided.

[0472] In one aspect, a process for preparing the nucleic acids described herein is provided, the process comprising the following steps: (a) Provide a first segment of the nucleic acid, the first segment encoding a disease-related antigen or an antigenic portion thereof; (b) Provide a second segment of the nucleic acid, the second segment encoding a subunit of a self-assembled protein nanoparticle, preferably HisB or DPS; (c) Connecting the first segment and the second segment of the nucleic acid, preferably via a peptide linker; (d) Obtain the nucleic acid.

[0473] In one aspect, the use of the nucleic acids described herein for the preparation of recombinant virus-based vectors, recombinant poxviruses, recombinant VRPs, RNA molecules, or expression plasmids as described herein is provided.

[0474] In one aspect, a self-assembled protein nanoparticle comprising a fusion protein is provided.

[0475] Further description

[0476] Modified Ankara Vaccine Virus (MVA)

[0477] In the past, MVA was produced from chicken embryonic fibroblasts (CVA) of the Ankara vaccinia virus strain through 516 consecutive passages (see Mayr A et al., 1975. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 3:6-14). The virus was renamed from CVA to MVA at passage 570 to indicate a significant change in its properties. MVA was further passaged until the number of passages exceeded 570. Due to these long passages, the resulting MVA virus had about 31 kilobases missing from its genome sequence and was therefore described as a host cell with highly restricted replication in avian cells[7]. In various animal models, the resulting MVA was shown to be significantly non-virulent compared to the starting material with full replication capacity[8].

[0478] MVAs useful in the practice of this invention include MVA-572 (registered as ECACC V94012707 on January 27, 1994); MVA-575 (registered as ECACC V00120707 on December 7, 2000); MVA-I721 (cited in [2]); NIH clone 1 (registered as ATCC® PTA-5095 on March 27, 2003); and MVA-BN (registered as European Collection of Cell Cultures (ECACC) on August 30, 2000, with the number V00083008).

[0479] More preferably, the MVA used according to the present invention includes MVA-BN and MVA-BN derivatives. MVA-BN has been described in WO 02 / 042480. As described herein, "MVA-BN derivative" refers to any virus that exhibits substantially the same replication characteristics as MVA-BN but shows differences in one or more parts of its genome.

[0480] MVA-BN and its derivatives are non-replicating, meaning they cannot reproduce in vivo or in vitro. More specifically, in vitro, MVA-BN or its derivatives have been described as capable of reproductive replication in chicken embryonic fibroblasts (CEF), but not in human keratinocyte line HaCaT [9], human osteosarcoma cell line 143B (ECACC register number 91112502), human embryonic kidney cell line 293 (ECACC register number 85120602), and human cervical adenocarcinoma cell line HeLa (ATCC register number CCL-2). In addition, the viral amplification rate of MVA-BN or its derivatives in HeLa cells and HaCaT cell lines is at least two times smaller, more preferably three times smaller, than that of MVA-575. The tests and assays for these properties of MVA-BN and its derivatives are described in WO 02 / 42480 and WO 03 / 048184.

[0481] The term "cannot reproduce in vitro" as described above in human cell lines is, for example, described in WO02 / 42480, which also teaches how to obtain an MVA with the desired characteristics as described above. The term applies to viruses that have an in vitro viral amplification rate of less than 1 at 4 days post-infection, as determined using the assays described in WO 02 / 42480 or US 6,761,893.

[0482] Exemplary generation of recombinant MVA virus

[0483] Different methods can be applied to generate recombinant MVAs as disclosed herein. The DNA sequence to be inserted into the virus can be placed in an *E. coli* plasmid construct containing DNA homologous to a poxvirus DNA segment. Independently, the DNA sequence to be inserted can be attached to a promoter. A promoter-gene cassette can be positioned in the plasmid construct such that both ends of the promoter-gene cassette are flanked by DNA homologous to the DNA sequence, which is flanked by poxvirus DNA regions containing non-essential loci or containing no nucleotides. The resulting plasmid construct can be amplified and isolated by proliferation in *E. coli*. The isolated plasmid containing the DNA gene sequence to be inserted can be transfected into cell cultures, such as chicken embryonic fibroblasts (CEF), while simultaneously infecting the culture with the MVA. Recombination between the homologous sequence in the MVA viral genomic DNA and the plasmid can respectively generate MVAs modified by the presence of foreign or heterologous DNA sequences, such as nucleotide sequences encoding SARS-CoV-2 or EBV antigens.

[0484] Cells of suitable (i.e., permissive) cell cultures (e.g., CEF cells) can be infected with MVA virus. The infected cells can then be transfected with a first plasmid vector containing one or more foreign or heterologous genes, such as one or more nucleic acids as described herein; preferably under transcriptional control of a poxvirus expression control element. As explained above, the plasmid vector also contains a sequence capable of guiding the insertion of a foreign sequence into selected portions of the MVA virus genome. Optionally, the plasmid vector also contains a cassette containing a marker and / or selectable gene operatively linked to a poxvirus promoter. The use of the selectable or marker cassette facilitates the identification and isolation of the resulting recombinant MVA. However, the recombinant poxvirus can also be identified by PCR. Subsequently, another cell can be infected with the recombinant MVA obtained as described above and transfected with a second plasmid vector containing one or more second foreign or heterologous genes. The second plasmid vector will differ in guiding the integration of one or more second foreign genes into the poxvirus homologous sequence in the poxvirus genome if this gene is introduced into different insertion sites in the poxvirus genome. Following homologous recombination, recombinant viruses containing two or more foreign or heterologous genes can be isolated. For introducing additional foreign genes into recombinant viruses, the infection and transfection steps can be repeated by infecting with the recombinant virus isolated in a previous step and by transfecting with another vector containing one or more other foreign genes. Numerous other techniques are known for producing recombinant MVAs.

[0485] Unless otherwise stated, the practice of this invention will employ conventional techniques of immunology, molecular biology, microbiology, cell biology, and recombinant technologies, all of which are within the scope of the art. See, for example, Sambrook, Fritsch, and Maniatis, Molecular Cloning: A Laboratory Manual, 2nd ed., 1989; Current Protocols in Molecular Biology, eds. Ausubel FM et al., 1987; Methods in Enzymology (Academic Press, Inc.); PCR2: A Practical Approach, eds. MacPherson MJ, Flams BD, and Taylor GR, 1995; Antibodies: A Laboratory Manual, eds. Harlow and Lane, 1988; Staib et al., Construction and isolation of recombinant MVA, 2004.

[0486] Viral replicon particles (VRPs)

[0487] Alphaviruses belong to the family Omniviridae, specifically positive-sense single-stranded RNA viruses. Recombinant alphaviruses can induce high levels of heterologous gene expression, making them attractive vectors for vaccine development. The viral particle of an alphavirus consists of genomic RNA, which associates with the viral capsid protein (C) to form an icosahedral nucleocapsid, which is then surrounded by a lipid envelope derived from the host cell containing the viral envelope protein E1-E2 heterodimer.

[0488] The genomic RNA consists of two regions. The first region is directly translated from mRNA-like genomic RNA and encodes genes for non-structural proteins 1-4 (NSP1-4), which form a viral replicase complex. The replicase produces copies of the genomic RNA via a negative-strand intermediate. This negative-strand intermediate contains a subgenomic promoter from which the replicase transcribes additional, shorter subgenomic mRNAs containing a second region that encodes alphavirus structural proteins C, E3, E2, 6k, and E1. Recombinant alphavirus replicons can be generated by replacing the genes for the structural proteins with selected antigens. When alphavirus structural proteins are trans-presented to the alphavirus replicons, the replicons are packaged similarly to the packaging of a complete alphavirus genome. This results in the production of replication-deficient viral replicon particles (VRPs), which, when inoculated into animals, induce high levels of antigen expression, resulting in a robust immune response, but fail to produce any progeny viruses in the absence of any alphavirus structural proteins.

[0489] Many different alphaviruses have been used to produce VRPs, including the Old World alphaviruses Sindbisvirus (SINV) and Semliki Forrest Virus (SFV), as well as the New World Venezuelan equine encephalitis virus (VEEV), whose TC-83 vaccine strain (GenBank: L01443.1) has attracted much attention in vaccine development.

[0490] Exemplary generation of VRP derived from recombinant TC-83

[0491] Different methods can be applied to generate recombinant VRPs as disclosed herein. To insert an RNA sequence into the TC-83 replicon, replacing the sequence encoding TC-83 structural proteins, a recombinant replicon plasmid can be generated. This plasmid contains a CMV promoter to initiate the generation of VEEV replicon RNA containing the coding sequences for VEEV TrD (GenBank: L01442.2) 5' UTR, VEEV TC-83 non-structural proteins (nsp) 1, 2, 3, and 4, and a VEEV TC-83 subgenomic promoter and subgenomic 5' UTR. In the case of a complete TC-83 genome, followed by capsid and envelope genes, the plasmid contains two SapI restriction sites, which are removed from the replicon plasmid backbone after digestion, leaving overhangs corresponding to the subgenomic start codon (ATG) and stop codon (TAA). Between these overhangs, desired sequences, such as nucleotide sequences encoding SARS-CoV-2, EBV, or spirochetal antigens, can be introduced. Following the stop codon is the VEEV TC-83 3'UTR, or poly(A) sequence, which is the sequence of the HDV anti-genomic ribozyme termination replicon RNA. Following the HDV anti-genomic ribozyme is the SV40 poly(A) sequence. Furthermore, the replicon plasmid contains a ColE1 origin and a kanamycin resistance cassette for propagation in *E. coli*.

[0492] VRP stock solution is prepared by transfecting cells in a suitable cell culture (e.g., HEK293T suspension culture, see below) with three plasmids: two packaging plasmids driven by the cytomegalovirus (CMV) promoter derived from pcDNA3.1, namely, one encoding a capsid protein and the other encoding an envelope polyprotein E3-E2-6k-E1, and a recombinant replicon plasmid as described above. The replicon plasmid and the plasmid encoding the non-structural protein of the VEEV TC83 strain were obtained from GeneArt / ThermoFisher via gene synthesis.

[0493] HEK293T suspension cells for VRP preparation were obtained from the HEK293T Adhesive Cell Line (ATCC) by gradually depleting the serum in the growth medium to 1%. These cells were then grown on untreated plastic surfaces for adhesion growth under shaking conditions in a CO2 incubator on a track shaker at 37°C. One day prior to transfection, cells were grown at a growth rate of 1 × 10⁻⁶ cells / day. 6 Cells were seeded at 100 cells / ml in BalanCD medium containing 4 mM GlutaMAX, 0.1% Pluronic acid, and 1% FCS. On the day of transfection, cells were counted and the medium was replaced with serum-free DMEM.

[0494] Using PEIpro (Polyplus, Strassbourg, France) according to the manufacturer's instructions, at a PEI:DNA ratio of 3:1 (µl / µg), dissolve each 1×10⁻⁶ ml of HEK293T suspension culture (600-1000 ml). 6 Each cell was transfected with 1 µg of DNA at a plasmid molar ratio of 3:3:1 (capsid:enveloplast:replicon). Transfected cells were grown at 37°C / 125 rpm / 8% CO2, and the supernatant was harvested after 16–18 hours. VRP was harvested by ultracentrifuging the supernatant at 26,000 rpm for 2 hours on a 20% sucrose pad at 4°C, followed by resuspending the clumps in an appropriate volume of resuspension buffer. The VRP stock solution was titrated on Vero cells (ATTC) via transduction in several dilution steps. One day after transduction, transduced cells were quantified by staining with a dsRNA-specific mouse monoclonal antibody (J2, Jena Bioscience) and performing FACS analysis.

[0495] Example

[0496] The following embodiments are used to further illustrate this disclosure. They should not be construed as limiting the invention, the scope of which is defined by the appended claims.

[0497] Example 1: Materials and Methods

[0498] 1.1 Recombinant viral vector

[0499] The effect of self-forming protein nanoparticles on antigen immunogenicity was evaluated using viral vectors to deliver nucleic acid-encoding particles: MVA was used as the prototype DNA viral vector, while viral replicon particles (VRPs) were used as the RNA vector.

[0500] Three model antigens were used: the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein, the N-terminal domain of Epstein-Barr virus (EBV) surface glycoprotein 350 (gp350), and an artificial Lyme disease antigen based on the outer surface protein A (OspA) from borborygmus.

[0501] 1.1.1 Preparation of recombinant MVA

[0502] The recombinant MVA described in this article is derived from MVA-BN. ® (A modified Ankara vaccinia virus from the Bavarian Nordic, also referred to as “MVA-BN” in this article).

[0503] Bullfrog / Helicobacter pylori heterozygous ferritin (BFF) was used as a self-assembled protein nanoparticle fused to the SARS-CoV-2 spike RBD or EBV gp350 antigen.

[0504] 1.1.1.1 MVA-RBD monomers and MVA-RBD-BFF

[0505] Recombinant MVA-res065 and MVA-res067 (see Figure 28 ) are encoded as individual units (see Figure 1 Construct-1) or as a fusion protein with bullfrog / Helicobacter pylori heterozygous ferritin (BFF) as the receptor-binding domain (RBD) (see Construct-1). Figure 1 The SARS-CoV-2 spike protein RBD (construction-2) in the middle.

[0506] In this paper, MVA-res065 is also referred to as “MVA-RBD monomer”; MVA-res067 is also referred to as “MVA-RBD-BFF”.

[0507] To generate MVA-res065 and MVA-res067, the original SARS-CoV-2 spike (S) protein sequence (YP 009724390.1) containing the RBD (amino acids 331-524) was used as a basis. The amino acid sequence to be expressed contained the RBD amino acid sequence and additional amino acids of the S1 domain (located at the N-terminus and C-terminus of the RBD), thereby covering amino acids 320-537 of the original full-length SARS-CoV-2 S1 domain. A secretion tag (signal peptide) from human tissue plasminogen activator (htPA) was added to the N-terminus to allow efficient secretion of the S1 domain fragment including the RBD.

[0508] MVA-res067 encodes the htPA-RBD protein fused to the BFF for antigen oligomerization. The hybrid BFF protein is composed of amino acids 2-9 of bullfrog (American bullfrog) ferritin and amino acids 3-167 of Helicobacter pylori ferritin. Bullfrog ferritin is based on UniProt ID P07797.1, and Helicobacter pylori nonheme ferritin is based on UniProt ID Q9ZLI1.1. A nine-amino acid linker (SSGGASVLA) lies between the RBD and the hybrid BFF protein.

[0509] The inserted transgene's nucleotide sequence was optimized for human codon usage, and repetitive elements and G / C or A / T-rich polynucleotide segments were removed.

[0510] MVA expression of the RBD monomer and RBD-BFF fusion protein is driven by the Pr13.5 long promoter (Wennier et al., 2013

[10] ; WO 2014 / 063832). The RBD and RBD-BFF expression cassettes are inserted into the intergenic region (IGR) 64 / 65 of the MVA-BN (see

[10] ). Figure 28 ).

[0511] 1.1.1.2 MVA-gp350-GCN4 and MVA-gp350-BFF

[0512] The gene BLLF1, encoding glycoprotein 350 (gp350) of Epstein-Barr virus (EBV) strain B95-8, was selected for insertion into the MVA-BN genome. Recombinant MVA-mBN443B and MVA-mBN510 (see [link to MVA-BN genome]) were also used. Figure 28 The fragment (amino acids 1-434) of gp350 derived from EBV B95-8 strain is encoded by a fusion of the extracellular domain of gp350 into a tetramerized domain derived from GCN4 (see [link to relevant documentation]). Figure 8 The fusion protein contains the extracellular domain of gp350 (construction-3A); and the EBV gp350-BFF fusion protein containing amino acids 2-434 of the extracellular domain of gp350, with its N-terminus fused to a signal peptide from the light chain of mouse immunoglobulin κ and its C-terminus fused to BFF (see [link to EBV gp350-BFF fusion protein]). Figure 8 Components in -4).

[0513] In this article, MVA-mBN443B is also referred to as "MVA-gp350-GCN4", and MVA-mBN510 is also referred to as "MVA-gp350-BFF".

[0514] In MVA-mBN443B, a truncated form (amino acids 1-434) of the naturally occurring secretion signal at the N-terminus of the gp350 fragment after expression is fused to the synthetic polymerization domain of yeast GCN4

[11] . The gp350 protein sequence is based on GenBank entry YP 401667.1, and the yeast-derived GCN4 sequence is based on 2IPZ_A. A 13-amino acid linker (PKPSTPPGSSCGG) is inserted between gp350 and GCN4.

[0515] In the gp350-BFF fusion protein encoded by MVA-mBN510, the N-terminal portion (amino acids 2-434) of the gp350 extracellular domain is fused to the BFF for antigen oligomerization. Additionally, the signal peptide of the mouse Igκ light chain (IgK LC) is fused to the N-terminus to allow for efficient secretion. The resulting BFF-gp350 fusion protein lacks a transmembrane domain and is therefore intended to be secreted. A ten-amino acid linker (PKPSTPPGSS) is located between gp350 and the BFF.

[0516] All protein sequences were optimized for human codon usage at the nucleotide level, and repetitive elements and nucleotide segments were removed.

[0517] Expression of gp350-GCN4 in MVA-mBN443B and gp350-BFF in MVA-mBN510 is driven by the Pr13.5 long promoter (Wennier et al., 2013

[10] ; WO 2014 / 063832). For MVA-mBN443B, the gp350-GCN4 tetramer coding sequence is inserted into intergenic region (IGR) 88 / 89 of the MVA-BN genome; for MVA-mBN510, the gp350-BFF coding sequence is inserted into IGR 64 / 65 (see

[10] ). Figure 28 ).

[0518] Both recombinant MVAs encode additional EBV-derived antigens (i.e., BXLF2 encoding gH, BKRF2 encoding gL, BRLF1, BZLF1, and EBNA3A) (see [link to relevant documentation]). Figure 28 In MVA-mBN510, the encoded gH and gL are separated from each other by the P2A site.

[0519] 1.1.2 VRP preparation

[0520] Viral replicon particles (VRPs) are based on a live, attenuated Venezuelan equine encephalitis virus (VEEV) strain TC-83.

[0521] Bullfrog / Helicobacter pylori heterozygous ferritin (BFF) was used as a self-assembled protein nanoparticle fused to the SARS-CoV-2 spike RBD, EBV gp350, or Lyme disease antigen. In addition, nanoparticle candidates other than BFF were tested (see Example 6).

[0522] 1.1.2.1 VRP-RBD monomers and VRP-RBD-BFF

[0523] Recombinant VRP-BN035 is a viral replicon particle (VRP) that encodes a monomeric form of RBD (see [link to relevant documentation]). Figure 1Constructor-1 in the text), while VRP-BN033 encodes the RBD-BFF fusion protein (see Construct-1). Figure 1 Components in the middle - 2).

[0524] In this article, VRP-BN035 is also referred to as "VRP-RBD monomer"; VRP-BN033 is also referred to as "VRP-RBD-BFF".

[0525] To generate VRP-BN033 and VRP-BN035, construct-1 and construct-2 as described in 1.1.1.1 (see [link to documentation]) are used respectively. Figure 1 The sequences were inserted into replicons derived from VEEV TC-83. These sequences were codon-optimized and synthesized, with homologous overhangs from the 5' and 3' UTRs of the VEEV subgenome at each end, respectively, so that they could be inserted into the VEEV TC-83 replicon plasmids described above via homologous cloning (see “Exemplary Generation of VRPs Derived from Recombinant TC-83”).

[0526] 1.1.2.2 VRP-gp350-GCN4 and VRP-gp350-BFF

[0527] Recombinant VRP-BN043 is a viral replicon particle (VRP) that encodes gp350, derived from EBV and fused to a tetramerized domain derived from GCN4 (see [link to documentation]). Figure 8 The construct in the text is -3B), while VRP-BN052 encodes the gp350-BFF fusion protein (see [link to text]). Figure 8 Components in -4).

[0528] VRP-BN043 is also referred to as "VRP-gp350 GCN4" in this document. VRP-BN052 is also referred to as "VRP-gp350-BFF" in this document.

[0529] The sequences used to generate VRP-BN043 and VRP-BN052 are described in 1.1.1.2, but the sequences used here encoding the gp350-GCN4 fusion protein are preceded by a sequence encoding the mouse IgK light chain signal peptide (IgK LC SP) to aid secretion. These sequences were codon-optimized and synthesized, each ending with homologous overhangs from the 5' and 3' UTRs of the VEEV subgenome, respectively, for insertion into the VEEV TC-83 replicon plasmid described above via homologous cloning (see “Exemplary Generation of VRPs Derived from Recombinant TC-83”).

[0530] The two VRPs encode additional EBV antigens (i.e., BXLF2 encoding gH and BKRF2 encoding gL), which are separated from each other by the P2A site.

[0531] 1.1.2.3 VRP-OspAST1-5-6 and VRP-OspA-ST1-5-6-BFF

[0532] Recombinant VRP-BN083 is a viral replicon particle (VRP) encoding a tandem of three OspA C-terminal fragments: amino acids 126-273 from OspA serotype 1 (ST1) of *Borrelia burgdorferi* (strain B31), amino acids 126-273 from OspA ST5 of *Borrelia gamayi* (strain PHei), and amino acids 126-274 from OspAST6 of *Borrelia gamayi* (DK29). The OspA C-terminal fragments are separated from each other by (GGGGS)4 linkers and are fused at the N-terminus to the htPA signal peptide (see [link to ... Figure 12 The construct-5 in

[12] further describes the stabilization of the C-terminal fragment by introducing a disulfide bridge and the removal of all NXS / T N-glycosylated sequences by an N-to-Q mutation.

[0533] VRP-BN067 encodes the same fusion protein containing the C-terminal fragment of OspA, but is additionally fused to BFF via a nine-amino acid SSGGASVLA linker (see [link to BFF]). Figure 12 The constructor in -6).

[0534] VRP-BN083 is also referred to as “VRP-OspA ST1-5-6” in this document. VRP-BN067 is also referred to as “VRP-OspA ST1-5-6-BFF” in this document.

[0535] The sequences used to generate VRP-BN083 and VRP-BN067 were codon-optimized and synthesized, with homologous overhangs from the 5' and 3' UTRs of the VEEV subgenome at each end, respectively, so that they could be inserted into the VEEV TC-83 replicon plasmid described above by homologous cloning.

[0536] 1.1.2.4 VRP encoding RBD fused to nanoparticle candidates

[0537] Imidazole glycerol phosphate dehydratase from Mycobacterium tuberculosis (HisB, uniprot: P9WML9), dihydrolipoyl lysine residue acetyltransferase component of pyruvate dehydrogenase complex from Bacillus stearothermophilus (PdhC E2, uniprot: P11961), DNA protection protein during starvation from Escherichia coli K12 strain (DPS, uniprot: P0ABT2), and from Acidophilus mesenteriae ( Acidianus ambivalens ) thiooxygenase / reductase (SOR, uniprot: P29082) and from Bacillus spp. ( Bacillus sp.Mercakin decarboxylase (MrsD, uniprot: Q9RC23) from strain HIL-Y85 / 54728 was tested as a self-assembling nanoparticle capable of displaying the antigen. For this purpose, the BFF in the RBD-BFF replicon plasmid (see 1.1.2.1) was replaced with amino acids 9-210 of HisB, 185-428 of PdhC E2, 11-167 of DPS, 2-309 of SOR, and 2-194 of MrsD (see [link to 1.1.2.1]). Figure 15 (Constructors -7 to -11 in the text).

[0538] Additionally, a replicon plasmid was generated in which the positions of RBD, HisB, DPS, SOR, and MrsD were interchanged, such that the subunits forming the nanoparticles are now fused to the N-terminus of RBD (see [link]). Figure 17 Constructs-12 to-15 (in the original text). These sequences were codon-optimized and synthesized, with homologous overhangs from the 5' and 3' UTRs of the VEEV subgenome included at each end, so as to be inserted into the VEEV TC-83 replicon plasmid described above via homologous cloning.

[0539] Recombinant VRP-BN060 is a viral replicon particle (VRP) that encodes the RBD-DPS fusion protein (see [link to relevant documentation]). Figure 15 Construct-9 in [the text]. Recombinant VRP-BN070 is a viral replicon particle (VRP) that encodes the HisB-RBD fusion protein (see [the text]). Figure 17 Construct-12 in [the document]. Recombinant VRP-BN071 is a viral replicon particle (VRP) that encodes the DPS-RBD fusion protein (see [the document]). Figure 17 The constructor in -13).

[0540] In this article, VRP-BN060 is also referred to as "VRP-RBD-DPS", VRP-BN070 is also referred to as "VRP-HisB-RBD", and VRP-BN071 is also referred to as "VRP-DPS-RBD".

[0541] 1.1.2.5 VRP encoding EBV gp350 fused to nanoparticle candidates

[0542] Recombinant VRP-BN096 is a viral replicon particle (VRP) that encodes a gp350 sequence derived from EBV and fused to DPS as described in 1.1.1.2 (see [link to 1]). Figure 21 The construct-17 in the text, while VRP-BN098 encodes the same gp350 sequence but is fused into PdhC (see [link]). Figure 21 The constructor in -16).

[0543] To generate VRP-BN096 and VRP-BN098, the sequences encoding constructs-14 and-15 were codon-optimized and synthesized, with homologous overhangs from the 5' and 3' UTRs of the VEEV subgenome included at each end, respectively, so that they could be inserted into the VEEV TC-83 replicon plasmid described above via homologous cloning.

[0544] VRP-BN096 is also referred to as "VRP-gp350-DPS" in this document. VRP-BN098 is also referred to as "VRP-gp350-PdhC" in this document.

[0545] 1.1.2.6 VRP encoding RBD-BFF / gp350-BFF multi-antigen nanoparticles

[0546] VRP-BN072 is a viral replicon particle (VRP) containing nucleic acid encoding a gp350-BFF fusion protein (described in 1.1.1.2), followed by a T2A site and an RBD-BFF fusion protein (described in 1.1.1.1) (see [link to documentation]). Figure 23 In the example of builder-18). To generate VRP-BN072, builder-2 (see [link]). Figure 1 ) and Builder-4 (see Figure 8 The sequence fusion, separated by T2A sites, is inserted into a replicon derived from VEEV TC-83 via homologous cloning.

[0547] 1.1.2.7 VRP encoding OspA multi-antigen nanoparticles

[0548] VRP-BN068 is a viral replicon particle (VRP) encoding a tandem of three OspA C-terminal fragments (i.e., amino acid 126-273 of OspA serotype 2 (ST2) from *Borrelia auriculata* (K78 strain), amino acid 126-273 of OspA ST4 from *Borrelia bavaria* (PBi strain), and amino acid 126-274 of OspA ST3 from *Borrelia galbana* (PBr)). This tandem is fused to the BFF via a nine-amino acid SSGGASVLA linker. The OspA C-terminal fragments are separated from each other by (GGGGS)4 linkers and are fused to the htPA signal peptide at their N-terminus (see [link to BFF]). Figure 26 The construct-19 in

[12] further describes the stabilization of the C-terminal fragment by introducing a disulfide bridge and the removal of all NXS / T N-glycosylated sequences by an N-to-Q mutation.

[0549] VRP-BN069 encodes two OspA-BFF fusion proteins encoded in VRP-BN067 (see 1.1.2.3) and VRP-BN068, which are separated by a T2A site (see [link to 1]). Figure 26 The constructor in the middle -20).

[0550] VRP-BN068 is also referred to as “VRP-OspA ST2-4-3-BFF” in this document. VRP-BN069 is also referred to as “VRP-OspA ST1-5-6-BFF / OspA ST2-4-3-BFF” in this document.

[0551] The sequence used to generate VRP-BN068 was codon-optimized and synthesized, with homologous overhangs from the 5' and 3' UTRs of the VEEV subgenome at each end, for insertion into the VEEVTC-83 replicon plasmid described above via homologous cloning. To generate VRP-BN069, construct-6 ( Figure 12 ) and Construct-19 ( Figure 26 The sequence fusion, separated by T2A sites, is inserted into a replicon derived from VEEV TC-83 via homologous cloning.

[0552] 1.2 mRNA, saRNA, and plasmid DNA

[0553] The code was generated as a single entity (see Figure 1 Construct-1) or as a fusion protein of RBD and bullfrog / Helicobacter pylori heterozygous ferritin (BFF) (see Construct-1) Figure 1 The nucleic acid of the SARS-CoV-2 spike receptor binding domain (RBD) of the construct-2) is in the following forms: (i) an expression plasmid containing the corresponding gene under the control of the CMV promoter, (ii) a self-amplified RNA (saRNA) based on the VEEV replicon, and (iii) a capped and polyadenylated mRNA.

[0554] mRNA and saRNA were generated from a DNA template via in vitro transcription (IVT) using the HiScribe® T7 High-Yield RNA Synthesis Kit (NEB, E2040S). CleanCap AU (TriLink, N-7114-1) was added to the IVT reaction mixture to generate capped RNA. Following IVT, the RNA was purified using the Monarch® RNA Cleanup Kit (NEB, T2050S).

[0555] Plasmids containing templates for mRNA or saRNA were cloned. Two plasmids containing templates for saRNA were generated using plasmid pCR-Blunt II-TOPO (Invitrogen) as a vector. These two templates share the same sequence as the replicon plasmid used to prepare VRP (see Example 1.1.2.1), but with a T7 promoter instead of a CMV promoter preceding the replicon sequence. A poly(A) tail with approximately 120 adenines was added after the replicon sequence. Additionally, a PaqCI restriction site was incorporated after the poly(A) tail for linearization of the template plasmid. After IVT, the two resulting saRNA molecules contained the same replicon sequence as VRP-BN033 and VRP-BN035, but with a pseudocap structure (CleanCap AU) and a long poly(A) tail with approximately 120 adenines.

[0556] Two plasmids containing templates for mRNA were generated using the plasmid pcDNA4 / TO / myc-His A (ThermoFisher) as a vector. These two mRNA templates contain the same coding sequences as the saRNA, for either the monomeric SARS-CoV-2 spike RBD protein or a fusion protein of the SARS-CoV-2 spike RBD and BFF. The coding sequences are flanked by 5' and 3' untranslated regions (UTRs). The 5' and 3' UTRs are derived from the human β-globulin (HBG) gene. A T7 promoter is introduced before the 5' UTR to initiate IVT. Additionally, an AT sequence is inserted between the T7 promoter and the 5' UTR to add a CleanCap-AU capping analog. Following the 3' UTR, a poly(A) tail consisting of approximately 120 adenine residues is added. Immediately following the poly(A) tail, a BaeI restriction site is introduced for linearization of the transcription template.

[0557] For plasmid DNA, two expression plasmids encoding construct-1 or construct-2 were prepared by subcloning the coding sequence into the HindIII and EcoRI restriction sites in the pcDNA3.1 vector. Figure 1 The inserted coding sequence is controlled by the CMV promoter to allow gene expression in eukaryotic cells.

[0558] 1.3 Analysis of antigen expression and nanoparticle assembly

[0559] 1.3.1 In vitro protein expression

[0560] The cellular expression and secretion of antigens, as well as the assembly of nanoparticles, were examined in cell culture.

[0561] For MVA infection, 0.5 × 106 One HeLa cell per well was seeded in a 6-well plate, and the next day was treated with 1.0 × 10⁶ cells. 7 InfU-related MVA infection. Cells and supernatant were harvested 20-24 hours later for analysis.

[0562] Instead of whole VRPs, use replicon plasmids derived from VEEVs, which can initiate replicon activation after transfection into cells. For transfection, use 1.3 × 10⁻⁶ plasmids. 6 HEK293T cells were seeded per well in 6-well plates, and transfected the cells the next day using PEIpro transfection reagent with 1 µg of the relevant replicon starter plasmid. Cells and supernatant were harvested and analyzed 16–24 hours later.

[0563] Protein expression analysis was performed using recombinant VRP derived from VEEV TC-83. For infection, 5 × 10⁻⁶ cells were used. 5 10 Vero cells / well were seeded in a 6-well plate, and the next day, 5 × 10⁶ cells were used as a buffer. 6 TU-related VRP infection. Cells and supernatant were harvested 16-24 hours later for analysis.

[0564] For transfection with mRNA, saRNA, or plasmid DNA, use 1.3 × 10⁻⁶ mRNA / saRNA / plasmid DNA. 6 HEK293T cells were seeded per well in 6-well plates and infected with 1 µg of relevant nucleic acid the next day. Cells and supernatant were harvested and analyzed after 16–48 hours.

[0565] 1.3.2 Western blot

[0566] The lysates and supernatants of cells infected with recombinant MVA, transfected with plasmid DNA encoding a recombinant replicon initiated by CMV, or transfected with mRNA, saRNA, or plasmid DNA were analyzed against the expressed antigen.

[0567] Cell lysates and supernatants were collected and analyzed by Western blotting. Lysates and supernatants were separated by electrophoresis (PAGE) on a 10% polyacrylamide gel under denaturing conditions, and supernatants were additionally run on 3–12% polyacrylamide gels under native conditions in the presence of G-250 dye. After electrophoresis, the gels were transferred to nitrocellulose membranes, which were then blocked with 10% skim milk powder in Tris-buffered saline (TBS-T) containing 0.1% Tween 20.

[0568] The following antigen-specific antibodies were used to detect the antigens: rabbit anti-SARS-CoV-2 spike antibody (SinoBiological #40592-T62); anti-EBV gp350 (72A1, Sigma #MAB10219); rabbit anti-ftnA (Cusabio #CSB-PA009053ZA01HUV); horseradish peroxidase (HRP) conjugated goat anti-rabbit antibody (Promega #W401B); and goat anti-rabbit antibody (Promega #W402B). All antibodies were diluted with 5% skim milk in Tris-buffered saline (TBS-T) containing 0.1% Tween 20. The detected bands were visualized using a chemiluminescent HRP substrate (Amersham ECL assay kit).

[0569] 1.4 In vivo immunogenicity study

[0570] 1.4.1 Mouse experiment

[0571] On day 0 (primary immunization) and day 21 (boost immunization), use 1×10 8 Or 1×10 7 InfU recombinant MVA, 1×10 8 Female Balb / c mice (6–8 weeks old, Janvier) were intramuscularly immunized with either TU VRP or 2.5 µg saRNA. Similarly, on day 0 (primary immunization) and day 21 (boost immunization), 1 × 10⁻⁶ TU was administered. 8 InfU recombinant MVA or 1×10 8 TU's VRP was used to immunize CD-1 mice intramuscularly. Blood was drawn between day 34 and day 42 post-primary immunization for serum separation. Total anti-antigen IgG titers in serum were analyzed by ELISA (see 1.4.2), and antigen-binding antibody titers (expressed as 50% inhibition) were assessed using the cPass technique (see 1.4.3). For T-cell analysis, mice were sacrificed on day 35 or day 42 post-primary immunization, and single-cell suspensions of spleen cells were analyzed by EliSpot (see Example 1.4.4).

[0572] 1.4.2 ELISA

[0573] Using anti-mouse IgG (H+L) antibody, serum anti-RBD Ig titers were analyzed by enzyme-linked immunosorbent assay (ELISA) on RBD-coated plates, with an initial dilution of 1:300, to determine the total anti-RBD Ig titer. Using HRP-conjugated anti-mouse IgG (Fc) antibody, serum anti-OspA-ST1 or anti-OspA-ST2 Ig titers were analyzed by ELISA on OspA-ST1 or OspA-ST2-coated plates, with an initial dilution of 1:300, to determine the total anti-OspA-ST1 or anti-OspA-ST2 Ig titer. Random titers (AU = arbitrary units) were calculated via a 4PL fitted curve with an intercept of OD = 0.3. Additionally, anti-RBD and anti-gp350 IgG titers were analyzed by standard-based ELISA. Therefore, serum was diluted in a 1:5 dilution sequence starting at 1:100 or 1:200, and standards for quantifying anti-RBD or anti-gp350 IgG serum antibodies were established using commercially available anti-RBD (R&D Systems; MAB105808) or anti-gp350 (Merck; MAB8183) antibodies. Data are presented as mean ± SEM.

[0574] 1.4.3 Neutralization assay (cPass)

[0575] cPass is a validated alternative virus neutralization test that measures the ability of immune serum to interfere with the binding of antigens to their receptors on human cells, specifically the ability of the SARS-CoV-2 spike RBD to bind to angiotensin-converting enzyme-2 (ACE2).

[0576] Specifically, serum samples were serially diluted in a 3-fold dilution series starting at a 1:100 dilution. RBD-HRP diluted 1:1000 was mixed with the serum sample at a 1:1 ratio and incubated at 37°C for 30 minutes. After incubation, the serum-RBD-HRP mixture was added to ACE2-coated plates and incubated at 37°C for 15 minutes. After washing, TMB solution was added to each well, and the plates were incubated in the dark at 25°C for 15 minutes. After this incubation period, the reaction was terminated, and the absorbance was immediately read at 450 nm using a microplate reader. The titer was calculated at 50% RBD binding inhibition compared to the negative control.

[0577] 1.4.4 ELISpot

[0578] Enzyme-linked immunospot (ELISpot) assay was used to detect IFN-γ-producing T cells. For this purpose, 0.5 × 10⁻⁶ cells were used. 6Spleen cells were seeded in anti-IFN-γ-coated ELISpot plates and restimulated with spike peptide pool A (containing the SARS-CoV-2 spike RBD region) (Genscript), gp350 peptide pool (JPT Peptide Technologies or Peptides & Elephants), or control medium. The ELISpot plates were incubated overnight at 37°C before color development. IFN-γ-producing cells were visualized using a biotin-conjugated anti-IFN-γ antibody combined with streptavidin-horseradish peroxidase (HRP) and 3-amino-9-ethylcarbazole (AEC) substrates. Spots were counted using an ELISPOT plate reader (Immunospot S6 universal analyzer).

[0579] 1.4.5 FACS

[0580] Prior to flow cytometry analysis, RBD-specific memory B cells and germinal center B cells were visualized using fluorescently labeled RBD proteins and different antibody combinations. Simply put, single cells were stained with ZombieAqua-containing PBS (Biolegend) viability dye in 96-well V-plates at 4°C for 20 minutes. After incubation, cells were washed twice with fluorescence-activated cell sorting (FACS) buffer (PBS supplemented with 2% FCS and 0.02% sodium azide) and then stained with AF488 or AF647-labeled RBD proteins at 4°C for 10 minutes to stain RBD-specific B cells. The labeled RBD proteins were obtained from R&D Systems. A 50 µL antibody mixture containing anti-GL7-PerCp-Cy5.5, anti-CD38-PE-eFLuor610, anti-IgG1-BV711, anti-IgG2a / b-BV650, anti-IgM-BV605, anti-CD3-BV510, anti-IgD-APC-Cy7, and anti-CD45R-AF700 was added to each well. All antibodies were obtained from BD Biosciences, Biolegend, or ThermoFisher Scientific. Cells were restained for 20 min, followed by two washes with FACS buffer. Finally, cells were filtered through a 100 µm membrane and analyzed on an LSR-II flow cytometer (BD Biosciences).

[0581] Example 2: Effects of bullfrog / Helicobacter pylori heterozygous ferritin (BFF) nanoparticles on the expression and immunogenicity of SARS-CoV-2 spike receptor-binding domain (RBD) antigen delivered by MVA or VRP.

[0582] The receptor-binding domain (RBD) of the SARS-CoV-2 spike protein is used as the first model antigen. The RBD is the target of most neutralizing antibodies against SARS-CoV-2, and high titers of anti-RBD antibodies are known to be associated with protection against the disease.

[0583] 2.1 SARS-CoV-2 spike RBD antigen constructs with and without BFF nanoparticles

[0584] Two antigen constructs were designed: the first contained an RBD of the SARS-CoV-2 spike protein and a signal peptide fused to it with human tissue plasminogen activator (htPA) (see [link]). Figure 1 The first type contains construct-1; and the second type contains RBD and htPA signal peptides similar to construct-1, but the RBD is additionally fused to bullfrog / Helicobacter pylori heterozygous ferritin (BFF) (see [link to original text]). Figure 1 (Construction-2 in the text). During the synthesis of the RBD monomer or RBD-BFF fusion protein, the signal peptide is cleaved and therefore no longer present in the mature protein.

[0585] Recombinant MVAs and VRPs encoding construct-1 or construct-2 were prepared as described in Examples 1.1.1 and 1.1.2, respectively.

[0586] 2.2 Western blot analysis of RBD and RBD-BFF proteins encoded by recombinant MVA

[0587] HeLa cells were infected with a recombinant MVA encoding either the monomeric RBD protein or the RBD-BFF fusion protein (MOI 10). On the second day, cell lysates and supernatants were collected and analyzed by Western blotting (see Example 1.3.2).

[0588] The results are shown in Figure 2 In the study, protein bands of expected size indicated the expression (lysis buffer) and secretion (supernatant) of RBD and RBD-BFF, as well as the assembly of nanoparticles (supernatant, native conditions).

[0589] The calculated molecular weight of the monomeric SARS-CoV-2 spike protein RBD is 24.48 kDa, which is further increased due to the presence of two N-glycans added to the protein during processing in the secretory pathway (apparent molecular weight in Western blot is approximately 30 kDa). The calculated molecular weight of the RBD-BFF fusion protein is 45.29 kDa, which is similarly increased due to the presence of the same two N-glycans. The assembled 24-meric RBD-BFF nanoparticles have a molecular weight of 1.09 mDa (24 × 45.29 kDa), plus the additional weight from the glycans.

[0590] Under denaturing electrophoresis conditions, a band of approximately 30 kDa was detected in the lysate and supernatant of cells infected with MVA-RBD monomers. Figure 2 A, Figure 2 Lane 1 in B indicates successful expression and secretion of RBD monomers. A band of approximately 45 kDa was detected in the lysate and supernatant of MVA-RBD-BFF infected cells. Figure 2 A, Figure 2 Lane 2 in B also indicates the successful expression and secretion of the RBD-BFF fusion protein.

[0591] When the cell supernatant was subjected to electrophoresis under native conditions, a faint band with a molecular weight of approximately 60 kDa was observed in cells infected with MVA-RBD. Figure 2 Lane 1 in C indicates that some dimerization of the monomeric RBD occurs in solution. However, most notably, a clearly defined high molecular weight band was detected in the supernatant of MVA-RBD-BFF-infected cells. Figure 2 Lane 2 in C indicates that the RBD-BFF fusion protein assembles into nanoparticles.

[0592] Therefore, recombinant MVA, as an example of a DNA viral vector, demonstrates delivery of self-assembled RBD-BFF nanoparticles.

[0593] 2.3 Western blot analysis of VRP-encoded RBD and RBD-BFF proteins

[0594] HEK293T cells were used with a protein encoding the monomer RBD ( Figure 1 The recombinant replicon initiated by the CMV of construct-1 or encoding the RBD-BFF fusion protein (in the text) Figure 1 The plasmid DNA of the recombinant replicon initiated by CMV in construct-2 was transfected. The next day, cell lysates and supernatants were collected and analyzed by Western blotting.

[0595] The results are shown in Figure 3 For a review of the molecular weights of RBD and RBD-BFF proteins and the corresponding sizes of their protein bands, see Example 2.2 above.

[0596] Under denaturing electrophoresis conditions, monomeric RBD was detected in the lysate and supernatant of cells transfected with VRP-RBD. Figure 3 A, Figure 3 Lane 1 in B). Similarly, RBD-BFF was detected in the lysate and supernatant of cells transfected with VRP-RBD-BFF. Figure 3 A, Figure 3Lane 2 in B). Therefore, the VRP-encoded RBD and RBD-BFF proteins were successfully expressed and secreted.

[0597] Following natural electrophoresis, a faint band with a molecular weight of approximately 60 kDa was observed in VRP-RBD-infected cells. Figure 3 Lane 1 in C indicates that the monomeric RBD dimerizes in solution, while a clearly defined high molecular weight band is detected in the supernatant of VRP-RBD-BFF infected cells. Figure 3 Lane 2 in C indicates that the RBD-BFF fusion protein assembles into nanoparticles.

[0598] Therefore, VRP, as an example of an RNA viral vector, demonstrates the delivery of self-assembled BFF-RBD nanoparticles.

[0599] 2.4 Immune response to RBD or RBD-BFF delivered by recombinant MVA or VRP

[0600] To assess the immunogenicity of the RBD antigen (whether or not it is presented on BFF nanoparticles), Balbc mice were immunized with the corresponding recombinant MVA or VRP on days 0 and 21.

[0601] The recombinant MVA encoding the monomer RBD (MVA-RBD monomer) was compared with the recombinant MVA expressing the BFF-RBD fusion protein (MVA-RBD-BFF). Figure 4 AC), and compared the VRP encoding the monomer RBD (VRP-RBD monomer) with the VRP encoding the BFF-RBD fusion protein (VRP-RBD-BFF). Figure 4 DF).

[0602] Figure 4 The results presented show that when RBD is presented on self-forming nanoparticles BFF, it strongly induces a humoral immune response (see [link]). Figure 4 (MVA-RBD-BFF and VRP-RBD-BFF in the text). Total anti-RBD IgG was significantly increased compared to non-particulate antigens (see [link to relevant documentation]). Figure 4 A, Figure 4 (D refers to "MVA-RBD monomers" and "VRP-RBD monomers"). Furthermore, serum samples were used to measure the titer of neutralizing RBD-binding antibodies. For this purpose, a commercially available alternative virus neutralization assay (Genscript-cPass) was used, and the 50% inhibition titer was determined by generating serial dilution curves. This is the titer at which serum antibodies inhibit 50% of RBD-ACE2 binding. Similar to the total IgG titer, neutralizing RBD antibodies were significantly elevated compared to non-particulate antigens ( Figure 4 B Figure 4 E).

[0603] In addition to humoral immune responses, T-cell responses were also assessed. Spleen cells were isolated on day 34 (14 days after booster immunization) and subjected to IFN-γ ELISpot analysis (see Example 1.4.4). IFN-γ spots were counted and visualized. Figure 4 C Figure 4 In F, strong SARS-CoV-2 spike-specific T cell responses were induced in all animal test groups, and no difference was detected between RBD monomers and RBD-BFF.

[0604] Overall, the data demonstrate that BFF-mediated antigen presentation induces robust T-cell responses, but most importantly, it significantly enhances antibody responses regardless of whether the antigen is delivered by recombinant MVA or VRP.

[0605] 2.5 Recombinant MVA-delivered RBD or RBD-BFF induce germinal centers and memory B cells

[0606] Following intramuscular immunization, the antigen rapidly reaches the draining lymph nodes and initiates the immune response. Recognition of the antigen by B cells and T cells activates these cells and generates germinal centers (GCs) in the lymph nodes. Germinal centers are highly specialized clusters of B and T cells, in which antigen-specific B cells are maturing and may eventually become highly specific memory B cells or antibody-producing plasma cells. Therefore, germinal centers are a prerequisite for strong antibody responses and B cell memory.

[0607] To examine whether the nanoparticle-associated antigen expressed by recombinant MVA is a potent inducer of germinal center responses, 1×10⁻⁶ was used. 8 Balb / c mice were intramuscularly immunized with InfU of MVA-RBD, MVA-RBD-BFF, or an equal volume of Tris-buffered saline (TBS) as buffer controls. Inguinal and popliteal lymph nodes (draining lymph nodes) were isolated 7 or 14 days post-immunization to analyze the ability of recombinant MVA to induce GC B cells and memory B cells. The lymph nodes were collected and processed, and individual cells were stained with fluorescently labeled antibodies and fluorescently labeled RBD protein for flow cytometry analysis (see Example 1.4.5). Results are shown in... Figure 5 middle.

[0608] Analysis of B cells in lymph nodes showed that MVA-RBD-BFF induced a high percentage of GC B cells up to day 7. Figure 5 A), leading to a high abundance of memory B cells on day 14 ( Figure 5B). These results indicate that MVA-RBD-BFF is a better inducer of GC and memory B cell responses compared to MVA-RBD.

[0609] Example 3: Effects of BFF nanoparticles on RBD antigen expression and immunogenicity when delivered by mRNA, saRNA, or plasmid DNA

[0610] The study investigated whether nanoparticle assembly and increased antibody induction would also occur when antigens were delivered by “naked” nucleic acids (i.e., mRNA, self-amplified RNA (saRNA), or plasmid DNA).

[0611] 3.1 mRNA, saRNA, or plasmid DNA encoding RBD antigen constructs with and without BFF nanoparticles

[0612] Each type of "naked" nucleic acid encodes either construct-1 or construct-2 (see...) Figure 1 mRNA, saRNA, and plasmid DNA were prepared as described in Example 1.2.

[0613] 3.2 Western blot analysis of RBD and RBD-BFF proteins encoded by mRNA, saRNA, or plasmid DNA

[0614] HEK293T cells were transfected with mRNA, saRNA, or plasmid DNA encoding construct-1 or construct-2. For transfection, HEK293T cells seeded in 6-well plates were transfected with 1 µg of mRNA or saRNA per well using the jetMESSENGER RNA transfection reagent (PolyPlus). For plasmid DNA transfection, HEK293T cells seeded in 6-well plates were transfected with 1 µg of DNA per well using the PEIpro transfection reagent (PolyPlus). Twenty-four hours post-transfection, cell lysates and supernatants were collected and analyzed by Western blotting.

[0615] The results are shown in Figure 6 For a review of the molecular weights of the RBD monomer and the RBD-BFF fusion protein and the corresponding sizes of their protein bands, see Example 2.2.

[0616] Under denaturing electrophoresis conditions, a band of approximately 30 kDa (i.e., the apparent molecular weight of RBD) was detected in the blots of lysates and supernatants of cells transfected with mRNA, saRNA, or plasmid DNA encoding the monomeric RBD (see [link to original text]). Figure 6 A, Figure 6Lane 1 in B), and a band of approximately 45 kDa (indicating the RBD-BFF fusion protein) was detected in the blots of lysates and supernatants of cells transfected with mRNA, saRNA, or plasmid DNA encoding the RBD-BFF fusion protein (see also lane 1 in B). Figure 6 A, Figure 6 Lane 2 in B). This indicates that construct-1 and construct-2 were expressed after delivery of all three types of "naked" nucleic acids. However, the expression levels differed, with the lowest levels in cells transfected with mRNA and comparable levels in cells transfected with saRNA or plasmid DNA.

[0617] Clearly defined high molecular weight bands were detected in the blot of the supernatant obtained under natural electrophoresis conditions (see [link]). Figure 6 Lane 2 in C shows that RBD-BFF assembles into nanoparticles regardless of the type of nucleic acid used for delivery.

[0618] 3.3 Immune response to RBD or RBD-BFF antigens delivered by saRNA

[0619] To assess the immunogenicity of saRNA expressing BFF nanoparticle-forming protein fused to the antigen RBD, mice were immunized on days 0 and 21 with either saRNA encoding the monomeric RBD (saRNA-RBD) or saRNA encoding the RBD fused to BFF (saRNA-RBD-BFF) mixed with in vivo JET PEIpro transfection reagent (PolyPlus). Buffer immunization served as a control.

[0620] Figure 7 The results presented in A show that when RBD is presented on self-forming nanoparticles BFF and expressed by saRNA, it strongly induces a humoral immune response.

[0621] In addition, T cell responses were assessed. Spleen cells were isolated on day 42 and subjected to IFN-γ ELISpot analysis (see Example 1.4.4). For this purpose, cells were restimulated with 0.5 × 10⁻⁶ SARS-CoV-2 spike peptide pool A (Genscript) containing the RBD region. 6 One spleen cell. IFN-γ spots were counted and presented on... Figure 7 In B, both saRNA vaccination groups induced strong SARS-CoV-2 spike-specific T cell responses, and no difference was detected between RBD monomeric and RBD-BFF saRNA expression.

[0622] Overall, these data demonstrate that when the RBD-BFF fusion protein is encoded by saRNA, BFF-mediated antigen presentation induces T cell responses and significantly enhances antibody responses.

[0623] Example 4: Effects of BFF nanoparticles on the expression and immunogenicity of Epstein-Barr virus (EBV) gp350 antigen delivered by MVA or VRP

[0624] The results obtained using RBD monomers and RBD-BFF fusion proteins were re-examined using another model antigen, namely the N-terminal domain of Epstein-Barr virus (EBV) surface glycoprotein 350 (gp350) (see Example 2). EBV gp350, as well as other EBV proteins (such as gH and gL), are essential for viral entry into B cells and epithelial cells. They are also major targets of antibody responses.

[0625] 4.1 EBV gp350 antigen constructs with and without BFF nanoparticles

[0626] Two antigen constructs were designed: the first contained EBV gp350 fused to a tetramerizing domain derived from GCN4 and a mouse immunoglobulin κ light chain (IgK LC) signal peptide (see [link to EBV gp350]). Figure 8 Constructor-3A and Constructor-3B); and the second one also contains EBV gp350 fused to the IgK LC signal peptide, but EBV gp350 is fused to BFF instead of a tetramerized domain derived from GCN4 (see Constructor-3A and Constructor-3B). Figure 8 ,Constructor-4).

[0627] Recombinant MVAs and VRPs encoding constructs-3A,-3B, or-4 were prepared as described in Examples 1.1.1.2 and 1.1.2.2, respectively.

[0628] 4.2 Western blot analysis of gp350-GCN4 and gp350-BFF proteins encoded by recombinant MVA

[0629] HeLa cells were used with a protein encoding tetrameric gp350-GCN4 ( Figure 8 The construct-3A) or gp350-BFF fusion protein ( Figure 8 Recombinant MVA (MOI 10) was used to infect cells with construct-4. Cell lysates and supernatants were collected the following day and analyzed by Western blotting. Results are shown in... Figure 9 middle.

[0630] The polypeptide backbone of a single subunit of the tetrameric gp350-GCN4 glycoprotein has a molecular weight of 50.5 kDa. During protein synthesis and translocation to the cellular secretion pathway, the molecular weight increases by approximately 30 kDa through the addition of multiple N-glycans. The GCN4-tetramer dissociates into two covalently linked dimers during electrophoretic denaturation and does not further dissociate in the absence of a reducing agent, resulting in an apparent molecular weight of approximately 160 kDa. The polypeptide backbone of the gp350-BFF fusion glycoprotein has a molecular weight of 70.4 kDa, which increases to approximately 100 kDa through the addition of N-glycans. Therefore, the molecular weight of the gp350-BFF nanoparticles assembled from 24 subunits is approximately 2.4 mDa.

[0631] Recombinant MVA showed lower expression of gp350-GCN4 than gp350-BFF, making the protein almost invisible by Western blotting in cell lysates separated under denaturing electrophoresis conditions (see [link]). Figure 9 Lane 3A in A). However, a band of approximately 160 kDa in the supernatant, expected to be of this size, confirmed the expression and secretion of gp350-GCN4 (see lane 3A in A). Figure 9 Lane 3A in B).

[0632] Following natural electrophoresis, gp350-GCN4 produced clearly defined bands between 242 kDa and 480 kDa (see [link]). Figure 9 Lane 3 in C), and high molecular weight bands were observed for gp350-BFF (see lane 3 in C). Figure 9 Lane 4 in C demonstrates that gp350-GCN4 assembles into a tetramer and gp350-BFF assembles into nanoparticles.

[0633] Therefore, the recombinant MVA showed that not only was the SARS-CoV-2 RBD antigen delivered onto the BFF nanoparticles (see Example 2.2), but also the EBV gp350 antigen was delivered.

[0634] 4.3 Immune responses to gp350 or gp350-BFF induced by recombinant MVA or VRP

[0635] The in vivo immunogenicity of recombinant MVA-encoded tetrameric gp350 (MVA-gp350-GCN4) was compared with that of MVA-encoded gp350-BFF fusion protein (MVA-gp350-BFF). Figure 10 A, Figure 10 B), and compared the VRP-encoded tetrameric gp350 (VRP-gp350-GCN4) with the VRP-encoded gp350-BFF fusion protein (VRP-gp350-BFF). Figure 10 C Figure 10 D). Therefore, Balb / c mice were immunized with the corresponding recombinant MVA or VRP on days 0 and 21 as a primary / boost immunization.

[0636] Figure 10 A, Figure 10 The results presented in C show that, compared to tetrameric gp350 ( Figure 10 Compared to “MVA-gp350-GCN4” and “VRP-gp350-GCN4”, when gp350 is presented on self-forming nanoparticles BBF ( Figure 10 When the levels of “MVA-gp350-BFF” and “VRP-gp350-BFF” were elevated, the total anti-gp350 IgG level significantly increased.

[0637] In addition, T cell responses were assessed. Spleen cells were isolated on day 35 (MVA) or day 42 (VRP) post-primary immunization and IFN-γ ELISpot analysis was performed. For this purpose, cells were restimulated with a gp350 peptide pool at a concentration of 0.5 × 10⁻⁶. 6 One spleen cell. IFN-γ spots were counted and presented on... Figure 10 B Figure 10 In D, this showed that gp350-specific T cell responses were induced in all animal test groups receiving either recombinant MVA or VRP. No difference was detected between the gp350 tetramer and the RBD-BFF expression vector.

[0638] 4.4 Immunological response of recombinant MVA-delivered gp350 or gp350-BFF in CD-1 mice

[0639] Next, the immunogenicity of MVA-gp350-BFF was tested in an outbred mouse model (i.e., CD-1 mice), which is characterized by a diverse combination of MHC haplotypes and thus presents a more human-like condition. In contrast, Balb / c mice (see, for example, Example 4.3) are an inbred mouse strain characterized by a single haplotype.

[0640] On days 0 and 21, CD-1 mice were immunized intramuscularly with MVA-gp350-GCN4, MVA-gp350-BFF, or TBS buffer for primary / boost immunization. Gp350-specific humoral responses were analyzed on day 40 post-primary immunization.

[0641] like Figure 11 As shown, MVA-gp350-BFF encoding BFF fusion induced significantly higher anti-gp350 IgG titers than MVA-gp350-GCN4 encoding tetrameric gp350. Figure 11A). No gp350-specific antibodies were found in control mice injected with TBS. Figure 11 A).

[0642] In addition, the antigen-specific T cell response following CD-1 immunization in mice was analyzed. Spleens were isolated on day 41 post-primary immunization for the preparation of single-cell suspensions. Spleen cells were then restimulated overnight with a gp350 peptide pool (PP). The number of antigen-specific T cells producing IFNγ was counted using ELISpot assay. Analysis of antigen-specific T cells following CD-1 immunization in mice showed that both MVA-gp350-GCN4 and MVA-gp350-BFF induced comparable levels of gp350-specific T cell responses. Figure 11 B).

[0643] In summary, the recombinant MVA encoding gp350 fused to the nanoparticle BFF (MVA-gp350-BFF) induced significantly higher anti-gp350 IgG titers in outbred CD1 mice compared to the recombinant MVA encoding tetrameric gp350-GCN4. Simultaneously, antigen-specific T-cell responses to gp350 were preserved. This demonstrates that increasing antigen-specific antibodies by fusing the antigen to the BFF backbone can convert mouse populations containing various MHC haplotypes. Given the high polymorphism of human MHC genes and the existence of multiple distinct HLA haplotypes in the human population, the fact that the nanoparticle effect is not specific to any particular mouse strain or MHC haplotype is an important observation.

[0644] Example 5: Effects of BFF nanoparticles on Lyme disease antigen expression and immunogenicity

[0645] The results obtained using the bacterial model antigen, Borrelia burgdorferi OspA, were re-examined using the SARS-CoV-2 RBD (see Example 2) and EBV gp350 (see Example 4) antigens. OspA is an outer surface protein of Borrelia burgdorferi (the causative agent of Lyme disease), which plays a role in the transmission of the bacteria from the tick midgut to the salivary glands. Previous work has shown that OspA vaccination can induce a protective immune response against Lyme disease.

[0646] 5.1 Lyme disease antigen constructs with and without BFF nanoparticles

[0647] Two antigen constructs were designed: the first containing the htPA signal peptide, followed by a tandem of the C-terminal fragments (CF) of three serotypes of OspA (see [link to original text]). Figure 12 The second type contains the same OspA CF tandem that is fused to the BFF (see 5); and the third type contains the same OspA CF tandem that is fused to the BFF (see 5). Figure 12 The constructor in -6).

[0648] Recombinant VRPs encoding construct-5 or construct-6 were prepared as described in Example 1.1.2.3.

[0649] 5.2 Immunological response to VRP-delivered OspA-ST1-5-6 or OspA-ST1-5-6-BFF antigens

[0650] The in vivo immunogenicity of VRP-encoded monomer OspA-ST1-5-6 (“VRP-OspA-ST1-5-6”) was compared with that of VRP-encoded OspA-ST1-5-6-BFF fusion protein (“VRP-OspA-ST1-5-6-BFF”). Figure 13 Therefore, Balb / c mice were immunized with the appropriate VRP on days 0 and 21.

[0651] Figure 13 The results presented showed that OspA-ST1-5-6 strongly induced a humoral immune response when presented on self-forming nanoparticles (BFF) (see “VRP-OspA-ST1-5-6-BFF”). Total anti-OspA-ST1 IgG was significantly increased compared to non-particulate antigens (see “VRP-OspA-1-5-6”).

[0652] In summary, similar to the results obtained using the SARS-CoV-2 RBD and EBV gp350 antigens, the results obtained using the OspA-ST1-5-6 antigen also demonstrate that BFF-mediated antigen presentation significantly enhances antibody responses when the antigen-BFF fusion protein is encoded by VRP.

[0653] Example 6: Effects of nanoparticle candidates as alternatives to BFF on the expression and immunogenicity of SARS-CoV-2 spike RBD antigen

[0654] To expand the available nanoparticle library beyond BFF, a protein database (PDB) was screened for the structures of homologous oligomers and self-assembled symmetrical multimers of bacteria or archaea. Based on their size, oligomeric state, and the surface exposure of their ends, five candidates (one 60-mer, two 24-mers, and two 12-mers) were selected as potential nanoparticle antigen presentation platforms for further screening.

[0655] The selected nanoparticles are as follows (see Figure 14 ):

[0656] 6.1 RBD antigen constructs with nanoparticle candidates

[0657] Five antigen constructs were designed, each containing an RBD of the SARS-CoV-2 spike protein. The N-terminus of the RBD was fused to the signal peptide of htPA, and the C-terminus was fused to a subunit of one of the five nanoparticle candidates (see [link to relevant documentation]). Figure 15 (Constructors -7 to -11).

[0658] The nucleic acids encoding constructs-7 through-11 were cloned into the VEEV replicon plasmid to generate recombinant VRPs, as described in Example 1.1.2.4.

[0659] 6.2 Western blot analysis of VRP-encoded RBD-nanoparticle candidate fusion proteins

[0660] Expression and nanoparticle assembly were analyzed by transfecting HEK293T cells with plasmid DNA containing a replicon of a recombinant CMV promoter encoding the SARS-CoV-2 spike RBD-nanoparticle fusion protein. Cell lysates and supernatants were collected the following day and analyzed by Western blotting (see Example 1.3.2). Results are shown in... Figure 16 middle.

[0661] A band slightly below 50 kDa was detected in the lysate of HEK293T cells transfected with the VEEV replicon plasmid encoding the SARS-CoV-2 spike RBD-HisB fusion protein (calculated MW = 47.1 kDa, excluding glycosylation). Figure 16 Lane A, lane 7), but no band was detected in the supernatant. Figure 16 B, Lane 7).

[0662] A band slightly above 50 kDa was detected in the lysate of cells transfected with the VEEV replicon plasmid encoding the SARS-CoV-2 spike protein RBD-PdhC (calculated MW = 51.8 kDa, glycosylation-free). Figure 16 Lane A, lane 8). When running the electrophoresis gel under denaturing conditions, bands of the same size were detected in the cell supernatant. Figure 16 B, lane 8), but when running the gel under natural conditions, it deviates to the size of the maximum labeled band exceeding 1,236 kDa. Figure 16 C, lane 8). Therefore, the RBD-PdhC fusion protein was expressed, secreted, and assembled into nanoparticles.

[0663] A band of approximately 40 kDa was detected in the lysate of cells transfected with the VEEV replicon plasmid encoding the SARS-CoV-2 spike RBD-DPS fusion protein (calculated MW = 42.8 kDa, glycosylation-free). Figure 16A, lane 9). Similar-sized bands were detected in the cell supernatant under denaturing conditions. Figure 16 B, lane 9), while a band >720 kDa was detected in the natural imprint ( Figure 16 C, lane 9). Therefore, the RBD-DPS fusion protein was expressed, secreted, and assembled into nanoparticles.

[0664] A band of approximately 60 kDa was detected in the lysate of cells transfected with the VEEV replicon plasmid encoding the SARS-CoV-2 spike protein RBD-SOR (calculated MW = 60.4 kDa, glycosylation-free). Figure 16 A, lane 10), and a band of approximately 50 kDa was detected in the lysate of cells transfected with the VEEV replicon plasmid encoding the SARS-CoV-2 spike protein RBD-MrsD (calculated MW = 52.4 kDa, glycosylated-free). Figure 16 Lane A, lane 11). No bands were detected in the cell supernatant for either construct. Figure 16 B Figure 16 C (lanes 10 and 511) indicate protein secretion and nanoparticle assembly failure.

[0665] These results indicate that while all SARS-CoV-2 spike RBD-nanoparticle fusion proteins were expressed in replicon-transfected HEK293T cells, only SARS-CoV-2 spike RBD-PdhC and SARS-CoV-2 spike RBD-DPS were efficiently secreted. PdhC typically exists in 60-mer form (see [link to study]). Figure 14 Therefore, the size of the assembled SARS-CoV-2 spike RBD-PdhC nanoparticles should be approximately >3,000 kDa (60 × (51.8 kDa + MW)). 聚糖 Because this size exceeds the range covered by the size standard used (NativeMark™ unstained protein standard), a more precise size estimate is not possible, but the sharp edges and overall shape of the detected band are significant. Figure 16 Lane C (8) demonstrates the successful nanoparticle assembly of SARS-CoV-2 spike RBD-PdhC nanoparticles. DPS typically exists in 12-mer form (see [link]). Figure 14 Therefore, the molecular weight of the assembled SARS-CoV-2 spike RBD-DPS nanoparticles is expected to be >500 kDa (12 × (42.8 kDa + MW)). 聚糖 This is lower than the >720 kDa band detected in natural gels. Figure 16C, lane 9). However, migration behavior on natural gels depends largely on protein folding and assembly. Figure 16 The clear delineation of the band shown in lane C9 indicates successful particle assembly, rather than nonspecific polymerization (such as aggregation) leading to an increase in apparent size when comparing the bands detected in denatured and natural gels.

[0666] Overall, these results indicate that both PdhC and DPS can be used for nanoparticle antigen presentation.

[0667] 6.3 RBD antigen constructs with nanoparticle candidates, wherein the RBD and nanoparticles are fused in reverse orientation.

[0668] In the currently described SARS-CoV-2 spike RBD-nanoparticle fusion protein, the nanoparticles (i.e., BFF and all tested nanoparticle candidates) are fused to the SARS-CoV-2 spike RBD via their N-terminus. However, some antigens are typically anchored to the pathogen at their N-terminus, so if their C-terminus is fused to the N-terminus of the nanoparticle, they will be displayed in an "inverted" orientation.

[0669] Although BFF can only fuse to the antigen at its C-terminus, both ends are exposed on the HisB, DPS, SOR, and MrsD nanoparticles because the N-terminus is located inside the assembled nanoparticles, and PdhC only has its N-terminus exposed on the particle surface (see [link to article]). Figure 14 To evaluate whether these nanoparticles are suitable for C-terminal display of the SARS-CoV-2 spike RBD, four additional constructs were designed (see [link to documentation]). Figure 17 The constructs contain HisB (constructor-12), DPS (constructor-13), SOR (constructor-14), or MrsD (constructor-15), with their respective C-termini fused to the N-terminus of the RBD. In these constructs, the N-terminus of each nanoparticle candidate is fused to the htPA signal peptide (see [link to relevant documentation]). Figure 17 ).

[0670] The recombinant VRP encoding one of constructs-12 to-15 was prepared as described in Example 1.1.2.4.

[0671] 6.4 Western blot analysis of VRP-encoded RBD-nanoparticle candidate fusion proteins

[0672] HEK293T cells were transfected with a plasmid encoding one of constructs 12 through 15, as described in Example 1.3.1 above. Cell lysates and supernatants were collected and analyzed by Western blotting (see Example 1.3.2). Results are shown in... Figure 18 middle.

[0673] The calculated molecular weight of the reverse fusion protein was the same as that of the corresponding N-terminal SARS-CoV-2 spike RBD fusion protein (see Example 6.2). Bands of the expected size were detected in cell lysates transfected with each replicon plasmid. Figure 18 A).

[0674] However, although all reverse fusion proteins were expressed in detectable amounts in transfected cells ( Figure 18 A), but only the HisB-RBD and DPS-RBD fusion proteins are secreted, as indicated by bands of expected size in the corresponding supernatant. Figure 18 (B, lanes 12 and 13). Furthermore, the high molecular weight bands detectable under natural conditions indicate successful nanoparticle assembly of the two secreted fusion proteins.

[0675] Therefore, both HisB and DPS can be used to present membrane antigens that are initially anchored in the membrane via their N-terminus in a spatially correct manner.

[0676] 6.5 Immunological response to VRP-delivered RBD-nanoparticle candidate fusion protein

[0677] Mice were intramuscularly immunized on days 0 and 21 with VRP-RBD monomer, VRP-RBD-DPS, or VRP encoding inverse fusion proteins (i.e., VRP-DPS-RBD and VRP-HisB-RBD). Serum was separated from blood samples collected on days 14 and 35 and used for ELISA to detect RBD-specific total antibody titers or cPass assays to determine RBD neutralizing antibody titers. Results are shown in... Figure 19 middle.

[0678] To confirm the previous findings of RBD-BFF (see...) Figure 4 ), fusing the N-terminus of the VRP that initiates DPS or HisB nanoparticles to the RBD antigen also induced a stronger RBD antibody response on day 35 than when VRP-RBD was delivered as a monomeric RBD antigen. Figure 19 A). VRP-DPS-RBD and VRP encoding the reverse fusion protein (i.e., VRP-RBD-DPS) induce similar total anti-RBD IgG titers, while VRP-HisB-RBD induces even higher titers. Figure 19 A).

[0679] Furthermore, the titer of neutralizing RBD-binding antibodies was measured using serum samples from day 35. A significant increase in RBD-binding neutralizing antibodies was observed in all VRP-nanoparticle immunization groups compared to VRP-RBD monomers. Figure 19B).

[0680] In addition, T-cell responses were assessed. Spleen cells were isolated on day 35 (14 days after booster immunization), and IFN-γ ELISpot analysis was performed by restimulation with SARS-CoV-2 spike peptide pool A (Genscript). Strong SARS-CoV-2 spike-specific T-cell responses were induced in all vaccination groups, and no difference was detected between RBD monomers and RBD-nanoparticles expressing VRP. Figure 19 C).

[0681] Overall, VRP delivery of SARS-CoV-2 RBD fused to nanoparticle candidates DPS or HisB showed highly efficient elicitation of anti-RBD antibodies and T cell responses following intramuscular immunization. The orientation of the RBD antigen within the fusion protein (i.e., whether it is fused to the N-terminus or the C-terminus to DPS) did not alter the efficiency of neutralizing RBD antibody-induced responses. Therefore, DPS and HisB are useful alternatives to BFF.

[0682] 6.6 Immunological response of VRP-delivered RBD nanoparticle candidate fusion protein in CD-1 mice

[0683] The immunogenicity of VRP expressing RBD antigens as monomers or fused to self-forming nanoparticles was tested in an outbred mouse model characterized by diverse MHC haplotype combinations, thus exhibiting a more human-like pattern. CD-1 mice were immunized intramuscularly on days 0 and 21 with VRP RBD monomers, VRP-HisB-RBD, VRP-DPS-RBD, or VRP RBD-BFF. RBD-specific humoral responses were analyzed on day 42 post-primary immunization. Results are shown in… Figure 20 middle.

[0684] VRP-HisB-RBD, VRP-DPS-RBD, and VRP-RBD-BFF induce higher anti-RBD IgG titers than VRP-RBD monomers. Figure 20 A). No RBD-specific antibodies were found in buffer-immunized control mice. Figure 20 A).

[0685] In addition, the antigen-specific T cell response following CD-1 immunization in mice was analyzed. Spleens were isolated on day 42 post-primary immunization for the preparation of single-cell suspensions. The spleen cells were then restimulated overnight with an RBD peptide pool. The number of antigen-specific T cells producing IFNγ was counted using an ELISpot assay. Analysis of antigen-specific T cells following CD-1 immunization in mice showed that all VRP immunization groups induced a comparable level of RBD-specific T cell response (…). Figure 20 B).

[0686] In summary, VRP expressing RBD fused to nanoparticles BFF, HisB, and DPS induced higher anti-RBD IgG titers in outbred CD1 mice while preserving antigen-specific T-cell responses. This demonstrates that increasing antibody levels by fusing antigens to the nanoparticle backbone can transform mouse populations containing various MHC haplotypes. Given the high polymorphism of human MHC genes and the existence of multiple distinct HLA haplotypes in the human population, the fact that the nanoparticle effect is not specific to any particular mouse strain is an important observation.

[0687] 6.7 gp350 antigen construct with nanoparticle candidates

[0688] To test the immunogenicity of different nanoparticle candidates for presenting gp350, two novel VRP constructs were developed. Figure 21 Specifically, VRP-DPS fused to the gp350 and VRP-PdhC fused to the gp350 were examined. PdhC is a 60-mer (see...). Figure 14 It also offers a higher antigenic titer compared to DPS.

[0689] 6.8 Immunological response to VRP-delivered gp350-nanoparticle candidate fusion protein

[0690] Mice were immunized with VRP-gp350, VRP-gp350-BFF, VRP-DPS-gp350, and VRP-PdhC-gp350, respectively, on days 0 and 21. Antibody responses against gp350 induced by VRP expressing tetrameric gp350 (VRP-gp350-GCN4) were compared with antibody responses induced by VRP expressing gp350 fused to BFF, DPS, or PdhC. Figure 22 The results presented showed that gp350 strongly induced a humoral immune response when presented on one of the self-assembled nanoparticles. Antibody responses were comparable across different nanoparticles regardless of their size.

[0691] Example 7: Multi-antigen nanoparticles - Expression and immunogenicity of two different antigens displayed on the same BFF nanoparticle

[0692] Furthermore, the possibility of inducing an immune response against two unrelated antigens presented on the same nanoparticle was explored. Such dual-antigen nanoparticles, also known as "mosaic" nanoparticles, would allow the induction of an immune response against two different antigens from a single vaccine carrier, where both antigens would benefit from the increased immunogenicity resulting from their display on the nanoparticle.

[0693] 7.1 Multiantigen nanoparticle constructs for displaying SARS-CoV-2 spike RBD and EBV gp350 on BFF

[0694] The gp350-BBFF and RBD-BFF encoded by T2A sites were prepared as described in Example 1.1.2.6 (see Example 1.1.2.6). Figure 23 The recombinant VRP of the construct-18 in the middle.

[0695] 7.2 Western blot analysis of RBD-BFF / gp350 multi-antigen nanoparticle proteins

[0696] HEK293T cells were used with the encoding construct-18 ( Figure 23 ), Component-2 ( Figure 1 ) or Construct-4 ( Figure 8 The cells were transfected with a plasmid containing a replicator of the protein for comparison, as described in Example 1.3.1 above. Cell supernatants were collected and analyzed by native Western blotting (see Example 1.3.2). The results are shown in... Figure 24 middle.

[0697] When using anti-RBD antibodies ( Figure 24 When A), a band was detected in the cell supernatant expressing construct-18 or construct-2. When using anti-gp350 antibody ( Figure 24 In case B), bands were detected in the cell supernatant expressing construct-18 or construct-4. When using antiferritin antibody, bands were detected in the cell supernatant expressing all three constructs (see [link to relevant documentation]). Figure 24 C).

[0698] These findings confirmed that two antigens, SARS CoV-2 RBD and EBV gp350, were expressed by cells transfected with a replicon plasmid encoding construct-18. As described above (Example 2.2), the assembled 24-mer RBD-BFF nanoparticles had a molecular weight > 1.1 mDa (24 × 45.29 kDa plus the additional weight from the added glycan), while the highly glycosylated gp350-BFF had a molecular weight of approximately 2.4 mDa at assembly. This corresponds perfectly to the band positions detected in the supernatant of cells transfected with replicon plasmids encoding construct-2 or construct-4. The band detected in the supernatant of cells transfected with a replicon plasmid encoding construct-18 was detected at a position indicating a molecular weight between the assembled RBD-BFF 24-mer and the gp350-BFF 24-mer, thus indicating successful assembly of the dual-antigen nanoparticles.

[0699] 7.3 Immunological response to VRP-encoded RBD-BFF / gp350-BFF multiantigen nanoparticles

[0700] Mice were given primary / boost intramuscular immunizations on days 0 and 21 using VRP or buffer containing bivalent nanoparticles as controls. Serum was collected on day 35 to determine anti-gp350 and anti-RBD antibody responses. Results are shown in... Figure 25 middle.

[0701] VRP-RBD-BFF-gp350-BFF induces antigen-specific antibody titers against two antigens. Figure 25 A, Figure 25 B). However, compared to single antigen VRP, a decrease in antibody titer was detected for anti-RBD IgG titers (B). Figure 25 A). Anti-gp350 IgG titers appear to be less affected by the presentation of mixed nanoparticles. Figure 25 B).

[0702] In addition, antigen-specific T-cell responses were analyzed. Spleens were isolated on day 35 post-primary immunization for the preparation of single-cell suspensions. The spleen cells were then processed using an RBD peptide pool (…). Figure 25 C) or gp350 peptide pool ( Figure 25 D) Restimulation overnight. Antigen-specific T cells producing IFN-γ were counted using an ELISpot assay. Analysis of antigen-specific T cells after primary / boost immunization showed that VRP-RBD-BFF-gp350-BFF elicited both RBD-specific and gp350-specific T cell responses. Compared to VRP expressing the corresponding single antigen on BFF, the VRP immunization group induced comparable levels of RBD-specific T cell responses, while the gp350-specific T cell response was slightly reduced. Figure 25 C Figure 25 D).

[0703] In summary, the results show that BFF nanoparticles can be used to induce antibody responses against two unrelated antigens (i.e., antigens from different viruses (here: SARS-CoV-2 and EBV)) as well as T-cell responses. This would allow for the development of vaccines that simultaneously target different diseases.

[0704] 7.4 Multiantigen nanoparticle constructs for displaying two different Lyme disease antigens on BFF

[0705] To further evaluate the feasibility of multi-antigen nanoparticles and generate single recombinant VRPs encoding OspA fragments from six of the most relevant disease serotypes, OspA-ST1-5-6-BFF encoded by 2A sites separated from each other was prepared as described in Example 1.1.2.7. Figure 12The constructs in (-6) and OspA-ST2-4-3-BFF ( Figure 26 The constructor in (-19), that is Figure 26 The VEEV TC83 replicon plasmid of construct-20 in the text.

[0706] 7.5 Immunological response to VRP-encoded OspA-ST1-5-6-BFF / OspA-ST2-4-3-BFF multiantigen nanoparticles

[0707] The VRP-OspA-ST1-5-6-BFF / OspA-ST2-4-3-BFF encoding construct -19 ( Figure 26 The immunogenicity of VRP-OspA-ST1-5-6-BFF and OspA-ST2-4-3-BFF (i.e., two recombinant VRPs, each encoding only one of the two fusion proteins) was compared with that of VRP-OspA-ST1-5-6-BFF and OspA-ST2-4-3-BFF.

[0708] On days 0 and 21, mice were immunized intramuscularly with either VRP-OspA-ST1-5-6-BFF-OspA-ST2-4-3-BFF or with a 1:1 mixture of VRPs encoding the corresponding single antigen constructs (VRP-OspA-ST1-5-6-BFF and VRP-OspA-ST2-4-3-BFF, respectively). Serum was collected on day 35 to determine anti-OspAST1 and anti-OspAST2 antibody responses.

[0709] like Figure 27 As shown, VRP-OspA-ST1-5-6-BFF-OspA-ST2-4-3-BFF induces targeting OspA-ST1 ( Figure 27 A) and OspA-ST2 ( Figure 27 B) Antigen-specific antibody titers against the antigens. Importantly, the antibody titers against both antigens were comparable to those detected when mice were immunized with a mixture of VRPs encoding a single antigen (i.e., VRP-OspA-ST1-5-6-BFF and VRP-OspA-ST2-4-3-BFF).

[0710] In summary, VRPs exhibiting two distinct tandem forms of BFF nanoparticles expressing the OspA fragment of the spirochete on the surface are as effective as mixtures of two VRPs each expressing only one tandem form of BFF on the surface. This will allow for a more efficient vaccine manufacturing process, as only one type of VRP needs to be produced instead of two.

[0711] Final Note: Several documents are referenced throughout this specification. Each document referenced herein (including all patents, patent applications, scientific publications, manufacturers' specifications, instructions, etc.) is hereby incorporated in its entirety by reference. In any way that material incorporated by reference contradicts or is inconsistent with this specification, this specification supersedes any such material. Nothing herein should be construed as an admission that the invention is not entitled to any prior invention prior to such disclosure.

[0712] References

[0713] sequence

[0714] SEQ ID NO: 1 is the nucleic acid sequence encoding the SARS-CoV-2 spike RBD.

[0715] GTGCAGCCCACAGAGTCTATCGTGCGGTTCCCTAACATCACCAATCTGTGTCCTTTTGGCGAGGTGTTCAACGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTTGCCGACTACAGCGTGCTGTACAACTCTGCCAGCT TCTCCACCTTCAAGTGCTATGGCGTGTCTCCTACCAAGCTGAACGACCTGTGCTTCACCAACGTGTACGCTGACAGCTTCGTGATCAGAGGCGACGAAGTGAGACAGATTGCTCCTGGACAGACAGGCAAGATTGCCGATTACAACTACAAGCTCCCTGACGAC TTCACAGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACAGCAAAGTCGGAGGTAACTACAACTACCTGTACAGGCTGTTTCGGAAGTCCAACCTGAAGCCTTTCGAGAGAGACATCAGCACCGAGATCTATCAGGCAGGCAGCACACCTTGCAATGGCG TGGAAGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTCCAGCCTACAAATGGAGTGGGCTACCAGCCTTACAGAGTGGTGGTGCTGAGCTTCGAGCTTGCTGCATGCTCCTGCCACAGTGTGCGGACCTAAGAAAAGCACCAACCTGGTGAAGAACAAA

[0716] SEQ ID NO: 2 Amino acid sequence of SARS-CoV-2 spike RBD.

[0717] VQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDD FTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0718] SEQ ID NO: 3 encodes the nucleic acid sequence of EBV gp350.

[0719]

[0720] The amino acid sequence of SEQ ID NO: 4 EBV gp350.

[0721] MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRS KKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGE ISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTL

[0722] Nucleic acid sequence of bullfrog / Helicobacter pylori heterozygous ferritin SEQ ID NO: 5.

[0723] GAATCTCAAGTTCGGCAGCAGTTCAGCAAGGACATCGAGAAGCTGCTGAACGAGCAAGTGAACAAAGAGATGCAGAGCAGCAACCTGTACATGAGCATGAGCAGCTGGTGCTACACCCACAGCCTTGAT GGCGCCGGACTGTTCCTGTTTGATCACGCCGCCGAGGAATACGAGCACGCCAAGAAGCTGATCATCTTCCTGAACGAGAACAACGTGCCCGTGCAGCTGACCAGCATTTCTGCCCTGAGCACAAGTTCG AGGGCCTGACACAGATCTTTCCAGAAGGCCTACGAACACGAGCAGCACATTAGCGAGAGCATCAACAACATCGTGGACCACGCCATTAAGAGCAAGGATCACGCCACCTTCAACTTTCTGCAGTGGTACGT GGCCGAACAGCACGAGGAAGAGGTGCTGTTCAAGGACATCCTGGACAAGATCGAGCTGATCGGCAACGAGAACCACGGCCTGTATCTGGCCGACCAGTACGTGAAGGGAATCGCCAAGAGCAGAAAGAGC

[0724] The amino acid sequence of bullfrog / Helicobacter pylori heterozygous ferritin SEQ ID NO: 6.

[0725] ESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0726] SEQ ID NO: 7 is the nucleic acid sequence encoding HisB.

[0727] GCATCTAGAAGGGCCAGAATCGAGAGAAGAACCCGCGAGAGCGACATCGTGATCGAGCTGGATCTGGATGGCACAGGACAGGTGGCAGTGGATACAGGCGTGCCCTTCTACGACCACATGCTGACAGCTCTGGGCAGCCACGCCTCTTTCGACCTGACAGTTAGAGCCACCGGCGACGTGGAAATCGAGGCCCACCACACAATCGAGGACACCGCTATCGCTCTGGGAACAGCTCTTGGACAGGCCCTGGGCGATAAGAGAGGCATCAGAAGATTCGGCGACGCTTTCATCCCCATGGACGAGACACTGGCTCACGCTGCCGTTGACCTTAGCGGCAGACCTTACTGTGTGCATACCGGCGAGCCTGACCATCTGCAGCACACAACAATCGCCGGCAGCAGCGTGCCATACCACACCGTGATCAACAGACACGTGTTCGAGAGCCTGGCCGCCAACGCTAGAATCGCTCTGCATGTGCGGGTGCTGTACGGCAGAGATCCCCACCACATCACAGAGGCCCAGTACAAGGCTGTGGCCAGGGCTCTGAGACAGGCCGTTGAACCTGATCCTAGAGTGTCCGGCGTGCCATCTACAAAGGGTGCTCTG

[0728] SEQ ID NO: 8 Amino acid sequence of HisB

[0729] ASRRARIERRTRESDIVIELDLDGTGQVAVDTGVPFYDHMLTALGSHASFDLTVRATGDVEIEAHHTIEDTAIALGTALGQALGDKRGIRRFGDAFIPMDETLAHAAVDLSGRPYCVHTGEPDHLQHTTIAGSSVPYHTVINRHVFESLAANARIALHVRVLYGRDPHHITEAQYKAVARALRQAVEPDPRVSGVPSTKGAL

[0730] SEQ ID NO: 9 Nucleic acid sequence encoding PdhC

[0731] GCTGCTGCTAAACCTGCTACAACAGAGGGCGAGTTCCCCGAGACACGCGAGAAGATGTCTGGCATCAGAAGGGCTATCGCCAAGGCCATGGTGCACAGCAAGCACACAGCTCCTCACGTGACCCTGATGGACGAGGCCGATGTGACAAAGCTGGTGGCCCACAGAAAGAAGTTCAAGGCCATTGCCGCCGAGAAGGGAATCAAGCTGACCTTCCTGCCTTACGTGGTCAAGGCCCTGGTTTCTGCCCTGAGAGAATACCCCGTGCTGAACACCAGCATCGACGACGAGACAGAGGAAATCATCCAGAAGCACTACTACAACATCGGAATCGCCGCCGACACCGACAGAGGACTGCTGGTGCCTGTGATCAAGCACGCCGACAGAAAGCCCATCTTCGCCCTGGCTCAAGAGATCAACGAGCTGGCTGAGAAGGCCAGAGATGGCAAGCTGACACCCGGCGAAATGAAGGGCGCCAGCTGTACCATCACCAACATCGGTTCTGCTGGCGGCCAGTGGTTCACCCCAGTGATCAATCACCCTGAGGTGGCCATCCTCGGCATCGGCAGAATCGCTGAGAAGCCCATCGTCCGCGACGGCGAAATTGTGGCTGCTCCTATGCTGGCCCTGAGCCTGAGCTTCGACCACAGAATGATCGACGGCGCCACAGCTCAGAAGGCCCTGAACCACATCAAGAGACTGCTGAGCGACCCCGAGCTGCTGCTGATGGAAGCT

[0732] Amino acid sequence of SEQ ID NO: 10 PdhC.

[0733] AAAKPATTEGEFPETREKMSGIRRAIAKAMVHSKHTAPHVTLMDEADVTKLVAHRKKFKAIAAEKGIKLTFLPYVVKALVSALREYPVLNTSIDDETEEIIQKHYYNIGIAADTDRGLLVPVIKHADRKPIFALAQEINELAEKARDGKLTPGEMKGASCTITNIGSAGGQWFTPVINHPEVAILGIGRIAEKPIVRDGEIVAAPMLALSLSFDHRMIDGATAQKALNHIKRLLSDPELLLMEA

[0734] SEQ ID NO: 11 Nucleic acid sequence encoding DPS.

[0735] GCTACAAATCTGCTGTACACCAGAAACGACGTGTCCGACAGCGAGAAGAAGGCCACAGTCGAGCTGCTGAACAGACAAGTGATCCAGTTCATCGACCTGAGCCTGATCACCAAGCAGGCCCACTGGAACATGAGAGGCGCCAACTTTATCGCCGTGCACGAGATGCTGGACGGCTTCAGAACAGCCCTGATCGACCACCTGGACACCATGGCTGAAAGAGCTGTGCAGCTTGGCGGAGTGGCTCTGGGCACAACCCAAGTGATCAACAGCAAGACCCCTCTGAAGTCTTACCCTCTGGACATCCACAACGTGCAGGACCACCTGAAAGAACTGGCCGACAGATACGCCATCGTGGCCAATGATGTGCGGAAGGCTATCGGCGAGGCCAAGGACGATGATACCGCCGATATCCTGACAGCCGCCAGCAGAGATCTGGACAAGTTCCTGTGGTTCATCGAGAGCAACATCGAG

[0736] SEQ ID NO: 12 Amino acid sequence of DPS.

[0737] ATNLLYTRNDVSDSEKKATVELLNRQVIQFIDLSLITKQAHWNMRGANFIAVHEMLDGFRTALIDHLDTMAERAVQLGGVALGTTQVINSKTPLKSYPLDIHNVQDHLKELADRYAIVANDVRKAIGEAKDDDTADILTAASRDLDKFLWFIESNIE

[0738] SEQ ID NO: 13 is a nucleic acid sequence encoding SOR.

[0739] CCTAAACCTTACGTGGCCATCAACATGGCCGAGCTGAAGAACGAGCCCAAGACCTTCGAGATGTTCGCCAGCGTGGGCCCCAAAGTGTGCATGGTCACAGCTAGACACCCTGGCTTCGTGGGCTTCCAGAACCACATCCAGATCGGCATCCTGCCTTTCGGCAACAGATACGGCGGAGCTAAGATGGACATGACCAAAGAGTCCAGCACCGTCAGAGTGCTGCAGTACACCTTCTGGAAGGATTGGAAGGACCACGAGGAAATGCACAGACAGAACTGGTCCTACCTGTTCAGACTGTGCTACAGCTGCGCCAGCCAGATGATCTGGGGACCTTGGGAGCCCATCTACGAGATCATCTACGCCAACATGCCCATCAACACCGAGATGACCGACTTCACAGCCGTCGTGGGCAAGAAGTTCGCTGAGGGCAAGCCTCTGGACATCCCCGTGATCTCTCAGCCCTACGGCAAGAGAGTGGTGGCCTTCGCTGAGCACTCTGTGATCCCCGGCAAAGAGAAGCAGTTCGAGGACGCCATCGTGCGGACCCTGGAAATGCTGAAGAAGGCCCCTGGCTTTCTGGGCGCCATGGTGCTGAAAGAAATCGGCGTGTCCGGCATCGGCAGCATGCAGTTTGGCGCTAAGGGCTTCCACCAGGTGCTGGAAAACCCCGGCTCTCTGGAACCCGATCCTAACAACGTGATGTACAGCGTGCCCGAGGCCAAGAACACCCCTCAGCAGTATATCGTGCACGTGGAATGGGCCAACACAGACGCCCTGATGTTCGGCATGGGACGCGTGCTGCTGTACCCTGAACTGAGACAGGTGCACGACGAAGTGCTGGACACACTGGTGTACGGCCCCTACATCAGAATCCTGAATCCTATGATGGAAGGCACGTTCTGGCGCGAGTACCTGAACGAACAA

[0740] Amino acid sequence of SOR set forth in SEQ ID NO: 14.

[0741] PKPYVAINMAELKNEPKTFEMFASVGPKVCMVTARHPGFVGFQNHIQIGILPFGNRYGGAKMDMTKESSTVRVLQYTFWKDWKDHEEMHRQNWSYLFRLCYSCASQMIWGPWEPIYEIIYANMPINTEMTDFTAVVGKKFAEGKPLDIPVISQPYGKRVVAFAEHSVIPGKEKQFEDAIVRTLEMLKKAPGFLGAMVLKEIGVSGIGSMQFGAKGFHQVLENPGSLEPDPNNVMYSVPEAKNTPQQYIVHVEWANTDALMFGMGRVLLYPELRQVHDEVLDTLVYGPYIRILNPMMEGTFWREYLNEQ

[0742] SEQ ID NO: 15 Nucleic acid sequence encoding MrsD.

[0743] TCTATCAGCATCCTGAAGGACAAGAAGCTGCTGATCGGCATCTGCGGCAGCATCAGCTCTGTGGGCATCTCCAGCTACCTGCTGTACTTCAAGAGCTTCTTCAAAGAAATCCGGGTCGTGATGACCAAGACCGCCGAGGATCTGATCCCTGCTCACACCGTGTCCTACTTTTGCGACCACGTGTACAGCGAGCACGGCGAGAATGGCAAGAGACACAGCAACGTGGAAATCGGCAGATGGGCCGACATCTACTGCATCATCCCTGCCACCGCTAACATCCTGGGCCAGACAGCTAATGGCGTGGCCATGAACCTGGTGGCCACAACCGTTCTGGCTCACCCTCACAACACCATCTTTTTCCCCAACATGAACGACCTGATGTGGAACAAGACCGTGGTGTCCAGAAACATCGAGCAGCTGAGAAAGGACGGCCACATCGTGATCGAGCCTGTGGAAATCATGGCCTTCGAGATCGCCACCGGCACCAGAAAGCCTAACAGAGGCCTGATCACCCCTGACAAGGCCCTGCTGGCTATCGAGAAGGGCTTCAAAGAGAGAACAAAGCACCCCAGCCTGACC

[0744] The amino acid sequence of SEQ ID NO: 16 MrsD.

[0745] SISILKDKKLLIGICGSISSVGISSYLLYFKSFFKEIRVVMTKTAEDLIPAHTVSYFCDHVYSEHGENGKRHSNVEIGRWADIYCIIPATANILGQTANGVAMNLVATVLAHPHNTIFFPNMNDLMWNKTVVSRNIEQLRKDGHIVIEPVEIMAFEIATGTRKPNRGLITPDKALLAIEKGFKERTKHPSLT

[0746] The nucleic acid sequence encoding the SARS-CoV-2 spike RBD (“constructor-1”) with the htPA signal peptide in SEQ ID NO: 17 MVA.

[0747] ATGGATGCCATGAAGCGTGGACTGTGCTGTGTGCTGCTCCTGTGCGGAGCTGTGTTCGTTAGTGCCTCTGTGCAGCCCACAGAGTCTATCGTGCGGTTCCCTAACATCACCAATCTGTGCCCTTTTGGCGAGGTGTTCAACGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTTGCCGACTACAGCGTGCTGTACAACTCTGCCAGCTTCTCCACCTTCAAGTGCTATGGCGTGTCTCCTACCAAGCTGAACGACCTGTGCTTCACCAACGTGTACGCTGACAGCTTCGTGATCAGAGGCGACGAAGTGAGACAGATTGCTCCTGGACAGACAGGCAAGATTGCCGATTACAACTACAAGCTCCCTGACGACTTCACAGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACAGCAAAGTCGGAGGTAACTACAACTACCTGTACAGGCTGTTTCGGAAGTCCAACCTGAAGCCTTTCGAGAGAGACATCAGCACCGAGATCTATCAGGCAGGCAGCACACCTTGCAATGGCGTGGAAGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTCCAGCCTACAAATGGAGTGGGCTACCAGCCTTACAGAGTGGTGGTGCTGAGCTTCGAGCTGCTGCATGCTCCTGCCACAGTGTGCGGACCTAAGAAAAGCACCAACCTGGTGAAGAACAAA

[0748] SEQ ID NO: 18 Nucleic acid sequence encoding the SARS-CoV-2 spike RBD with htPA signal sequence ("Construct-1") in VRP.

[0749] ATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTCTCGGCTAGCGTGCAGCCCACAGAGTCTATCGTGCGGTTCCCTAACATCACCAATCTGTGTCCTTTTGGCGAGGTGTTCAACGCCACCAGATTCGCCTCTGTGTACGCCTGGAACCGGAAGCGGATCAGCAATTGCGTTGCCGACTACAGCGTGCTGTACAACTCTGCCAGCTTCTCCACCTTCAAGTGCTATGGCGTGTCTCCTACCAAGCTGAACGACCTGTGCTTCACCAACGTGTACGCTGACAGCTTCGTGATCAGAGGCGACGAAGTGAGACAGATTGCTCCTGGACAGACAGGCAAGATTGCCGATTACAACTACAAGCTCCCTGACGACTTCACAGGCTGTGTGATTGCCTGGAACAGCAACAACCTGGACAGCAAAGTCGGAGGTAACTACAACTACCTGTACAGGCTGTTTCGGAAGTCCAACCTGAAGCCTTTCGAGAGAGACATCAGCACCGAGATCTATCAGGCAGGCAGCACACCTTGCAATGGCGTGGAAGGCTTCAACTGCTACTTCCCACTGCAGTCCTACGGCTTCCAGCCTACAAATGGAGTGGGCTACCAGCCTTACAGAGTGGTGGTGCTGAGCTTCGAGCTGCTGCATGCTCCTGCCACAGTGTGCGGACCTAAGAAAAGCACCAACCTGGTGAAGAACAAA

[0750] The nucleic acid sequence encoding the SARS-CoV-2 spike RBD with htPA signal peptide ("Construct-1") in SEQ ID NO: 19 mRNA, saRNA and plasmid DNA (where the UTR sequence is underlined).

[0751] AU ACAUUUGCUUCUGACACAACUGUGUUCACUAGCAACCUCAAACAGACACCAUGGAUGCAAUGAAGAGAGGGCUCUGCUGUGUGCUGCUGCUGUGUGGAGCAGUCUUCGUCUCGGCUAGCGUGCAGCCCACAGAGUCUAUCGUGCGGUUCCCUAACAUCACCAAUCUGUGUCCUUUUGGCGAGGUGUUCAACGCCACCAGAUUCGCCUCUGUGUACGCCUGGAACCGGAAGCGGAUCAGCAAUUGCGUUGCCGACUACAGCGUGCUGUACAACUCUGCCAGCUUCUCCACCUUCAAGUGCUAUGGCGUGUCUCCUACCAAGCUGAACGACCUGUGCUUCACCAACGUGUACGCUGACAGCUUCGUGAUCAGAGGCGACGAAGUGAGACAGAUUGCUCCUGGACAGACAGGCAAGAUUGCCGAUUACAACUACAAGCUCCCUGACGACUUCACAGGCUGUGUGAUUGCCUGGAACAGCAACAACCUGGACAGCAAAGUCGGAGGUAACUACAACUACCUGUACAGGCUGUUUCGGAAGUCCAACCUGAAGCCUUUCGAGAGAGACAUCAGCACCGAGAUCUAUCAGGCAGGCAGCACACCUUGCAAUGGCGUGGAAGGCUUCAACUGCUACUUCCCACUGCAGUCCUACGGCUUCCAGCCUACAAAUGGAGUGGGCUACCAGCCUUACAGAGUGGUGGUGCUGAGCUUCGAGCUGCUGCAUGCUCCUGCCACAGUGUGCGGACCUAAGAAAAGCACCAACCUGGUGAAGAACAAAUGAUAAA GCUCGCUUUCUUGCUGUCCAAUUUCUAUUAAAGGUUCCUUUGUUCCCUAAGUCCAAC UACUAAACUGGGGGAUAUUAUGAAGGGCCUUGAGCAUCUGGAUUCUGCCUAAUAAAAAACAUUUAUUUUCAUUGCGC UCGCUUUCUUGCUGUCCAAUUUCUAUUAAAGGUUCCUUUGUUCCCUAAGUCCAACUACUAAACUGGGGGAUAUUAUG AAGGGCCUUGAGCAUCUGGAUUCUGCCUAAUAAAAAACAUUUAUUUUCAUUGC AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0752] SEQ ID NO: 20 encodes the amino acid sequence of the SARS-CoV-2 spike RBD with the htPA signal peptide ("Construct-1").

[0753] MDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTG KIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0754] The nucleic acid sequence in SEQ ID NO: 21 MVA encoding a SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) with htPA signal peptide.

[0755] ATG

[0756] The nucleic acid sequence in SEQ ID NO: 22 VRP encoding a SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) with the htPA signal peptide.

[0757] ATG

[0758] SEQ ID NO: 23 Nucleic acid sequences (with underlined UTR sequences) encoding SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) in mRNA, saRNA and plasmid DNA.

[0759] AU ACAUUUGCUUCUGACACAACUGUGUUCACUAGCAACCUCAAACAGACACC GCUCGCUUUCUUGCUGUCCAAUUUCUAUUAAAGGUUCCUUUGUUCCCUAAG UCCAACUACUAAACUGGGGGAUAUUAUGAAGGGCCUUGAGCAUCUGGAUUCUGCCUAAUAAAAAACAUUUAUUUUCA UUGCGCUCGCUUUCUUGCUGUCCAAUUUCUAUUAAAGGUUCCUUUGUUCCCUAAGUCCAACUACUAAACUGGGGGAU AUUAUGAAGGGCCUUGAGCAUCUGGAUUCUGCCUAAUAAAAAACAUUUAUUUUCAUUGC AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA

[0760] The amino acid sequence of SEQ ID NO: 24 of the SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-2”) with htPA signal peptide.

[0761] MDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQP YRVVVLSFELLHAPATVCGPKKSTNLVKNKSSGGASVLAESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFL NENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0762] The nucleic acid sequence encoding the EBV gp350-GCN4 fusion protein (“constructor-3A”) in SEQ ID NO: 25 MVA.

[0763] ATG

[0764] SEQ ID NO: 26 The nucleic acid sequence encoding the EBV gp350-GCN4 fusion protein (“constructor-3B”) with an IgK LC signal peptide in VRP.

[0765] ATG

[0766] The amino acid sequence of SEQ ID NO: 27 EBV gp350-GCN4 fusion protein (“constructor-3”).

[0767] MEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEE QQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPS GGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDF KCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLPKPSTPPGSSCGGMKVKQLVDKVEELLSKNYHLVNEVARLVKLVGERGG

[0768] SEQ ID NO: 28 Nucleic acid sequence encoding EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“constructor-4”) in MVA with IgK LC signal peptide.

[0769] ATG

[0770] SEQ ID NO: 29 The nucleic acid sequence encoding the EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-4”) with IgK LC signal peptide in VRP.

[0771] ATG

[0772] SEQ ID NO: 30 Amino acid sequence of EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-4”) with IgK LC signal peptide.

[0773] METDTLLLWVLLLWVPGSTGDEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTM WCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYC IQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLPKPSTPPGSSESQVRQQFSKDIE KLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0774] The nucleic acid sequence in SEQ ID NO: 31 VRP encoding a tandem fragment of the OspA serotype 1, 5 and 6 C-terminal fragments with the htPA signal peptide (OspA ST1-5-6) (“construct-5”).

[0775]

[0776] The amino acid sequence of the OspA serotype 1, 5 and 6 C-terminal fragment tandem (OspA ST1-5-6) (“construct-5”) with htPA signal peptide in VRP. SEQ ID NO: 32

[0777] MDAMKRGLCCVLLLCGAVFVSASFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKQFTLEGKVANDKTTLVVKCGTVTLSKQISKSGEVSVELQDTDSSAATKKTAAWNSGTSTLTITVNS KKTKDLVFTKENTITVQQYDSQGTKLEGSAVEITKLDEICNALKGGGGSGGGGSGGGGSGGGGSFNEKGEISEKTIVRAQGTRLEYTDIKSDKTGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVTL SKQISKSGEITVALDDTDSSGNKKSGTWDSGTSTLTISKQRTKTKQLVFTKEDTITVQNYDSAGTNLEGKAVEITTLKELCNALKGGGGSGGGGSGGGGSGGGGSFNGKGETSEKTIVRAQGTRLEY TDIKSDGSGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVVLSKNILKSGEITAALDDSDTTRATKKTGKWDSKTSTLTISVNSQKTKNLVFTKEDTITVQRYDSAGTNLEGKAVEITTLKELCNALK

[0778] The nucleic acid sequence in SEQ ID NO: 33 VRP encoding the tandem fragments of OspA serotype 1, 5 and 6 C-terminal fragments (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-6”).

[0779]

[0780] SEQ ID NO: 34 Amino acid sequence of OspA serotype 1, 5 and 6 C-terminal fragment tandem (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-6”) with htPA signal peptide in VRP.

[0781] MDAMKRGLCCVLLLCGAVFVSASFNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKQFTLEGKVANDKTTLVVKCGTVTLSKQISKSGEVSVELQDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENTITVQQYDSQGTKLEGSAVEITKLDEICNALKG GGGSGGGGSGGGGSGGGGSFNEKGEISEKTIVRAQGTRLEYTDIKSDKTGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVTLSKQISKSGEITVALDDTDSSGNKKSGTWDSGTSTLTISKQRTKTKQLVFTKEDTITVQNYDSAGTNLEGKAVEITTLKELCNALKGGGGSG GGGSGGGGSGGGGSFNGKGETSEKTIVRAQGTRLEYTDIKSDGSGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVVLSKNILKSGEITAALDDSDTTRATKKTGKWDSKTSTLTISVNSQKTKNLVFTKEDTITVQRYDSAGTNLEGKAVEITTLKELCNALKSSGGASVLA ESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0782] The nucleic acid sequence of SEQ ID NO: 35 VRP encoding the SARS-CoV-2 spike RBD-HisB fusion protein (“constructor-7”) with the htPA signal peptide.

[0783] ATG

[0784] SEQ ID NO: 36 Amino acid sequence of SARS-CoV-2 spike RBD-HisB fusion protein (“constructor-7”) with htPA signal peptide.

[0785] MDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQ IAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPA TVCGPKKSTNLVKNKSSGGASVLAASRRARIERRTRESDIVIELDLDGTGQVAVDTGVPFYDHMLTALGSHASFDLTVRATGDVEIEAHHTIEDTAIALGTALGQALGDKRGI RRFGDAFIPMDETLAHAAVDLSGRPYCVHTGEPDHLQHTTIAGSSVPYHTVINRHVFESLAANARIALHVRVLYGRDPHHITEAQYKAVARALRQAVEPDPRVSGVPSTKGAL

[0786] The nucleic acid sequence of SEQ ID NO: 37 VRP encoding the SARS-CoV-2 spike RBD-PdhC fusion protein (“constructor-8”) with the htPA signal peptide.

[0787] ATG

[0788] The amino acid sequence of SEQ ID NO: 38 of the SARS-CoV-2 spike RBD-PdhC fusion protein (“constructor-8”) with the htPA signal peptide.

[0789] MDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIA DYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKSSGGAS VLAAAAKPATTEGEFPETREKMSGIRRAIAKAMVHSKHTAPHVTLMDEADVTKLVAHRKKFKAIAAEKGIKLTFLPYVVKALVSALREYPVLNTSIDDETEEIIQKHYYNIGIAADTDRGLLV PVIKHADRKPIFALAQEINELAEKARDGKLTPGEMKGASCTITNIGSAGGQWFTPVINHPEVAILGIGRIAEKPIVRDGEIVAAPMLALSLSFDHRMIDGATAQKALNHIKRLLSDPELLLMEA

[0790] The nucleic acid sequence of SEQ ID NO: 39 VRP encoding the SARS-CoV-2 spike RBD-DPS fusion protein (“constructor-9”) with the htPA signal peptide.

[0791] ATG

[0792] SEQ ID NO: 40 Amino acid sequence of SARS-CoV-2 spike RBD-DPS fusion protein (“constructor-9”) with htPA signal peptide.

[0793] MDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQP TNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKSSGGASVLAATNLLYTRNDVSDSEKKATVELLNRQVIQFIDLSLITKQAHWNMRGANFIAVHEMLDGFRTALIDHLDTMAERAVQLGGVALGTTQVINSKTPLKSYPLDIHNVQDHLKELADRYAIVANDVRKAIGEAKDDDTADILTAASRDLDKFLWFIESNIE

[0794] SEQ ID NO: 41 Nucleic acid sequence encoding SARS-CoV-2 spike RBD-SOR fusion protein (“constructor-10”) with htPA signal peptide in VRP.

[0795] ATG

[0796] The amino acid sequence of SEQ ID NO: 42 of the SARS-CoV-2 spike RBD-SOR fusion protein (“constructor-10”) with the htPA signal peptide.

[0797] MDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIA WNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKSSGGASVLAPKPYVAINMAELKNEPKTFEMFASVGPKV CMVTARHPGFVGFQNHIQIGILPFGNRYGGAKMDMTKESSTVRVLQYTFWKDWKDHEEMHRQNWSYLFRLCYSCASQMIWGPWEPIYEIIYANMPINTEMTDFTAVVGKKFAEGKPLDIPVISQPYGKRVVAFAEHSVI PGKEKQFEDAIVRTLEMLKKAPGFLGAMVLKEIGVSGIGSMQFGAKGFHQVLENPGSLEPDPNNVMYSVPEAKNTPQQYIVHVEWANTDALMFGMGRVLLYPELRQVHDEVLDTLVYGPYIRILNPMMEGTFWREYLNEQ

[0798] The nucleic acid sequence of SEQ ID NO: 43 VRP encoding the SARS-CoV-2 spike RBD-MrsD fusion protein (“constructor-11”) with the htPA signal peptide.

[0799] ATG

[0800] The amino acid sequence of SEQ ID NO: 44 of the SARS-CoV-2 spike RBD-MrsD fusion protein (“constructor-11”) with the htPA signal peptide.

[0801] MDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDE VRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFEL LHAPATVCGPKKSTNLVKNKSSGGASVLASISILKDKKLLIGICGSISSVGISSYLLYFKSFFKEIRVVMTKTAEDLIPAHTVSYFCDHVYSEHGENGKRHSNVEIGRWAD IYCIIPATANILGQTANGVAMNLVATTVLAHPHNTIFFPNMNDLMWNKTVVSRNIEQLRKDGHIVIEPVEIMAFEIATGTRKPNRGLITPDKALLAIEKGFKERTKHPSLT

[0802] The nucleic acid sequence of SEQ ID NO: 45 VRP encoding the HisB-SARS-CoV-2 spike RBD fusion protein (“Constructor-12”) with the htPA signal peptide.

[0803] ATG

[0804] SEQ ID NO: 46 Amino acid sequence of HisB-SARS-CoV-2 spike RBD fusion protein (“constructor-12”) with htPA signal peptide.

[0805] MDAMKRGLCCVLLLCGAVFVSASASRRARIERRTRESDIVIELDLDGTGQVAVDTGVPFYDHMLTALGSHASFDLTVRATGDVEIEAHHTIEDTAIALGTALGQALGDKRGIR RFGDAFIIPMDETLAHAAVDLSGRPYCVHTGEPDHLQHTTIAGSSVPYHTVINRHVFESLAANARIALHVRVLYGRDPHHITEAQYKAVARALRQAVEPDPRVSGVPSTKGALS SGGASVLAVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYK LPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0806] The nucleic acid sequence of SEQ ID NO: 47 VRP encoding the DPS-SARS-CoV-2 spike RBD fusion protein (“constructor-13”) with the htPA signal peptide.

[0807] ATG

[0808] The amino acid sequence of SEQ ID NO: 48 of the DPS-SARS-CoV-2 spike RBD fusion protein (“constructor-13”) with the htPA signal peptide.

[0809] MDAMKRGLCCVLLLCGAVFVSASATNLLYTRNDVSDSEKKATVELLNRQVIQFIDLSLITKQAHWNMRGANFIAVHEMLDGFRTALIDHLDTMAERAVQLGGVALGTTQVINSKTPLKSYPLDIHNVQDHLKELADRYAIVANDVRKAIGEAKDDDTADILTAASRDLDKFLWFIESNIESSGGASVLAVQPTESIVRFPNIT NLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0810] The nucleic acid sequence of SEQ ID NO: 49 VRP encoding the SOR-SARS-CoV-2 spike RBD fusion protein (“constructor-14”) with the htPA signal peptide.

[0811] ATG

[0812] SEQ ID NO: 50 Amino acid sequence of SOR-SARS-CoV-2 spike RBD fusion protein (“constructor-14”) with htPA signal peptide.

[0813] MDAMKRGLCCVLLLCGAVFVSASPKPYVAINMAELKNEPKTFEMFASVGPKVCMVTARHPGFVGFQNHIQIGILPFGNRYGGAKMDMTKESSTVRVLQYTFWKDWKDHEEMHRQNWSYLFRLCYSCASQMIWGPWEPIY EIIYANMPINTEMTDFTAVVGKKFAEGKPLDIPVISQPYGKRVVAFAEHSVIPGKEKQFEDAIVRTLEMLKKAPGFLGAMVLKEIGVSGIGSMQFGAKGFHQVLENPGSLEPDPNNVMYSVPEAKNTPQQYIVHVEWANT DALMFGMGRVLLYPELRQVHDEVLDTLVYGPYIRILNPMMEGTFWREYLNEQSSGGASVLAVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYA DSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0814] The nucleic acid sequence of SEQ ID NO: 51 VRP encoding the MrsD-SARS-CoV-2 spike RBD fusion protein (“Constructor-15”) with the htPA signal peptide.

[0815] ATG

[0816] The amino acid sequence of MrsD-SARS-CoV-2 spike RBD fusion protein (“constructor-15”) with htPA signal peptide, SEQ ID NO: 52.

[0817] MDAMKRGLCCVLLLCGAVFVSASSISILKDKKLLIGICGSISSVGISSYLLYFKSFFKEIRVVMTKTAEDLIPAHTVSYFCDHVYSEHGENGKRHSNVEIGRWADIYCII PATANILGQTANGVAMNLVATTVLAHPHNTIFFPNMNDLMWNKTVVSRNIEQLRKDGHIVIEPVEIMAFEIATGTRKPNRGLITPDKALLAIEKGFKERTKHPSLTSSGGA SVLAVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLP DDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0818] The nucleic acid sequence of SEQ ID NO: 53 VRP encoding the EBV gp350-PdhC fusion protein (“Constructor-16”) with an IgK LC signal peptide.

[0819]

[0820] The amino acid sequence of the EBV gp350-PdhC fusion protein (“constructor-16”) with the IgK LC signal peptide in VRP, SEQ ID NO: 54.

[0821] METDTLLLWVLLLWVPGSTGDEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETV PYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVP MVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLPKPSTPPGSSAAAKPATTEGEFPETREKMSGIRRAIAKAMVHSKHTAPHVTLMDEADVTKLVAHRKKFKAIAAEKGI KLTFLPYVVKALVSALREYPVLNTSIDDETEEIIQKHYYNIGIAADTDRGLLVPVIKHADRKPIFALAQEINELAEKARDGKLTPGEMKGASCTITNIGSAGGQWFTPVINHPEVAILGIGRIAEKPIVRDGEIVAAPMLALSLSFDHRMIDGATAQKALNHIKRLLSDPELLLMEA

[0822] Nucleic acid sequence of SEQ ID NO: 55 VRP encoding EBVgp350-DPS fusion protein (“Constructor-17”) with IgK LC signal peptide.

[0823]

[0824] Amino acid sequence of EBVgp350-DPS fusion protein (“constructor-17”) containing IgK LC signal peptide in VRP, SEQ ID NO: 56.

[0825] METDTLLLWVLLLWVPGSTGDEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDV FGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGP KASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLPKPSTPPGSSA TNLLYTRNDVSDSEKKATVELLNRQVIQFIDLSLITKQAHWNMRGANFIAVHEMLDGFRTALIDHLDTMAERAVQLGGVALGTTQVINSKTPLKSYPLDIHNVQDHLKELADRYAIVANDVRKAIGEAKDDDTADILTAASRDLDKFLWFIESNIE

[0826] The nucleic acid sequence of SEQ ID NO: 57 VRP encoding EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with IgK LC signal peptide and SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with htPA signal peptide (“Constructor-18”).

[0827]

[0828] SEQ ID NO: 58 The amino acid sequence of EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with IgK LC signal peptide and SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein with htPA signal peptide (“Constructor-18”) separated by the T2A site (T2A site is indicated in bold).

[0829] METDTLLLWVLLLWVPGSTGDEAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTM WCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYC IQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLPKPSTPPGSSESQVRQQFSKDIE KLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS SGEGRGSLLTCGDVEENPGPMDAMKRGLCCVLLLCGAVFVSASVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQP YRVVVLSFELLHAPATVCGPKKSTNLVKNKSSGGASVLAESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFL NENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0830] The nucleic acid sequence in SEQ ID NO: 59 VRP encoding the tandem fragments of OspA serotype 2, 4 and 3 C-terminal fragments (OspA ST2 4 3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“construct-19”).

[0831]

[0832] Amino acid sequence of the OspA serotype 2, 4 and 3 C-terminal fragment tandem (OspA ST2-4-3)-bullfrog / Helicobacter pylori hybrid ferritin fusion protein ("Construct-19") with htPA signal peptide in VRP of SEQ ID NO: 60.

[0833] MDAMKRGLCCVLLLCGAVFVSASFNEKGELSAKTMTREQGTKLEYTEMKSDGTGKAKEVLKQFTLEGKVANDKVTLEVKCGTVTLSKEIAKSGEVTVALQDTQTTQATKKTGAWDSKTSTLTISVNSKKTTQLVFTKQDTITVQKYDSAGTNLEGTAVEIKTLDELCNALKGGGGSGGGGSGGGGSGGGGSFNAKGELSEKTILRAQGTRLEYTEIKSDGTGKAKEVLKDFALEGTLAADKTTLKVTCGTVVLSKHIPNSGEITVELQDSQSTQATKKTGKWDSQTSTLTISVNSKKTKNIVFTKEDTITVQKYDSAGTNLEGNAVEIKTLDELCNALKGGGGSGGGGSGGGGSGGGGSFNDKGKLSEKVVTRAQGTRLEYTEIKNDGSGKAKEVLKGFALEGTLTDGGETKLTVTCGTVTLSKQISKSGEITVALQDTETTPADKKTGEWKSDTSTLTISKNSQKPKQLVFTKENTITVQNYNRAGNALEGSPAEIKDLAELCAALKSSGGASVLAESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0834] The nucleic acid sequences in SEQ ID NO: 61 VRP encoding the tandem fragments of OspA serotype 1, 5, and 6 C-terminal fragments with htPA signal peptide (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein and the tandem fragments of OspA serotype 2, 4, and 3 C-terminal fragments with htPA signal peptide (OspA ST243)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“Constructor-20”).

[0835]

[0836] The amino acid sequences of the OspA serotype 1, 5 and 6 C-terminal fragment tandem with htPA signal peptide (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein and the OspA serotype 2, 4 and 3 C-terminal fragment tandem with htPA signal peptide (OspA ST243)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein (“constructor-20z”) separated by the P2A site in SEQ ID NO: 62 VRP (T2A site is indicated in bold).

[0837]

[0838] SEQ ID NO: 63 is the nucleic acid sequence encoding the SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0839]

[0840] SEQ ID NO: 64 Amino acid sequence of SARS-CoV-2 spike RBD-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0841] VQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLH APATVCGPKKSTNLVKNKSSGGASVLAESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVP VQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0842] The nucleic acid sequence encoding the EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein in SEQ ID NO: 65 MVA.

[0843]

[0844] SEQ ID NO: 66 Amino acid sequence of EBV gp350-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0845] EAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVT LPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKC

[0846] SEQ ID NO: 67 encodes the nucleic acid sequence of the OspA serotype 1, 5 and 6 C-terminal tandem fragment (OspA ST1-5-6)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0847]

[0848] SEQ ID NO: 68 Amino acid sequence of the OspA serotype 1, 5 and 6 C-terminal fragment tandem (OspA ST1-5-6)-bullfrog / Helicobacter pylori hybrid ferritin fusion protein.

[0849] FNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKQFTLEGKVANDKTTLVVKCGTVTLSKQISKSGEVSVELQDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENTITVQQYDSQGTKLEGSAVEITKLDEICNALKGGGGSGGGGSGGGGSGGGGSFNEKGEISEKTIVRAQGTRLEYTDIKSDKTGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVTLSKQISKSGEITVALDDTDSSGNKKSGTWDSGTSTLTISKQRTKTKQLVFTKEDTITVQNYDSAGTNLEGKAVEITTLKELCNALKGGGGSGGGGSGGGGSGGGGSFNGKGETSEKTIVRAQGTRLEYTDIKSDGSGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVVLSKNILKSGEITAALDDSDTTRATKKTGKWDSKTSTLTISVNSQKTKNLVFTKEDTITVQRYDSAGTNLEGKAVEITTLKELCNALKSSGGASVLAESQVRQQFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0850] SEQ ID NO: 69 Nucleic acid sequence encoding the SARS-CoV-2 spike RBD-PdhC fusion protein.

[0851]

[0852] SEQ ID NO: 70 Amino acid sequence of SARS-CoV-2 spike RBD-PdhC fusion protein.

[0853] VQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNKSSGGASVLAAAAKPATTEGEFPETREKMSGIRRAIAKAMVHSKHTAPHVTLMDEADVTKLVAHRKKFKAIAAEKGIKLTFLPYVVKALVSALREYPVLNTSIDDETEEIIQKHYYNIGIAADTDRGLLVPVIKHADRKPIFALAQEINELAEKARDGKLTPGEMKGASCTITNIGSAGGQWFTPVINHPEVAILGIGRIAEKPIVRDGEIVAAPMLALSLSFDHRMIDGATAQKALNHIKRLLSDPELLLMEA

[0854] SEQ ID NO: 71 Nucleic acid sequence encoding SARS-CoV-2 spike RBD-DPS fusion protein.

[0855]

[0856] SEQ ID NO: 72 SARS-CoV-2 associated with RBD-DPS.

[0857] VQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQT GKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYLYRLFRKSNLKPFERDISTEIQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVV VLSFELLHAPATVCGPKKSTNLVKNKSSGGASVLAATNLLYTRNDVSDSEKKATVELLNRQVIQFIDLSLITKQAHWNMRGANFIAVHEMLDGFRT ALIDHLDTMAERAVQLGGVALGTTQVINSKTPLKSYPLDIHNVQDHLKELADRYAIVANDVRKAIGEAKDDDTADILTAASRDLDKFLWFIESNIE

[0858] SEQ ID NO: 73 HisB-SARS-CoV-2 contains a RBD linker.

[0859]

[0860] SEQ ID NO: 74 Amino acid sequence of HisB-SARS-CoV-2 spike RBD fusion protein.

[0861] ASRRARIERRTRESDIVIELDLDGTGQVAVDTGVPFYDHMLTALGSHASFDLTVRATGDVEIEAHHTIEDTAIALGTALGQALGDKRGIRRFGDAFIPMDETLAHAAVDLSGRPYCVHTGEPDHLQHTTIAGSSVPYHTVINRHVFESLAANARIALHVRVLYGRDPHHITEAQYKAVARALRQAVEPDPRVSGVPSTKGALSSGGASVLAVQPTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0862] SEQ ID NO: 75 Nucleic acid sequence encoding DPS-SARS-CoV-2 spike RBD fusion protein.

[0863]

[0864] The amino acid sequence of the DPS-SARS-CoV-2 spike RBD fusion protein. SEQ ID NO: 76

[0865] ATNLLYTRNDVSDSEKKATVELLNRQVIQFIDLSLITKQAHWNMRGANFIAVHEMLDGFRTALIDHLDTMAERAVQLGGVALGTTQVINSKTPLKSYPLDIHNVQDHLKELADRYAIVANDVRKAIGEAKDDDTADILTAASRDLDKFLWFIESNIESSGGASVLAVQPTESIVRFPNITNLCPFGEVFNAT RFASVYAWNRKRISNCVADYSVLYNSASFSTFKCYGVSPTKLNDLCFTNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSKVGGNYNYLYRLFRKSNLKPFERDISTEIYQAGSTPCNGVEGFNCYFPLQSYGFQPTNGVGYQPYRVVVLSFELLHAPATVCGPKKSTNLVKNK

[0866] SEQ ID NO: 77 encodes the nucleic acid sequence of the EBV gp350-PdhC fusion protein.

[0867]

[0868] SEQ ID NO: 78 Amino acid sequence of EBV gp350-PdhC fusion protein.

[0869] EAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVYLIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQSNIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLPKPSTPPGSSAAAKPATTEGEFPETREKMSGIRRAIAKAMVHSKHTAPHVTLMDEADVTKLVAHRKKFKAIAAEKGIKLTFLPYVVKALVSALREYPVLNTSIDDETEEIIQKHYYNIGIAADTDRGLLVPVIKHADRKPIFALAQEINELAEKARDGKLTPGEMKGASCTITNIGSAGGQWFTPVINHPEVAILGIGRIAEKPIVRDGEIVAAPMLALSLSFDHRMIDGATAQKALNHIKRLLSDPELLLMEA

[0870] SEQ ID NO: 79 Nucleic acid sequence encoding EBV gp350-DPS fusion protein.

[0871]

[0872] The amino acid sequence of the SEQ ID NO: 80 EBV gp350-DPS fusion protein.

[0873] EAALLVCQYTIQSLIHLTGEDPGFFNVEIPEFPFYPTCNVCTADVNVTINFDVGGKKHQLDLDFGQLTPHTKAVYQPRGAFGGSENATNLFLLELLGAGELALTMRSKKLPINVTTGEEQQVSLESVDVYFQDVFGTMWCHHAEMQNPVY LIPETVPYIKWDNCNSTNITAVVRAQGLDVTLPLSLPTSAQDSNFSVKTEMLGNEIDIECIMEDGEISQVLPGDNKFNITCSGYESHVPSGGILTSTSPVATPIPGTGYAYSLRLTPRPVSRFLGNNSILYVFYSGNGPKASGGDYCIQS NIVFSDEIPASQDMPTNTTDITYVGDNATYSVPMVTSEDANSPNVTVTAFWAWPNNTETDFKCKWTLTSGTPSGCENISGAFASNRTFDITVSGLGTAPKTLIITRTATNATTTTHKVIFSKAPESTTTSPTLPKPSTPPGSSATNLLYT RNDVSDSEKKATVELLNRQVIQFIDLSLITKQAHWNMRGANFIAVHEMLDGFRTALIDHLDTMAERAVQLGGVALGTTQVINSKTPLKSYPLDIHNVQDHLKELADRYAIVANDVRKAIGEAKDDDTADILTAASRDLDKFLWFIESNIE

[0874] SEQ ID NO: 81 encodes the nucleic acid of the OspA serotype 2, 4 and 3 C-terminal tandem fragment (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0875]

[0876] SEQ ID NO: 82 is the amino acid sequence of the OspA serotype 2, 4 and 3 C-terminal fragment tandem (OspA ST2-4-3)-bullfrog / Helicobacter pylori heterozygous ferritin fusion protein.

[0877] FNEKGELSAKTMTREQGTKLEYTEMKSDGTGKAKEVLKQFTLEGKVANDKVTLEVKCGTVTLSKEIAKSGEVTVALQDTQTTQATKKTGAWDSKTSTLTISVNSKKTTQLVFTKQDTITVQKYDSAGTNLEGTAVEIKTLDELCNALKGGGGSGGGGSGGGGSGGG GSFNAKGELSEKTILRAQGTRLEYTEIKSDGTGKAKEVLKDFALEGTLAADKTTLKVTCGTVVLSKHIPNSGEITVELQDSQSTQATKKTGKWDSQTSTLTISVNSKKTKNIVFTKEDTITVQKYDSAGTNLEGNAVEIKTLDELCNALKGGGGSGGGGSGGGGSGG GGSFNDKGKLSEKVVTRAQGTRLEYTEIKNDGSGKAKEVLKGFALEGTLTDGGETKLTVTCGTVTLSKQISKSGEITVALQDTETTPADKKTGEWKSDTSTLTISKNSQKPKQLVFTKENTITVQNYNRAGNALEGSPAEIKDLAELCAALKSSGGASVLAESQVRQ QFSKDIEKLLNEQVNKEMQSSNLYMSMSSWCYTHSLDGAGLFLFDHAAEEYEHAKKLIIFLNENNVPVQLTSISAPEHKFEGLTQIFQKAYEHEQHISESINNIVDHAIKSKDHATFNFLQWYVAEQHEEEVLFKDILDKIELIGNENHGLYLADQYVKGIAKSRKS

[0878] SEQ ID NO: 83 is the nucleic acid sequence encoding the htPA signal peptide.

[0879] ATGGATGCAATGAAGAGAGGGCTCTGCTGTGTGCTGCTGCTGTGTGGAGCAGTCTTCGTCTCGGCTAGC

[0880] The amino acid sequence of the htPA signal peptide, SEQ ID NO: 84.

[0881] MDAMKRGLCCVLLLCGAVFVSAS

[0882] SEQ ID NO: 85 is the nucleic acid sequence encoding the IgK LC signal peptide.

[0883] ATGGATGCCATGAAGCGTGGACTGTGCTGTGTGCTGCTCCTGTGCGGAGCTGTGTTCGTTAGTGCCTCT

[0884] The amino acid sequence of the IgK LC signal peptide, SEQ ID NO: 86.

[0885] METDTLLLWVLLLWVPGSTGD

[0886] SEQ ID NO: 87 is a nucleic acid sequence encoding a 9aa linker sequence between the SARS-CoV-2 spike RBD and bullfrog / Helicobacter pylori heterozygous ferritin, HisB, PdhC, DPS, SOR, or MrsD.

[0887] AGCAGCGGCGGAGCCTCTGTGCTGGCC

[0888] The amino acid sequence of the SEQ ID NO: 88 9aa linker sequence.

[0889] SSGGASVLA

[0890] SEQ ID NO: 89 is the nucleic acid sequence encoding the 10aa linker sequence between EBV gp350 and bullfrog / Helicobacter pylori heterozygous ferritin.

[0891] CCTAAGCCCAGCACACCTCCTGGCAGCTCT

[0892] The amino acid sequence of the SEQ ID NO: 90 10aa linker sequence.

[0893] PKPSTPPGSS

[0894] SEQ ID NO: 91 is a nucleic acid sequence encoding the 13aa linker sequence between the EBV gp350 and GCN4 tetramerization domains.

[0895] CCTAAGCCCAGCACACCTCCTGGCAGCTCTTGTGGAGGC

[0896] The amino acid sequence of the SEQ ID NO: 92 13aa linker sequence.

[0897] PKPSTPPGSSCGG

[0898] The nucleic acid sequence encoding the (GGGGS)4 linker sequence of SEQ ID NO: 93.

[0899] GGCGGTGGCGGCTCTGGCGGAGGTGGAAGCGGAGGAGGAGGAAGTGGCGGAGGCGGTTCT

[0900] The amino acid sequence encoding the (GGGGS)4 linker sequence of SEQ ID NO: 94.

[0901] GGGGSGGGGSGGGGSGGGGS

[0902] SEQ ID NO: 95 encodes the nucleic acid sequence of the T2A peptide cleavage site.

[0903] AGCGGAGAGGGCAGAGGAAGTCTGCTAACATGCGGTGACGTCGAGGAGAATCCTGGACCT

[0904] SEQ ID NO: 96 The amino acid sequence of the T2A peptide cleavage site.

[0905] SGEGRGSLLTCGDVEENPGP

[0906] Nucleic acid sequence of SEQ ID NO:97 Pr13.5long promoter.

[0907] TAAAAATAGAAACTATAATCATATAATAGTGTAGGTTGGTAGTATTGCTCTTGTGACTAGAGACTTTAGTTAAGGTACTGTAAAAATAGAAACTATAATCATATAATAGTGTAGGTTGGTAGTA

[0908] SEQ ID NO: 98 encodes a nucleic acid sequence containing the GCN4 polymerization domain.

[0909] ATGAAAGTGAAGCAGCTGGTGGACAAGGTGGAAGAACTGCTGAGCAAGAACTACCACCTCGTGAATGAGGTGGCACGGCTCGTGAAGCTCGTGGGAGAAAGAGGTGGC

[0910] SEQ ID NO: 99 encodes the amino acid sequence of the GCN4 polymerization domain.

[0911] MKVKQLVDKVEELLSKNYHLVNEVARLVKLVGERGG

[0912] SEQ ID NO: 100 is the nucleic acid sequence encoding the fusion protein of the OspA C-terminal fragment ST1-5-6.

[0913]

[0914] SEQ ID NO: 101 is the amino acid sequence of OspA C terminal fragment ST1-5-6.

[0915] FNEKGEVSEKIITRADGTRLEYTGIKSDGSGKAKEVLKQFTLEGKVANDKTTLVVKCGTVTLSKQISKSGEVSVELQDTDSSAATKKTAAWNSGTSTLTITVNSKKTKDLVFTKENTITVQQYDSQGTKLEGSAVEITKLDEICNALKGGGGSGGGSGGGSGGGSGFNGKEISEKTIVRAQGTRLEYTDIKSDKTGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVTLSKQISKSGEITVALDDTDSSGNKKSGTWDSGTSLTISKQRTKTKQLVFTKEDTITVQNYDSAGTNEGKAVEITTLKELCNALKGGGGSGGGSGGGSGGGSFNGKGETSEKTIVRAQGTRLEYTDIKSDGSGKAKEVLKDFTLEGTLAADGKTTLKVTCGTVVLSKNILKSGEITAALDDSDTTTRATKKTGKWDSKTSTLTISVNNSQKTKNLVFTKEDTITVQRYDSAGTNEGKAVEITTLKELCNALK

[0916] SEQ ID NO: 102 is the nucleic acid sequence coded for OspA C terminal fragment ST2-4-3.

[0917]

[0918] SEQ ID NO: 103 is the amino acid sequence of the OspA C terminal fragment ST2-4-3.

[0919] FNEKGELSAKTMTREQGTKLEYTEMKSDGTGKAKEVLKQFTLEGKVANDKVTLEVKCGTVTLSKEIAKSGEVTVALQDTQTTQATKKTGAWDSKTSTLTISVNSKKTTQLVFTKQDTITVQKYDSAGTNLEGTAVEIKTLDELCNALKGGGGSGGGGGSGGGGGSGGGGGSFNAKGELSEKTILRAQGTRLEYTEIKSDGTGKAKEVLKDFALEGTLAADKTTLKVTCGTVVLSKHIPNSGEITVELQDSQSTQATKKTGKWDSQTSTLTISVNNSKKTKNIVFTKEDTITVQKYDSAGTNLEGNAVEIKTLDELCNALKGGGGSGGGGGSGGGGGSGGGGSFNDKGKLSEKVVTRAQGTRLEYTEIKNDGSGKAKEVLKGFALEGTLTDGGETKLTVTTCGTVTLSKQISKSGEITVALQDTETTPADKKTGEWKSDTSTLTISKNSQKPKQLVFTKENTITVQNYNRAGNALEGSPAEIKDLAELCAALK

Claims

1. A pharmaceutical composition comprising a recombinant virus-based vector, the recombinant virus-based vector comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle.

2. The pharmaceutical composition of claim 1, wherein the recombinant virus-based vector is a recombinant vaccinia virus, preferably a recombinant vaccinia virus, and more preferably a recombinant modified Ankara vaccinia virus (MVA).

3. The pharmaceutical composition of claim 1, wherein the vector based on the recombinant virus is a recombinant viral replicon particle (VRP), preferably derived from Venezuelan equine encephalitis virus (VEEV), more preferably derived from VEEV TC83 strain and / or TrD strain.

4. A recombinant viral replicon particle (VRP) comprising a heterologous nucleic acid operatively linked to a promoter, wherein the heterologous nucleic acid encodes a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle.

5. The pharmaceutical composition of any one of claims 1 to 3, or the recombinant VRP of claim 4, wherein the self-assembled protein nanoparticles are selected from the group consisting of: heterozygous bullfrog / Helicobacter pylori heterozygous ferritin (BFF); imidazole glycerol phosphate dehydratase (HisB), preferably derived from Mycobacterium tuberculosis; acetyltransferase of pyruvate dehydrogenase (PDH) complex (PdhC), preferably derived from Bacillus stearothermophilus; and DNA-binding protein (DPS) from starved cells, preferably derived from Escherichia coli.

6. The pharmaceutical composition of claim 5, or the recombinant VRP of claim 5, wherein the self-assembled protein nanoparticles are HisB, PdhC, or DPS.

7. The pharmaceutical composition of claim 5, or the VRP of claim 5, wherein the self-assembled protein nanoparticles are selected from the group consisting of BFF, PdhC, and DPS, and wherein in each case the N-terminus of the subunit of the self-assembled nanoparticles is attached to the C-terminus of the disease-associated antigen.

8. The pharmaceutical composition of claim 5, or the VRP of claim 5, wherein the self-assembled protein nanoparticle is HisB or DPS, and wherein in each case the C-terminus of the subunit of the self-assembled nanoparticle is attached to the N-terminus of the disease-associated antigen.

9. The pharmaceutical composition of any one of claims 1 to 3 and 5 to 8, or the recombinant VRP of any one of claims 4 to 8, wherein the disease-associated antigen is an infectious disease-associated antigen, preferably a viral or bacterial antigen.

10. The pharmaceutical composition of claim 9, or the recombinant VRP of claim 9, wherein the infectious disease-associated antigen is derived from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), preferably comprising or composed of the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein (SARS-CoV-2 S RBD).

11. The pharmaceutical composition of claim 9, or the recombinant VRP of claim 9, wherein the infectious disease-associated antigen is derived from Epstein-Barr virus (EBV), preferably comprising or composed of EBV surface glycoprotein 350 (EBV gp350).

12. The pharmaceutical composition of claim 9, or the recombinant VRP of claim 9, wherein the infectious disease-associated antigen is derived from Treponema pallidum, preferably from Treponema pallidum outer surface protein A (OspA), more preferably comprising or consisting of a tandem of three OspA C-terminal fragments.

13. The pharmaceutical composition of any one of claims 1 to 3 and 5 to 12, or the recombinant VRP of any one of claims 4 to 12, wherein the heterologous nucleic acid further encodes a signal peptide that binds to the fusion protein, preferably, the signal peptide is a human tissue plasminogen activator (htPA) signal peptide or a mouse immunoglobulin κ light chain (IgK LC) signal peptide.

14. The pharmaceutical composition of any one of claims 1 to 3 and 5 to 13, or the recombinant VRP of any one of claims 4 to 13, for the prevention or treatment of a disease, preferably an infectious disease or cancer.

15. The pharmaceutical composition used in claim 14, or the recombinant VRP used in claim 14, wherein the infectious disease-associated antigen is derived from SARS-CoV-2, and the disease is COVID-19 or long COVID.

16. The pharmaceutical composition used in claim 14, or the recombinant VRP used in claim 14, wherein the infectious disease-associated antigen is derived from EBV, and the disease is EBV infection or EBV-related cancer.

17. The pharmaceutical composition used as claimed in claim 14, or the recombinant VRP used as claimed in claim 14, wherein the infectious disease-associated antigen is derived from Treponema pallidum, and the disease is Lyme disease or Treponema pallidum infection.

18. A method for preparing recombinant VRP according to any one of claims 4 to 17, the method comprising the following steps: (1) Provide plasmid DNA encoding a self-amplifying replicon RNA, preferably a replicon RNA controlled by a cytomegalovirus (CMV) promoter, the replicon RNA encoding a fusion protein containing a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle; (2) Transfect VRP production cells with the plasmid DNA provided in step (1), and further transfect the VRP production cells with a packaging plasmid driven by a first CMV promoter encoding alphavirus capsid protein and a packaging plasmid driven by a second CMV promoter encoding alphavirus envelope protein; (3) Cultivate the transfected VRP production cells described in step (2); (4) Obtain the recombinant VRP.

19. A plasmid DNA encoding a self-amplifying replicon RNA, preferably a replicon RNA controlled by a cytomegalovirus (CMV) promoter, the replicon RNA encoding a fusion protein comprising a disease-associated antigen or an antigenic portion thereof, the disease-associated antigen or an antigenic portion thereof binding to a subunit of a self-assembled protein nanoparticle.

20. A fusion protein comprising a disease-associated antigen or an antigenic portion thereof, said disease-associated antigen or antigenic portion thereof being conjugated to a subunit of a self-assembled protein nanoparticle, wherein said self-assembled protein nanoparticle is an imidazole glycerol phosphate dehydratase (HisB), preferably derived from Mycobacterium tuberculosis; an acetyltransferase of a pyruvate dehydrogenase (PDH) complex (PdhC), preferably derived from Bacillus stearothermophilus; or a DNA-binding protein (DPS) derived from starved cells, preferably derived from Escherichia coli.

21. A nucleic acid encoding the fusion protein of claim 20.

22. A self-assembling protein nanoparticle, said self-assembling protein nanoparticle comprising the fusion protein of claim 20.

Citation Information

Patent Citations

  • Modified vaccinia ankara virus variant

    US6761893B2

  • Modified vaccinia ankara virus variant

    WO2002042480A2

  • Flavivirus NS1 subunit vaccine

    WO2003048184A2

  • Pr13.5 promoter for robust t-cell and antibody responses

    WO2014063832A1

  • Epstein-BARR virus vaccines

    WO2015054639A1